Other Sites:
Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About: RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE
RJR: Recommended Bibliography 19 Nov 2026 at 01:36 Created:
Alzheimer Disease — Current Literature
Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.
Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion
Citations The Papers (from PubMed®)
RevDate: 2026-11-18
CmpDate: 2026-11-18
Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 51(6):723-731.
Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 60%-70% of patients with dementia, and it is estimated that over one million Canadians will be living with dementia by 2030. Disease-modifying therapies (DMTs) targeting the underlying pathophysiology of AD are currently in development. Several models have demonstrated that the potential arrival of Alzheimer's DMTs will most likely overwhelm the already-constrained Canadian healthcare system. Canada does not have a strategy to address the extensive requirements of using DMTs, including providing an early diagnosis of AD, confirming DMT eligibility via amyloid biomarkers, and conducting ongoing treatment monitoring. Thus, a multidisciplinary group of experts involved in AD care in Canada gathered to review (1) the current barriers to diagnosis and management of AD; (2) how existing clinic models, including those used in multiple sclerosis (MS), could be applied to address key barriers in AD; and (3) how to design and implement optimal care pathways in the future. The actions outlined in this review will help clinicians and healthcare systems improve readiness to integrate the use of disease-modifying therapies in Alzheimer's disease, if such therapies are approved in Canada.
Additional Links: PMID-38052729
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid38052729,
year = {2024},
author = {Frank, A and Ismail, Z and Wilson, M and Gauthier, S and Verret, L and Hsiung, GR and Borrie, M},
title = {Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.},
journal = {The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques},
volume = {51},
number = {6},
pages = {723-731},
doi = {10.1017/cjn.2023.322},
pmid = {38052729},
issn = {0317-1671},
abstract = {Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 60%-70% of patients with dementia, and it is estimated that over one million Canadians will be living with dementia by 2030. Disease-modifying therapies (DMTs) targeting the underlying pathophysiology of AD are currently in development. Several models have demonstrated that the potential arrival of Alzheimer's DMTs will most likely overwhelm the already-constrained Canadian healthcare system. Canada does not have a strategy to address the extensive requirements of using DMTs, including providing an early diagnosis of AD, confirming DMT eligibility via amyloid biomarkers, and conducting ongoing treatment monitoring. Thus, a multidisciplinary group of experts involved in AD care in Canada gathered to review (1) the current barriers to diagnosis and management of AD; (2) how existing clinic models, including those used in multiple sclerosis (MS), could be applied to address key barriers in AD; and (3) how to design and implement optimal care pathways in the future. The actions outlined in this review will help clinicians and healthcare systems improve readiness to integrate the use of disease-modifying therapies in Alzheimer's disease, if such therapies are approved in Canada.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
[Mechanisms of Shenghui Decoction in activating PPARα to promote microglial phagocytosis and degradation of Aβ].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 51(20):5858-5866.
This study aimed to elucidate the potential mechanisms by which Shenghui Decoction(SHD) promotes microglial cells to phagocytose and degrade surrounding deposited β-amyloid protein(Aβ) through the peroxisome proliferator-activated receptor α(PPARα)/transcription factor EB(TFEB) signaling pathway. Multiple approaches, including Western blot, real-time quantitative PCR(RT-qPCR), molecular docking, reporter gene assays, and immunofluorescence, were employed for verification. Mouse microglial cells(BV2 cells) were divided into the control group, model group, positive control(WY14643) group, and SHD low-, medium-, and high-dose groups(50, 100, and 200 μg·mL~(-1)), respectively. An Aβ-induced BV2 cell injury model was established, and different reagents were added according to group assignment. BV2 cell viability was assessed using the MTT assay. Fluorescently labeled Aβ_(1-42)(FAM-Aβ_(1-42))was used to evaluate Aβ phagocytosis and degradation in each group. Reporter gene assays were performed to determine the transcriptional activities of PPARα and TFEB. RT-qPCR was conducted to detect the expression of low-density lipoprotein receptor(LDLR), autophagy-related genes 5 and 7(Atg5 and Atg7), and lysosome-associated membrane protein 2(LAMP2). Western blot was used to determine the expression levels of PPARα, LDLR, TFEB nuclear translocation, microtubule-associated protein 1 light chain 3 Ⅰ and Ⅱ(LC3Ⅰ and LC3Ⅱ), P62, and LAMP2 proteins. Immunofluorescence was employed to further validate TFEB nuclear translocation. Molecular docking analysis was conducted to evaluate the binding between SHD active constituents and the ligand-binding domain of PPARα. The results showed that SHD had no significant effect on BV2 cell viability at concentrations of 50-300 μg·mL~(-1). SHD enhanced Aβ phagocytosis and degradation, upregulated LDLR expression, significantly increased the nuclear translocation and expression levels of PPARα and nuclear TFEB proteins, and enhanced the transcriptional activities of PPARα and TFEB. SHD significantly upregulated the expression of the autophagy-related genes Atg5 and Atg7 and the lysosome-related gene LAMP2, increased the protein expression levels of LC3Ⅱ/LC3Ⅰ and LAMP2, and significantly decreased P62 protein expression. Molecular docking results indicated that 50 active constituents in SHD could bind to the ligand-binding domain of PPARα and form stable hydrogen bonds, with binding energies <-5 kcal·mol~(-1). In summary, SHD improves the autophagic-lysosomal function in BV2 cells, thereby facilitating the phagocytosis and degradation of Aβ. This underlying mechanism is likely associated with the activation of the PPARα/TFEB signaling pathway.The findings of this study help elucidate the modern scientific connotation of SHD and may provide a rational therapeutic strategy for the clinical prevention and treatment of Alzheimer's disease.
Additional Links: PMID-43045127
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045127,
year = {2026},
author = {Wang, YM and Wang, M and Huang, YL and Xu, DY and Gao, G and Zhang, XW and Zhang, ZQ and Xie, ZS},
title = {[Mechanisms of Shenghui Decoction in activating PPARα to promote microglial phagocytosis and degradation of Aβ].},
journal = {Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica},
volume = {51},
number = {20},
pages = {5858-5866},
doi = {10.19540/j.cnki.cjcmm.20260714.703},
pmid = {43045127},
issn = {1001-5302},
mesh = {*Microglia/drug effects/metabolism/cytology ; Animals ; *Drugs, Chinese Herbal/pharmacology ; Mice ; *PPAR alpha/metabolism/genetics ; *Phagocytosis/drug effects ; *Amyloid beta-Peptides/metabolism/genetics ; Cell Line ; Signal Transduction/drug effects ; Autophagy/drug effects ; Humans ; },
abstract = {This study aimed to elucidate the potential mechanisms by which Shenghui Decoction(SHD) promotes microglial cells to phagocytose and degrade surrounding deposited β-amyloid protein(Aβ) through the peroxisome proliferator-activated receptor α(PPARα)/transcription factor EB(TFEB) signaling pathway. Multiple approaches, including Western blot, real-time quantitative PCR(RT-qPCR), molecular docking, reporter gene assays, and immunofluorescence, were employed for verification. Mouse microglial cells(BV2 cells) were divided into the control group, model group, positive control(WY14643) group, and SHD low-, medium-, and high-dose groups(50, 100, and 200 μg·mL~(-1)), respectively. An Aβ-induced BV2 cell injury model was established, and different reagents were added according to group assignment. BV2 cell viability was assessed using the MTT assay. Fluorescently labeled Aβ_(1-42)(FAM-Aβ_(1-42))was used to evaluate Aβ phagocytosis and degradation in each group. Reporter gene assays were performed to determine the transcriptional activities of PPARα and TFEB. RT-qPCR was conducted to detect the expression of low-density lipoprotein receptor(LDLR), autophagy-related genes 5 and 7(Atg5 and Atg7), and lysosome-associated membrane protein 2(LAMP2). Western blot was used to determine the expression levels of PPARα, LDLR, TFEB nuclear translocation, microtubule-associated protein 1 light chain 3 Ⅰ and Ⅱ(LC3Ⅰ and LC3Ⅱ), P62, and LAMP2 proteins. Immunofluorescence was employed to further validate TFEB nuclear translocation. Molecular docking analysis was conducted to evaluate the binding between SHD active constituents and the ligand-binding domain of PPARα. The results showed that SHD had no significant effect on BV2 cell viability at concentrations of 50-300 μg·mL~(-1). SHD enhanced Aβ phagocytosis and degradation, upregulated LDLR expression, significantly increased the nuclear translocation and expression levels of PPARα and nuclear TFEB proteins, and enhanced the transcriptional activities of PPARα and TFEB. SHD significantly upregulated the expression of the autophagy-related genes Atg5 and Atg7 and the lysosome-related gene LAMP2, increased the protein expression levels of LC3Ⅱ/LC3Ⅰ and LAMP2, and significantly decreased P62 protein expression. Molecular docking results indicated that 50 active constituents in SHD could bind to the ligand-binding domain of PPARα and form stable hydrogen bonds, with binding energies <-5 kcal·mol~(-1). In summary, SHD improves the autophagic-lysosomal function in BV2 cells, thereby facilitating the phagocytosis and degradation of Aβ. This underlying mechanism is likely associated with the activation of the PPARα/TFEB signaling pathway.The findings of this study help elucidate the modern scientific connotation of SHD and may provide a rational therapeutic strategy for the clinical prevention and treatment of Alzheimer's disease.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Microglia/drug effects/metabolism/cytology
Animals
*Drugs, Chinese Herbal/pharmacology
Mice
*PPAR alpha/metabolism/genetics
*Phagocytosis/drug effects
*Amyloid beta-Peptides/metabolism/genetics
Cell Line
Signal Transduction/drug effects
Autophagy/drug effects
Humans
RevDate: 2026-11-17
CmpDate: 2026-11-17
[Effects of Tongqiao Huoxue Decoction on cognitive dysfunction and expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 51(20):5930-5938.
To investigate the effects of Tongqiao Huoxue Decoction(TQHX) on cognitive dysfunction and the expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease(AD), Sprague-Dawley(SD) rats were randomly divided into a sham-operated group, an AD group, a low-dose TQHX group, a medium-dose TQHX group, a high-dose TQHX group, and a positive control group. Following 28 days of treatment with TQHX or the positive control drug memantine, the homeostasis model assessment of insulin resistance(HOMA-IR) was determined. Cognitive function was evaluated using the Morris water maze. Hematoxylin-eosin(HE) staining and silver staining were performed to examine neuronal and synaptic morphology in the hippocampal CA1 region, and neuronal regeneration was assessed by immunofluorescence staining for doublecortin(DCX). The mitochondrial membrane potential(MMP) of brain tissue cells was measured using the JC-1 fluorescent probe, and adenosine triphosphate(ATP) levels were determined. The content of Aβ in brain tissue and the levels of malondialdehyde(MDA) and superoxide dismutase(SOD) were measured. Serum inflammatory cytokine levels were determined by ELISA. The expression of insulin signaling pathway-related proteins in brain tissue was detected by Western blot. The results showed that, compared with the sham-operated group, the AD group exhibited significantly increased HOMA-IR, escape latency, Aβ content, MDA levels, tumor necrosis factor-α(TNF-α), interleukin(IL)-1β and IL-8 levels, as well as increased ratios of phosphorylated glycogen synthase kinase-3β(p-GSK-3β)/glycogen synthase kinase-3β(GSK-3β) and phosphorylated nuclear factor-κB p65(p-NF-κB p65)/nuclear factor-κB p65(NF-κB p65), whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, insulin receptor(IR) protein expression, the ratio of phosphorylated insulin receptor substrate 1(p-IRS1)/insulin receptor substrate 1(IRS1), the ratio of phosphorylated phosphoinositide 3-kinase(p-PI3K)/phosphoinositide 3-kinase(PI3K), and the ratio of phosphorylated protein kinase B(p-AKT)/protein kinase B(AKT) were significantly decreased. Compared with the AD group, all TQHX treatment groups and the positive control group showed decreased HOMA-IR, escape latency, Aβ content, MDA levels, TNF-α, IL-1β, IL-8 levels, and the p-GSK-3β/GSK-3β and p-NF-κB p65/NF-κB p65 ratios, whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, IR protein expression, and the p-IRS1/IRS1, p-PI3K/PI3K, and p-AKT/AKT ratios were all increased. Moreover, these effects showed a dose-dependent trend among the TQHX groups. Compared with the high-dose TQHX group, no significant changes were observed in any of the measured parameters in the positive control group. In conclusion, TQHX improves cognitive dysfunction and insulin resistance in AD rats and upregulates the expression of insulin signaling pathway-related proteins.
Additional Links: PMID-43045134
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045134,
year = {2026},
author = {Zhou, Y and Che, ZX and Chen, LJ and Lei, XJ and Xing, Y and Cai, ZR and Ma, YX and Bai, LN},
title = {[Effects of Tongqiao Huoxue Decoction on cognitive dysfunction and expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease].},
journal = {Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica},
volume = {51},
number = {20},
pages = {5930-5938},
doi = {10.19540/j.cnki.cjcmm.20260630.901},
pmid = {43045134},
issn = {1001-5302},
mesh = {Animals ; *Drugs, Chinese Herbal/administration & dosage ; *Alzheimer Disease/drug therapy/metabolism/genetics/psychology ; Signal Transduction/drug effects ; Rats ; Rats, Sprague-Dawley ; *Insulin/metabolism/genetics ; Male ; Doublecortin Protein ; *Cognitive Dysfunction/drug therapy/metabolism/genetics ; Humans ; Hippocampus/drug effects/metabolism ; Glycogen Synthase Kinase 3 beta/metabolism/genetics ; Insulin Receptor Substrate Proteins/metabolism/genetics ; Superoxide Dismutase/metabolism/genetics ; Tumor Necrosis Factor-alpha/genetics/metabolism ; },
abstract = {To investigate the effects of Tongqiao Huoxue Decoction(TQHX) on cognitive dysfunction and the expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease(AD), Sprague-Dawley(SD) rats were randomly divided into a sham-operated group, an AD group, a low-dose TQHX group, a medium-dose TQHX group, a high-dose TQHX group, and a positive control group. Following 28 days of treatment with TQHX or the positive control drug memantine, the homeostasis model assessment of insulin resistance(HOMA-IR) was determined. Cognitive function was evaluated using the Morris water maze. Hematoxylin-eosin(HE) staining and silver staining were performed to examine neuronal and synaptic morphology in the hippocampal CA1 region, and neuronal regeneration was assessed by immunofluorescence staining for doublecortin(DCX). The mitochondrial membrane potential(MMP) of brain tissue cells was measured using the JC-1 fluorescent probe, and adenosine triphosphate(ATP) levels were determined. The content of Aβ in brain tissue and the levels of malondialdehyde(MDA) and superoxide dismutase(SOD) were measured. Serum inflammatory cytokine levels were determined by ELISA. The expression of insulin signaling pathway-related proteins in brain tissue was detected by Western blot. The results showed that, compared with the sham-operated group, the AD group exhibited significantly increased HOMA-IR, escape latency, Aβ content, MDA levels, tumor necrosis factor-α(TNF-α), interleukin(IL)-1β and IL-8 levels, as well as increased ratios of phosphorylated glycogen synthase kinase-3β(p-GSK-3β)/glycogen synthase kinase-3β(GSK-3β) and phosphorylated nuclear factor-κB p65(p-NF-κB p65)/nuclear factor-κB p65(NF-κB p65), whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, insulin receptor(IR) protein expression, the ratio of phosphorylated insulin receptor substrate 1(p-IRS1)/insulin receptor substrate 1(IRS1), the ratio of phosphorylated phosphoinositide 3-kinase(p-PI3K)/phosphoinositide 3-kinase(PI3K), and the ratio of phosphorylated protein kinase B(p-AKT)/protein kinase B(AKT) were significantly decreased. Compared with the AD group, all TQHX treatment groups and the positive control group showed decreased HOMA-IR, escape latency, Aβ content, MDA levels, TNF-α, IL-1β, IL-8 levels, and the p-GSK-3β/GSK-3β and p-NF-κB p65/NF-κB p65 ratios, whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, IR protein expression, and the p-IRS1/IRS1, p-PI3K/PI3K, and p-AKT/AKT ratios were all increased. Moreover, these effects showed a dose-dependent trend among the TQHX groups. Compared with the high-dose TQHX group, no significant changes were observed in any of the measured parameters in the positive control group. In conclusion, TQHX improves cognitive dysfunction and insulin resistance in AD rats and upregulates the expression of insulin signaling pathway-related proteins.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Drugs, Chinese Herbal/administration & dosage
*Alzheimer Disease/drug therapy/metabolism/genetics/psychology
Signal Transduction/drug effects
Rats
Rats, Sprague-Dawley
*Insulin/metabolism/genetics
Male
Doublecortin Protein
*Cognitive Dysfunction/drug therapy/metabolism/genetics
Humans
Hippocampus/drug effects/metabolism
Glycogen Synthase Kinase 3 beta/metabolism/genetics
Insulin Receptor Substrate Proteins/metabolism/genetics
Superoxide Dismutase/metabolism/genetics
Tumor Necrosis Factor-alpha/genetics/metabolism
RevDate: 2026-11-17
CmpDate: 2026-11-18
Utility of transcranial magnetic stimulation in the diagnosis of neurologic disorders.
Handbook of clinical neurology, 220:263-281.
Transcranial magnetic stimulation (TMS) techniques provide unique insights into human motor cortical physiology and have emerged as an important diagnostic investigation in a variety of neurologic disorders. Single-, paired-, and triple-pulse TMS techniques, incorporating the conventional amplitude-based and threshold tracking methodology, have established clinical and diagnostic utility in amyotrophic lateral sclerosis (ALS), dementias, movement and functional disorders, myelopathies, and neuroinflammatory diseases. Cortical hyperexcitability has emerged as an important diagnostic aid in ALS, and recent commercialization of the threshold-tracking software may facilitate translation into clinical practice. Single-pulse TMS measures have exhibited diagnostic utility in myelopathy even in the absence of radiologic changes. Short-latency afferent inhibition (SAI), reflecting central cholinergic transmission, is reduced in Alzheimer disease and mild cognitive impairment, serving as a surrogate diagnostic biomarker. Triple stimulation technique enhances the detection of upper motor neuron dysfunction and may aid diagnostic demyelinating neuropathies by establishing the presence of proximal conduction block in the cervical nerve root region. The present review discusses the physiologic processes underlying TMS measures and focuses on their diagnostic utility in neurologic diseases.
Additional Links: PMID-43045278
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045278,
year = {2026},
author = {Menon, P and VAN DEN Bos, M and Vucic, S},
title = {Utility of transcranial magnetic stimulation in the diagnosis of neurologic disorders.},
journal = {Handbook of clinical neurology},
volume = {220},
number = {},
pages = {263-281},
doi = {10.1016/B978-0-443-27442-8.00002-0},
pmid = {43045278},
issn = {0072-9752},
mesh = {Humans ; *Transcranial Magnetic Stimulation/methods ; *Nervous System Diseases/diagnosis/physiopathology ; *Evoked Potentials, Motor/physiology ; *Motor Cortex/physiopathology ; },
abstract = {Transcranial magnetic stimulation (TMS) techniques provide unique insights into human motor cortical physiology and have emerged as an important diagnostic investigation in a variety of neurologic disorders. Single-, paired-, and triple-pulse TMS techniques, incorporating the conventional amplitude-based and threshold tracking methodology, have established clinical and diagnostic utility in amyotrophic lateral sclerosis (ALS), dementias, movement and functional disorders, myelopathies, and neuroinflammatory diseases. Cortical hyperexcitability has emerged as an important diagnostic aid in ALS, and recent commercialization of the threshold-tracking software may facilitate translation into clinical practice. Single-pulse TMS measures have exhibited diagnostic utility in myelopathy even in the absence of radiologic changes. Short-latency afferent inhibition (SAI), reflecting central cholinergic transmission, is reduced in Alzheimer disease and mild cognitive impairment, serving as a surrogate diagnostic biomarker. Triple stimulation technique enhances the detection of upper motor neuron dysfunction and may aid diagnostic demyelinating neuropathies by establishing the presence of proximal conduction block in the cervical nerve root region. The present review discusses the physiologic processes underlying TMS measures and focuses on their diagnostic utility in neurologic diseases.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Transcranial Magnetic Stimulation/methods
*Nervous System Diseases/diagnosis/physiopathology
*Evoked Potentials, Motor/physiology
*Motor Cortex/physiopathology
RevDate: 2026-11-17
Developmental and age-acquired somatic mutations in neurodegenerative diseases.
Trends in genetics : TIG pii:S0168-9525(26)00263-5 [Epub ahead of print].
Classical genetic studies have assumed a uniform genome across the body, but humans are genetic mosaics harboring distinct somatic mutations acquired during development and aging. The role of somatic mosaicism in neurodegenerative disease remains poorly understood. In this article, we review somatic mosaicism in two contexts: developmental mosaics arising during embryogenesis and age-associated clonal expansions. Developmental mosaics are established contributors to neurodevelopmental disorders, with emerging evidence linking them to adult-onset neurodegeneration, including amyotrophic lateral sclerosis and Alzheimer's disease. Postnatal clonal expansions in microglia and hematopoietic cells may further promote systemic inflammation and disease progression. We synthesize these findings into a framework in which developmental and age-acquired mutations contribute to neuronal vulnerability, disease heterogeneity, and the pathogenesis of sporadic neurodegenerative disorders.
Additional Links: PMID-43045628
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045628,
year = {2026},
author = {Nayak, S and Lodato, MA},
title = {Developmental and age-acquired somatic mutations in neurodegenerative diseases.},
journal = {Trends in genetics : TIG},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.tig.2026.10.004},
pmid = {43045628},
issn = {0168-9525},
abstract = {Classical genetic studies have assumed a uniform genome across the body, but humans are genetic mosaics harboring distinct somatic mutations acquired during development and aging. The role of somatic mosaicism in neurodegenerative disease remains poorly understood. In this article, we review somatic mosaicism in two contexts: developmental mosaics arising during embryogenesis and age-associated clonal expansions. Developmental mosaics are established contributors to neurodevelopmental disorders, with emerging evidence linking them to adult-onset neurodegeneration, including amyotrophic lateral sclerosis and Alzheimer's disease. Postnatal clonal expansions in microglia and hematopoietic cells may further promote systemic inflammation and disease progression. We synthesize these findings into a framework in which developmental and age-acquired mutations contribute to neuronal vulnerability, disease heterogeneity, and the pathogenesis of sporadic neurodegenerative disorders.},
}
RevDate: 2026-11-17
Topological visual perception and innate defense: Shared subcortical pathway for early diagnosis and neural plasticity intervention in brain disorders.
Neural regeneration research pii:01300535-990000000-01415 [Epub ahead of print].
The superior colliculus-pulvinar-amygdala subcortical pathway has long been recognized as a key pathway mediating innate defensive behaviors and rapid threat detection. Emerging evidence indicates that this pathway additionally supports unconscious topological visual perception, a primitive, evolutionarily conserved visual function that extracts global object structure independently of emotional valence. Notably, topological perception and threat detection are functionally distinct yet engage shared anatomical nodes within the superior colliculus-pulvinar-amygdala pathway, likely through partially segregated local subcircuits. As an emotion-neutral, robust, and unconscious marker, topological perception is hypothesized to be a potential functional probe for early subclinical dysfunction across brain disorders. Cumulative cross-sectional evidence suggests that functional impairments within the superior colliculus-pulvinar-amygdala pathway may emerge at early or subclinical stages across multiple neurodegenerative, mood-related, and neurodevelopmental disorders (e.g., Alzheimer's disease, Parkinson's disease, affective disorders, schizophrenia, and autism spectrum disorder), though longitudinal cohort data are still required to verify whether these alterations constitute genuine preclinical pathological events that precede overt clinical symptoms. Importantly, this pathway retains strong intrinsic neural plasticity and regenerative potential, supporting its suitability for early non-invasive intervention. This review summarizes the dual functions of the superior colliculus-pulvinar-amygdala pathway in fundamental topological visual perception and threat-detection-related defense, and outlines its specific structural and functional abnormalities across various brain disorders. We further systematically evaluate interventions including behavioral training, real-time neurofeedback, temporal interference stimulation, transcranial ultrasound, and pro-regenerative pharmacologic agents to restore circuit function and enhance neural plasticity. We propose that the superior colliculus-pulvinar-amygdala pathway represents a promising novel transdiagnostic target for early diagnosis and neural plasticity-based regenerative intervention in brain disorders, although validation in large-scale human longitudinal cohorts is still required.
Additional Links: PMID-43045651
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045651,
year = {2026},
author = {Huang, Y and Wei, Y and Mao, Y and Li, J},
title = {Topological visual perception and innate defense: Shared subcortical pathway for early diagnosis and neural plasticity intervention in brain disorders.},
journal = {Neural regeneration research},
volume = {},
number = {},
pages = {},
doi = {10.4103/NRR.NRRONLINE-D-26-00917},
pmid = {43045651},
issn = {1673-5374},
abstract = {The superior colliculus-pulvinar-amygdala subcortical pathway has long been recognized as a key pathway mediating innate defensive behaviors and rapid threat detection. Emerging evidence indicates that this pathway additionally supports unconscious topological visual perception, a primitive, evolutionarily conserved visual function that extracts global object structure independently of emotional valence. Notably, topological perception and threat detection are functionally distinct yet engage shared anatomical nodes within the superior colliculus-pulvinar-amygdala pathway, likely through partially segregated local subcircuits. As an emotion-neutral, robust, and unconscious marker, topological perception is hypothesized to be a potential functional probe for early subclinical dysfunction across brain disorders. Cumulative cross-sectional evidence suggests that functional impairments within the superior colliculus-pulvinar-amygdala pathway may emerge at early or subclinical stages across multiple neurodegenerative, mood-related, and neurodevelopmental disorders (e.g., Alzheimer's disease, Parkinson's disease, affective disorders, schizophrenia, and autism spectrum disorder), though longitudinal cohort data are still required to verify whether these alterations constitute genuine preclinical pathological events that precede overt clinical symptoms. Importantly, this pathway retains strong intrinsic neural plasticity and regenerative potential, supporting its suitability for early non-invasive intervention. This review summarizes the dual functions of the superior colliculus-pulvinar-amygdala pathway in fundamental topological visual perception and threat-detection-related defense, and outlines its specific structural and functional abnormalities across various brain disorders. We further systematically evaluate interventions including behavioral training, real-time neurofeedback, temporal interference stimulation, transcranial ultrasound, and pro-regenerative pharmacologic agents to restore circuit function and enhance neural plasticity. We propose that the superior colliculus-pulvinar-amygdala pathway represents a promising novel transdiagnostic target for early diagnosis and neural plasticity-based regenerative intervention in brain disorders, although validation in large-scale human longitudinal cohorts is still required.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-18
Computational identification of amyloid-mimicking microbial peptides with predicted MHC-II presentation relevance to Alzheimer's disease.
NPJ systems biology and applications, 12(1):.
Accumulating evidence suggests a link between gut microbiota, host immunity, and Alzheimer's disease (AD), while specific MHC-II alleles have been associated with disease susceptibility or protection. Here, we applied a computational framework to investigate whether microbial proteins contain amyloid-like motifs capable of interacting with Aβ42 and whether such peptides are differentially presented by distinct MHC-II alleles. We identified an aggregation-prone core within Aβ42 and screened AD-associated gut microbial proteomes to detect homologous peptide motifs. Predicted antigen presentation was evaluated using IEDB, and potential co-aggregation was assessed in silico. We identified microbial amyloid-mimicking peptides predicted to be presented by AD-associated MHC-II alleles, whereas fewer candidate peptides were identified for the protective alleles. Several peptides shared sequence similarity with Aβ42 aggregation motifs and demonstrated predicted structural compatibility for co-aggregation. These findings suggest a potential link between microbial peptide mimicry, antigen presentation, and amyloid biology. This study is computational and hypothesis-generating, providing a systems-level framework for understanding microbiota-immune interactions in AD.
Additional Links: PMID-43045717
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045717,
year = {2026},
author = {Gong, W},
title = {Computational identification of amyloid-mimicking microbial peptides with predicted MHC-II presentation relevance to Alzheimer's disease.},
journal = {NPJ systems biology and applications},
volume = {12},
number = {1},
pages = {},
pmid = {43045717},
issn = {2056-7189},
support = {25K23670//Japan Society for the Promotion of Science/ ; },
mesh = {*Alzheimer Disease/immunology/metabolism/genetics ; Amyloid beta-Peptides/metabolism/chemistry/immunology ; Humans ; *Histocompatibility Antigens Class II/immunology/metabolism ; Peptide Fragments/immunology ; *Computational Biology/methods ; *Amyloid/metabolism ; Antigen Presentation/immunology ; *Peptides/immunology ; Amino Acid Sequence ; Immunoinformatics ; Alleles ; },
abstract = {Accumulating evidence suggests a link between gut microbiota, host immunity, and Alzheimer's disease (AD), while specific MHC-II alleles have been associated with disease susceptibility or protection. Here, we applied a computational framework to investigate whether microbial proteins contain amyloid-like motifs capable of interacting with Aβ42 and whether such peptides are differentially presented by distinct MHC-II alleles. We identified an aggregation-prone core within Aβ42 and screened AD-associated gut microbial proteomes to detect homologous peptide motifs. Predicted antigen presentation was evaluated using IEDB, and potential co-aggregation was assessed in silico. We identified microbial amyloid-mimicking peptides predicted to be presented by AD-associated MHC-II alleles, whereas fewer candidate peptides were identified for the protective alleles. Several peptides shared sequence similarity with Aβ42 aggregation motifs and demonstrated predicted structural compatibility for co-aggregation. These findings suggest a potential link between microbial peptide mimicry, antigen presentation, and amyloid biology. This study is computational and hypothesis-generating, providing a systems-level framework for understanding microbiota-immune interactions in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Alzheimer Disease/immunology/metabolism/genetics
Amyloid beta-Peptides/metabolism/chemistry/immunology
Humans
*Histocompatibility Antigens Class II/immunology/metabolism
Peptide Fragments/immunology
*Computational Biology/methods
*Amyloid/metabolism
Antigen Presentation/immunology
*Peptides/immunology
Amino Acid Sequence
Immunoinformatics
Alleles
RevDate: 2026-11-17
'Light and sound' therapy for Alzheimer's flops in long-anticipated trial.
Additional Links: PMID-43045786
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045786,
year = {2026},
author = {Mullard, A},
title = {'Light and sound' therapy for Alzheimer's flops in long-anticipated trial.},
journal = {Nature},
volume = {},
number = {},
pages = {},
doi = {10.1038/d41586-026-03770-0},
pmid = {43045786},
issn = {1476-4687},
}
RevDate: 2026-11-17
CmpDate: 2026-11-18
Neuroprotective effects of the petroleum ether fraction of Teucrium polium in free and lipid nanoparticle formulations on cognitive deficits and oxidative stress in an ICV-STZ-induced Alzheimer's-like rat model.
Journal of molecular histology, 58(1):.
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and neuronal loss. Current pharmacological treatments provide only partial symptomatic relief. This study investigated the neuroprotective effects of the petroleum ether fraction of Teucrium polium (T. polium), administered in both free and lipid nanoparticle formulations (T. polium-LNP), in a rat model of AD-like pathology induced by intracerebroventricular streptozotocin (ICV-STZ).
METHODS: Adult male Wistar rats were divided into five groups: Control, ICV-STZ, ICV-STZ + Memantine, ICV-STZ + T. polium, and ICV-STZ + T. polium-LNP. Cognitive function was assessed using the Morris water maze (MWM) and novel object recognition (NOR) tests. Serum oxidative stress markers-including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activity-were measured. Hippocampal CA1 histopathology and hippocampal mRNA expression of Bax, Bcl-2, and p53 were also evaluated.
RESULTS: The ICV-STZ-induced AD-like model was associated with memory impairment, increased serum MDA levels, reduced TAC levels and SOD activity, and hippocampal CA1 neuronal damage, accompanied by increased Bax and p53 expression and decreased Bcl-2 expression. Treatment with T. polium and T. polium-LNP improved cognitive performance, particularly spatial memory in the MWM, and attenuated several pathological changes. Both treatments reduced serum MDA levels and decreased CA1 neuronal degeneration.
CONCLUSION: In this experimental AD-like rat model, both formulations of T. polium were associated with improvements in cognitive performance, serum oxidative status markers, and hippocampal tissue changes. Although T. polium-LNP showed numerically greater effects on several outcomes, direct comparisons between the free T. polium extract and T. polium-LNP were statistically significant only for CA1 neuronal damage. Further mechanistic and long-term studies are needed to clarify the potential relevance of these findings to AD-related neuroprotection.
Additional Links: PMID-43045851
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045851,
year = {2026},
author = {Afshar, FK and Nematollahi-Mahani, SN and Haghpanah, T and Joushi, S and Ranjbar, M and Mirzaie, V and Payandeh, P and Sheikhbahaei, F and Solhjoo, S},
title = {Neuroprotective effects of the petroleum ether fraction of Teucrium polium in free and lipid nanoparticle formulations on cognitive deficits and oxidative stress in an ICV-STZ-induced Alzheimer's-like rat model.},
journal = {Journal of molecular histology},
volume = {58},
number = {1},
pages = {},
pmid = {43045851},
issn = {1567-2387},
mesh = {Animals ; *Oxidative Stress/drug effects ; *Alzheimer Disease/drug therapy/chemically induced/pathology ; *Teucrium/chemistry ; *Neuroprotective Agents/pharmacology/chemistry/therapeutic use ; Male ; Disease Models, Animal ; Rats, Wistar ; Rats ; Streptozocin ; *Nanoparticles/chemistry ; *Plant Extracts/pharmacology/chemistry ; *Lipids/chemistry ; *Cognitive Dysfunction/drug therapy ; Maze Learning/drug effects ; Hippocampus/drug effects ; Alkanes ; },
abstract = {BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and neuronal loss. Current pharmacological treatments provide only partial symptomatic relief. This study investigated the neuroprotective effects of the petroleum ether fraction of Teucrium polium (T. polium), administered in both free and lipid nanoparticle formulations (T. polium-LNP), in a rat model of AD-like pathology induced by intracerebroventricular streptozotocin (ICV-STZ).
METHODS: Adult male Wistar rats were divided into five groups: Control, ICV-STZ, ICV-STZ + Memantine, ICV-STZ + T. polium, and ICV-STZ + T. polium-LNP. Cognitive function was assessed using the Morris water maze (MWM) and novel object recognition (NOR) tests. Serum oxidative stress markers-including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activity-were measured. Hippocampal CA1 histopathology and hippocampal mRNA expression of Bax, Bcl-2, and p53 were also evaluated.
RESULTS: The ICV-STZ-induced AD-like model was associated with memory impairment, increased serum MDA levels, reduced TAC levels and SOD activity, and hippocampal CA1 neuronal damage, accompanied by increased Bax and p53 expression and decreased Bcl-2 expression. Treatment with T. polium and T. polium-LNP improved cognitive performance, particularly spatial memory in the MWM, and attenuated several pathological changes. Both treatments reduced serum MDA levels and decreased CA1 neuronal degeneration.
CONCLUSION: In this experimental AD-like rat model, both formulations of T. polium were associated with improvements in cognitive performance, serum oxidative status markers, and hippocampal tissue changes. Although T. polium-LNP showed numerically greater effects on several outcomes, direct comparisons between the free T. polium extract and T. polium-LNP were statistically significant only for CA1 neuronal damage. Further mechanistic and long-term studies are needed to clarify the potential relevance of these findings to AD-related neuroprotection.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Oxidative Stress/drug effects
*Alzheimer Disease/drug therapy/chemically induced/pathology
*Teucrium/chemistry
*Neuroprotective Agents/pharmacology/chemistry/therapeutic use
Male
Disease Models, Animal
Rats, Wistar
Rats
Streptozocin
*Nanoparticles/chemistry
*Plant Extracts/pharmacology/chemistry
*Lipids/chemistry
*Cognitive Dysfunction/drug therapy
Maze Learning/drug effects
Hippocampus/drug effects
Alkanes
RevDate: 2026-11-17
CmpDate: 2026-11-18
Late-onset Alzheimer's Disease Pathologies in a Novel hAβ/ApoE4 Mouse Line.
Molecular neurobiology, 63(1):.
Most Alzheimer's disease (AD) cases are late-onset and sporadic, yet existing mouse models predominantly reflect familial, autosomal-dominant forms. To address this gap, we present the first characterisation of hAβ/ApoE4 mice, which carry a humanised amyloid-beta (Aβ) sequence knocked into the endogenous amyloid precursor protein (APP) locus and a human apolipoprotein E4 (ApoE4) allele replacing murine ApoE, in the context of age-associated AD phenotypes. We aged hAβ/ApoE4 mice of both sexes to 12 months and assessed AD-relevant pathologies including cognition, spine loss, neurodegeneration, neuroinflammation and Aβ deposition. At 12 months, hAβ/ApoE4 mice exhibited spatial memory deficits in the Barnes maze as well as modestly reduced apical dendritic spine density without hippocampal neuronal loss. This model offers a platform for introducing environmental stressors and co-morbidities and establishes a reference point for the development of next-generation sporadic AD models.
Additional Links: PMID-43045944
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045944,
year = {2026},
author = {Rentsch, P and Konen, LM and Zhu, BH and Ganesan, K and Conn, I and Milham, L and Ballinger, S and Stayte, S and Vissel, B},
title = {Late-onset Alzheimer's Disease Pathologies in a Novel hAβ/ApoE4 Mouse Line.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43045944},
issn = {1559-1182},
mesh = {Animals ; *Alzheimer Disease/pathology/genetics/metabolism ; Dendritic Spines/pathology/metabolism ; *Amyloid beta-Peptides/metabolism ; Male ; *Apolipoprotein E4/metabolism/genetics ; Disease Models, Animal ; Humans ; Mice, Transgenic ; Female ; Hippocampus/pathology ; Amyloid beta-Protein Precursor/metabolism ; Age of Onset ; Mice ; Maze Learning ; },
abstract = {Most Alzheimer's disease (AD) cases are late-onset and sporadic, yet existing mouse models predominantly reflect familial, autosomal-dominant forms. To address this gap, we present the first characterisation of hAβ/ApoE4 mice, which carry a humanised amyloid-beta (Aβ) sequence knocked into the endogenous amyloid precursor protein (APP) locus and a human apolipoprotein E4 (ApoE4) allele replacing murine ApoE, in the context of age-associated AD phenotypes. We aged hAβ/ApoE4 mice of both sexes to 12 months and assessed AD-relevant pathologies including cognition, spine loss, neurodegeneration, neuroinflammation and Aβ deposition. At 12 months, hAβ/ApoE4 mice exhibited spatial memory deficits in the Barnes maze as well as modestly reduced apical dendritic spine density without hippocampal neuronal loss. This model offers a platform for introducing environmental stressors and co-morbidities and establishes a reference point for the development of next-generation sporadic AD models.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Alzheimer Disease/pathology/genetics/metabolism
Dendritic Spines/pathology/metabolism
*Amyloid beta-Peptides/metabolism
Male
*Apolipoprotein E4/metabolism/genetics
Disease Models, Animal
Humans
Mice, Transgenic
Female
Hippocampus/pathology
Amyloid beta-Protein Precursor/metabolism
Age of Onset
Mice
Maze Learning
RevDate: 2026-11-17
CmpDate: 2026-11-18
Sociodemographic and comorbidity factors mediate ethno-racial differences in plasma Alzheimer's disease biomarkers.
Alzheimer's research & therapy, 18(1):.
BACKGROUND: Ethno-racial disparities in Alzheimer's disease (AD) risk are well-documented, yet mechanisms underlying these differences remain poorly understood. This study investigates plasma AD biomarkers reflective of amyloid, tau, neurodegeneration, and inflammation across Hispanic, non-Hispanic Black/ African American, and non-Hispanic White adults, and examines whether social determinants of health (SDOH) and comorbidities mediate observed disparities.
METHODS: Data from the community-based Health and Aging Brain Study - Health Disparities (HABS-HD) included 1,256 Hispanic, 723 Black, and 1,243 non-Hispanic White participants. Group differences in plasma biomarkers (phosphorylated tau-217 [p-tau217], amyloid-β 42/40 ratio [Aβ42/40], phosphorylated tau-181 [p-tau181], total tau, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) were assessed using ANCOVA adjusted for age, sex, APOE-ε4 status, and cognitive status. Multiple mediation models tested whether social determinants of health (income, education, area deprivation, chronic stress, social support) and comorbidity factors (BMI, creatinine, total cholesterol, HbA1c, systolic blood pressure) mediate group differences, with covariates and mediators considered simultaneously, resulting in 22 mediation models.
RESULTS: Significant differences were observed across all plasma biomarkers. Both Black and Hispanic adults showed lower p-tau217 and p-tau181 compared to non-Hispanic White adults (p's < 0.001). Hispanic adults exhibited lower Aβ42/40 compared to both groups (p's < 0.05) and lower GFAP compared to non-Hispanic White adults (p = 0.002), but higher total tau (p's < 0.01) compared to both groups. Hispanics had higher NfL than Black adults (p < 0.001) but did not differ from non-Hispanic Whites, while Black adults had lower NfL than non-Hispanic White adults (p < 0.001). Comorbidity factors, particularly creatinine (10 of 22 models), BMI (8 models), and HbA1c (7 models), consistently mediated biomarker differences. SDOH factors demonstrated mediation for Aβ42/40, p-tau181, and NfL, with area deprivation and education as key mediators.
CONCLUSIONS: SDOH and comorbidities were associated with plasma AD biomarker differences observed across ethno-racial groups, though their influence varies by biomarker type and comparison group. Renal function (creatinine), metabolic factors (BMI, HbA1c), and structural disadvantages (area deprivation, education) emerged as critical factors. However, many effects remain unexplained, suggesting additional biological, environmental, or unmeasured social factors contribute to disparities. These findings highlight the need for precision medicine approaches that integrate biological, systemic health, and social contexts when interpreting biomarkers and guiding dementia prevention.
Additional Links: PMID-43046233
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046233,
year = {2026},
author = {Meeker, KL and Wisch, JK and Petersen, ME and Hall, J and Babulal, GM and Yaffe, K and Rissman, RA and Cohen, AD and O'Bryant, SE and Ances, BM and , },
title = {Sociodemographic and comorbidity factors mediate ethno-racial differences in plasma Alzheimer's disease biomarkers.},
journal = {Alzheimer's research & therapy},
volume = {18},
number = {1},
pages = {},
pmid = {43046233},
issn = {1758-9193},
support = {K01 AG083115/AG/NIA NIH HHS/United States ; R01 AG054073/AG/NIA NIH HHS/United States ; K01AG083115/AG/NIA NIH HHS/United States ; R01AG054073/AG/NIA NIH HHS/United States ; },
mesh = {Humans ; *Alzheimer Disease/blood/ethnology/epidemiology ; Male ; Female ; Biomarkers/blood ; Aged ; White People ; Amyloid beta-Peptides/blood ; tau Proteins/blood ; Hispanic or Latino ; Black or African American ; Comorbidity ; Aged, 80 and over ; Socioeconomic Disparities in Health ; Social Determinants of Health ; White ; Socioeconomic Factors ; },
abstract = {BACKGROUND: Ethno-racial disparities in Alzheimer's disease (AD) risk are well-documented, yet mechanisms underlying these differences remain poorly understood. This study investigates plasma AD biomarkers reflective of amyloid, tau, neurodegeneration, and inflammation across Hispanic, non-Hispanic Black/ African American, and non-Hispanic White adults, and examines whether social determinants of health (SDOH) and comorbidities mediate observed disparities.
METHODS: Data from the community-based Health and Aging Brain Study - Health Disparities (HABS-HD) included 1,256 Hispanic, 723 Black, and 1,243 non-Hispanic White participants. Group differences in plasma biomarkers (phosphorylated tau-217 [p-tau217], amyloid-β 42/40 ratio [Aβ42/40], phosphorylated tau-181 [p-tau181], total tau, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) were assessed using ANCOVA adjusted for age, sex, APOE-ε4 status, and cognitive status. Multiple mediation models tested whether social determinants of health (income, education, area deprivation, chronic stress, social support) and comorbidity factors (BMI, creatinine, total cholesterol, HbA1c, systolic blood pressure) mediate group differences, with covariates and mediators considered simultaneously, resulting in 22 mediation models.
RESULTS: Significant differences were observed across all plasma biomarkers. Both Black and Hispanic adults showed lower p-tau217 and p-tau181 compared to non-Hispanic White adults (p's < 0.001). Hispanic adults exhibited lower Aβ42/40 compared to both groups (p's < 0.05) and lower GFAP compared to non-Hispanic White adults (p = 0.002), but higher total tau (p's < 0.01) compared to both groups. Hispanics had higher NfL than Black adults (p < 0.001) but did not differ from non-Hispanic Whites, while Black adults had lower NfL than non-Hispanic White adults (p < 0.001). Comorbidity factors, particularly creatinine (10 of 22 models), BMI (8 models), and HbA1c (7 models), consistently mediated biomarker differences. SDOH factors demonstrated mediation for Aβ42/40, p-tau181, and NfL, with area deprivation and education as key mediators.
CONCLUSIONS: SDOH and comorbidities were associated with plasma AD biomarker differences observed across ethno-racial groups, though their influence varies by biomarker type and comparison group. Renal function (creatinine), metabolic factors (BMI, HbA1c), and structural disadvantages (area deprivation, education) emerged as critical factors. However, many effects remain unexplained, suggesting additional biological, environmental, or unmeasured social factors contribute to disparities. These findings highlight the need for precision medicine approaches that integrate biological, systemic health, and social contexts when interpreting biomarkers and guiding dementia prevention.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/blood/ethnology/epidemiology
Male
Female
Biomarkers/blood
Aged
White People
Amyloid beta-Peptides/blood
tau Proteins/blood
Hispanic or Latino
Black or African American
Comorbidity
Aged, 80 and over
Socioeconomic Disparities in Health
Social Determinants of Health
White
Socioeconomic Factors
RevDate: 2026-11-17
CmpDate: 2026-11-18
Furin deficiency in excitatory neurons leads to cognitive dysfunction and glutamatergic synaptic impairment.
Alzheimer's research & therapy, 18(1):.
BACKGROUND: Furin, a pivotal member of the proprotein convertase family, exhibits markedly diminished expression in both Alzheimer's disease (AD) patients and animal models. However, the precise mechanisms by which furin regulates AD-associated cognitive impairment have yet to be fully elucidated.
METHODS: In the present study, we generated excitatory neuron-specific Furin conditional knockout (Furin cKO) mice to investigate the effects and underlying mechanisms of furin deficiency on cognitive decline. We further overexpressed furin in excitatory neurons of 5×FAD transgenic AD model mice to explore the neuroprotective capacity of furin.
RESULTS: Compared with control littermates, Furin cKO mice displayed significant impairments in spatial memory alongside elevated anxiety-like behaviors, hippocampal atrophy, and blunted hippocampal long-term potentiation (LTP). Mechanistic analyses further revealed that these neurobehavioral and electrophysiological deficits stemmed from marked reductions in dendritic arbor complexity, spine density, and glutamatergic receptor expression throughout the hippocampus and cerebral cortex of Furin cKO mice. Conversely, neuron-specific overexpression of furin in excitatory neurons of 5×FAD transgenic mice exerted promising rescue effects on the cognitive deficits of this AD model. This functional restoration was accompanied by recovered dendritic and synaptic abundance, alleviated Aβ plaque deposition, and reduced reactive glial activation.
CONCLUSIONS: These data demonstrate that furin expression in excitatory neurons is critical for maintaining intact synaptic plasticity and normal cognitive function. Moreover, our findings indicate that furin likely serves as a promising therapeutic candidate for alleviating pathological progression in AD and other associated neurodegenerative disorders.
Additional Links: PMID-43046245
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046245,
year = {2026},
author = {Tian, S and Zhao, G and Zhang, Y and Yang, D and Zhang, X and Chang, YZ and Gao, G},
title = {Furin deficiency in excitatory neurons leads to cognitive dysfunction and glutamatergic synaptic impairment.},
journal = {Alzheimer's research & therapy},
volume = {18},
number = {1},
pages = {},
pmid = {43046245},
issn = {1758-9193},
support = {32170979//National Natural Science Foundation of China/ ; C2023205024//Natural Science Foundation of Hebei Province/ ; },
mesh = {Animals ; *Furin/deficiency/genetics/metabolism ; Mice, Transgenic ; *Neurons/metabolism/pathology ; Mice, Knockout ; *Cognitive Dysfunction/metabolism/pathology/genetics ; *Synapses/pathology/metabolism ; Hippocampus/pathology/metabolism ; Mice ; Disease Models, Animal ; Alzheimer Disease/pathology/metabolism/genetics ; Long-Term Potentiation/physiology ; Male ; Cerebral Cortex/pathology/metabolism ; },
abstract = {BACKGROUND: Furin, a pivotal member of the proprotein convertase family, exhibits markedly diminished expression in both Alzheimer's disease (AD) patients and animal models. However, the precise mechanisms by which furin regulates AD-associated cognitive impairment have yet to be fully elucidated.
METHODS: In the present study, we generated excitatory neuron-specific Furin conditional knockout (Furin cKO) mice to investigate the effects and underlying mechanisms of furin deficiency on cognitive decline. We further overexpressed furin in excitatory neurons of 5×FAD transgenic AD model mice to explore the neuroprotective capacity of furin.
RESULTS: Compared with control littermates, Furin cKO mice displayed significant impairments in spatial memory alongside elevated anxiety-like behaviors, hippocampal atrophy, and blunted hippocampal long-term potentiation (LTP). Mechanistic analyses further revealed that these neurobehavioral and electrophysiological deficits stemmed from marked reductions in dendritic arbor complexity, spine density, and glutamatergic receptor expression throughout the hippocampus and cerebral cortex of Furin cKO mice. Conversely, neuron-specific overexpression of furin in excitatory neurons of 5×FAD transgenic mice exerted promising rescue effects on the cognitive deficits of this AD model. This functional restoration was accompanied by recovered dendritic and synaptic abundance, alleviated Aβ plaque deposition, and reduced reactive glial activation.
CONCLUSIONS: These data demonstrate that furin expression in excitatory neurons is critical for maintaining intact synaptic plasticity and normal cognitive function. Moreover, our findings indicate that furin likely serves as a promising therapeutic candidate for alleviating pathological progression in AD and other associated neurodegenerative disorders.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Furin/deficiency/genetics/metabolism
Mice, Transgenic
*Neurons/metabolism/pathology
Mice, Knockout
*Cognitive Dysfunction/metabolism/pathology/genetics
*Synapses/pathology/metabolism
Hippocampus/pathology/metabolism
Mice
Disease Models, Animal
Alzheimer Disease/pathology/metabolism/genetics
Long-Term Potentiation/physiology
Male
Cerebral Cortex/pathology/metabolism
RevDate: 2026-11-18
CmpDate: 2026-11-18
Increases in a pivotal bioactive peptide in specific brain regions reflect the progression of pathology in Alzheimer's disease.
Alzheimer's research & therapy, 18(1):.
BACKGROUND: Abnormal activation of a developmental process driven by a bioactive peptide T14, is posited as a key mechanism in the degeneration of the primarily vulnerable nuclei during the prodromal phase of Alzheimer's Disease (AD).
METHODS: We use a range of anatomical, biochemical and genetic approaches to explore changes in T14 and its target, α7nAChR, in AD and in individuals with mood disorders, a frequent prelude to the disease.
RESULTS: Using paired samples from the same patients, levels of T14 and α7nAChR increased in the hippocampus across the AD continuum. In contrast, in early Braak stages, T14 levels in the midbrain reach a plateau and are primarily localised to glia. Moreover, in a cognitively healthy cohort, CSF derived ex vivo revealed a differential profile between T14 and tau levels in individuals with mood disorders, a well-known precursor to AD. These observations confirm a key role of T14 in the neuropathology of AD. Finally, we show a Braak-stage dependant and selective increase in an acetylcholinesterase isoform (AChE-R) already associated with AD pathology, where the profile corresponds closely to that of T14, thereby providing further clues regarding its provenance.
CONCLUSION: By highlighting region and cell-specific changes in the T14 profile as AD progresses, this study further validates a key role for T14 in the progression of neurodegeneration. Finally, the mood disorder-dependent changes based on T14 in CSF might reflect dysfunction in the primarily vulnerable isodendritic core and as such be viewed as a possible, albeit non-exclusive, prelude to AD. Collectively, these results underscore the importance of T14 in AD aetiology and could aid the development of precise and effective therapeutics to target its progression.
Additional Links: PMID-43046249
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046249,
year = {2026},
author = {Komorowska, J and Ranglani, S and McCann, H and Shepherd, CE and Bratslavsky, M and Seymour, T and Hasan, S and Oke, JL and Garcia-Rates, S and Greenfield, SA},
title = {Increases in a pivotal bioactive peptide in specific brain regions reflect the progression of pathology in Alzheimer's disease.},
journal = {Alzheimer's research & therapy},
volume = {18},
number = {1},
pages = {},
pmid = {43046249},
issn = {1758-9193},
mesh = {Humans ; *Alzheimer Disease/pathology/metabolism/genetics/cerebrospinal fluid ; Disease Progression ; tau Proteins/metabolism/cerebrospinal fluid ; Male ; Female ; *Brain/metabolism/pathology ; Aged ; Aged, 80 and over ; Mood Disorders/pathology/metabolism ; Acetylcholinesterase/metabolism ; },
abstract = {BACKGROUND: Abnormal activation of a developmental process driven by a bioactive peptide T14, is posited as a key mechanism in the degeneration of the primarily vulnerable nuclei during the prodromal phase of Alzheimer's Disease (AD).
METHODS: We use a range of anatomical, biochemical and genetic approaches to explore changes in T14 and its target, α7nAChR, in AD and in individuals with mood disorders, a frequent prelude to the disease.
RESULTS: Using paired samples from the same patients, levels of T14 and α7nAChR increased in the hippocampus across the AD continuum. In contrast, in early Braak stages, T14 levels in the midbrain reach a plateau and are primarily localised to glia. Moreover, in a cognitively healthy cohort, CSF derived ex vivo revealed a differential profile between T14 and tau levels in individuals with mood disorders, a well-known precursor to AD. These observations confirm a key role of T14 in the neuropathology of AD. Finally, we show a Braak-stage dependant and selective increase in an acetylcholinesterase isoform (AChE-R) already associated with AD pathology, where the profile corresponds closely to that of T14, thereby providing further clues regarding its provenance.
CONCLUSION: By highlighting region and cell-specific changes in the T14 profile as AD progresses, this study further validates a key role for T14 in the progression of neurodegeneration. Finally, the mood disorder-dependent changes based on T14 in CSF might reflect dysfunction in the primarily vulnerable isodendritic core and as such be viewed as a possible, albeit non-exclusive, prelude to AD. Collectively, these results underscore the importance of T14 in AD aetiology and could aid the development of precise and effective therapeutics to target its progression.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/pathology/metabolism/genetics/cerebrospinal fluid
Disease Progression
tau Proteins/metabolism/cerebrospinal fluid
Male
Female
*Brain/metabolism/pathology
Aged
Aged, 80 and over
Mood Disorders/pathology/metabolism
Acetylcholinesterase/metabolism
RevDate: 2026-11-18
CmpDate: 2026-11-18
When minimal assistance is not enough: A transitional approach for critical errors of older adults during instrumental activities of daily living: A mixed-methods study.
Australian occupational therapy journal, 73(6):.
INTRODUCTION: Older adults often experience neurocognitive challenges that threaten their independence. Instrumental activities of daily living (IADLs) are vital indicators of home safety, as even a single critical error, such as task failure, can affect the ability to live independently. A clearer understanding of which errors are critical and how verbal cognitive assistance from clinicians or caregivers can reduce such errors is needed.
OBJECTIVES: This study aims to (1) describe the critical errors committed by older adults from the continuum of cognitive functioning during multiple IADLs; (2) identify the types of verbal cognitive assistance provided to address these errors and facilitate independence and security; and (3) identify the transition points at which occupational therapists shift to more direct assistance.
METHODS: We analysed video-recorded IADL assessments of 40 older adults at home, 19 of whom had a formal diagnosis of Alzheimer's disease or mild cognitive impairment and 21 of whom had no official diagnosis (NOD). Standardised assessments based on ecological observations of four IADL tasks were used. Videos were transcribed to capture all errors and assistance provided. Deductive qualitative and descriptive statistical analyses (mean, proportion, etc.) were used to identify the main difficulties and assistance types.
None RESULTS: Twenty-eight participants, including 11 with NOD, made at least one critical error (e.g., turning the stove to high before cooking, crossing a road without looking); 19 made more than two, including four with NOD. Thirty-one participants received verbal assistance at least once, and 22 received assistance multiple times (six with NOD). Thirteen participants, including six with NOD, reached a transition point requiring maximal compensatory intervention.
CONCLUSION: Identifying and understanding critical errors highlights moments of vulnerability in daily life. Tailored verbal cognitive assistance helps manage these situations, enabling continued engagement, autonomy, and support for ageing in place even amid cognitive decline.
Additional Links: PMID-43046576
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046576,
year = {2026},
author = {Yaddaden, A and Bier, N and Pelletier, J and Lussier, M and Couture, M and Giroux, S and Bottari, C},
title = {When minimal assistance is not enough: A transitional approach for critical errors of older adults during instrumental activities of daily living: A mixed-methods study.},
journal = {Australian occupational therapy journal},
volume = {73},
number = {6},
pages = {},
pmid = {43046576},
issn = {1440-1630},
support = {/ALZ/Alzheimer's Association/United States ; AARG-18-561,893//Alzheimer's Association and Brain Canada Foundation/ ; 313739//Fonds de Recherche du Québec - Santé/ ; },
mesh = {Humans ; *Activities of Daily Living/psychology ; Aged ; Female ; Male ; Aged, 80 and over ; *Cognitive Dysfunction/rehabilitation ; *Alzheimer Disease/rehabilitation ; *Occupational Therapy/methods ; Independent Living ; Aging in Place ; Video Recording ; Cognition ; },
abstract = {INTRODUCTION: Older adults often experience neurocognitive challenges that threaten their independence. Instrumental activities of daily living (IADLs) are vital indicators of home safety, as even a single critical error, such as task failure, can affect the ability to live independently. A clearer understanding of which errors are critical and how verbal cognitive assistance from clinicians or caregivers can reduce such errors is needed.
OBJECTIVES: This study aims to (1) describe the critical errors committed by older adults from the continuum of cognitive functioning during multiple IADLs; (2) identify the types of verbal cognitive assistance provided to address these errors and facilitate independence and security; and (3) identify the transition points at which occupational therapists shift to more direct assistance.
METHODS: We analysed video-recorded IADL assessments of 40 older adults at home, 19 of whom had a formal diagnosis of Alzheimer's disease or mild cognitive impairment and 21 of whom had no official diagnosis (NOD). Standardised assessments based on ecological observations of four IADL tasks were used. Videos were transcribed to capture all errors and assistance provided. Deductive qualitative and descriptive statistical analyses (mean, proportion, etc.) were used to identify the main difficulties and assistance types.
None RESULTS: Twenty-eight participants, including 11 with NOD, made at least one critical error (e.g., turning the stove to high before cooking, crossing a road without looking); 19 made more than two, including four with NOD. Thirty-one participants received verbal assistance at least once, and 22 received assistance multiple times (six with NOD). Thirteen participants, including six with NOD, reached a transition point requiring maximal compensatory intervention.
CONCLUSION: Identifying and understanding critical errors highlights moments of vulnerability in daily life. Tailored verbal cognitive assistance helps manage these situations, enabling continued engagement, autonomy, and support for ageing in place even amid cognitive decline.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Activities of Daily Living/psychology
Aged
Female
Male
Aged, 80 and over
*Cognitive Dysfunction/rehabilitation
*Alzheimer Disease/rehabilitation
*Occupational Therapy/methods
Independent Living
Aging in Place
Video Recording
Cognition
RevDate: 2026-11-18
CmpDate: 2026-11-18
Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi-modal investigation of memory performance in US POINTER.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: The apolipoprotein E (APOE) ε4 allele is a key genetic risk factor for Alzheimer's disease (AD), but the etiology of impairment in non-carriers is less understood.
METHODS: We used regression and mediation models to test the cross-sectional relationships among APOE genotype, positron emission tomography amyloid and tau, vascular risk factors, and episodic memory within the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ancillary imaging dataset of non-demented older adults.
RESULTS: In our cohort (N = 880), APOE ε4 carriers showed higher global amyloid, higher meta-temporal tau, smaller hippocampal volume, poorer memory, and a stronger relationship between amyloid and tau standardized uptake value ratio (SUVR; ∆β = 0.22, p < 0.001). Tau predicted memory (p < 0.01) and partially mediated the APOE-memory association. In a stratified analysis, higher Framingham Heart Study risk score (FHS; p = 0.022) and not tau SUVR (p = 0.1) were associated with memory among APOE ε4 non-carriers, whereas tau SUVR (p = 0.048) but not FHS risk score (p = 0.55) was associated with memory amongst APOE ε4 carriers.
DISCUSSION: Drivers of cognitive performance appear to be specific to APOE ε4 carrier status, emphasizing the need to identify alternative, or contributing, disease mechanisms among non-carriers.
HIGHLIGHTS: The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is composed of older adults at elevated risk of cognitive decline and cardiovascular disease burden. Further multimodal neuroimaging data was collected through the POINTER Imaging ancillary study. At baseline evaluation, the apolipoprotein E (APOE) ε4 genotype was significantly associated with amyloid and tau pathology, hippocampal atrophy, and poor episodic memory performance. APOE ε4 genotype stratification analysis showed significant associations of Framingham cardiovascular risk score and smoking status with memory in non-carriers only. Etiological pathways of dementia may differ in contributive strength to cognitive deterioration within this at-risk cohort.
Additional Links: PMID-43046580
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046580,
year = {2026},
author = {Min, E and Harrison, TM and Landau, SM and Vemuri, P and Snyder, H and Carrillo, MC and Baker, L and Espeland, MA and Maillard, P and Whitmer, RA and DeCarli, C},
title = {Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi-modal investigation of memory performance in US POINTER.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43046580},
issn = {1552-5279},
support = {R01 AG062689/AG/NIA NIH HHS/United States ; P30 AG072972/AG/NIA NIH HHS/United States ; POINTER-19-611541/ALZ/Alzheimer's Association/United States ; },
mesh = {Humans ; Female ; Positron-Emission Tomography ; Magnetic Resonance Imaging ; Male ; Aged ; *Apolipoprotein E4/genetics ; Genotype ; *Brain/diagnostic imaging/pathology ; tau Proteins/metabolism ; Cross-Sectional Studies ; Biomarkers ; Memory, Episodic ; United States ; *Apolipoproteins E/genetics ; Risk Factors ; *Memory/physiology ; Neuropsychological Tests ; Heterozygote ; },
abstract = {INTRODUCTION: The apolipoprotein E (APOE) ε4 allele is a key genetic risk factor for Alzheimer's disease (AD), but the etiology of impairment in non-carriers is less understood.
METHODS: We used regression and mediation models to test the cross-sectional relationships among APOE genotype, positron emission tomography amyloid and tau, vascular risk factors, and episodic memory within the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ancillary imaging dataset of non-demented older adults.
RESULTS: In our cohort (N = 880), APOE ε4 carriers showed higher global amyloid, higher meta-temporal tau, smaller hippocampal volume, poorer memory, and a stronger relationship between amyloid and tau standardized uptake value ratio (SUVR; ∆β = 0.22, p < 0.001). Tau predicted memory (p < 0.01) and partially mediated the APOE-memory association. In a stratified analysis, higher Framingham Heart Study risk score (FHS; p = 0.022) and not tau SUVR (p = 0.1) were associated with memory among APOE ε4 non-carriers, whereas tau SUVR (p = 0.048) but not FHS risk score (p = 0.55) was associated with memory amongst APOE ε4 carriers.
DISCUSSION: Drivers of cognitive performance appear to be specific to APOE ε4 carrier status, emphasizing the need to identify alternative, or contributing, disease mechanisms among non-carriers.
HIGHLIGHTS: The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is composed of older adults at elevated risk of cognitive decline and cardiovascular disease burden. Further multimodal neuroimaging data was collected through the POINTER Imaging ancillary study. At baseline evaluation, the apolipoprotein E (APOE) ε4 genotype was significantly associated with amyloid and tau pathology, hippocampal atrophy, and poor episodic memory performance. APOE ε4 genotype stratification analysis showed significant associations of Framingham cardiovascular risk score and smoking status with memory in non-carriers only. Etiological pathways of dementia may differ in contributive strength to cognitive deterioration within this at-risk cohort.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Positron-Emission Tomography
Magnetic Resonance Imaging
Male
Aged
*Apolipoprotein E4/genetics
Genotype
*Brain/diagnostic imaging/pathology
tau Proteins/metabolism
Cross-Sectional Studies
Biomarkers
Memory, Episodic
United States
*Apolipoproteins E/genetics
Risk Factors
*Memory/physiology
Neuropsychological Tests
Heterozygote
RevDate: 2026-11-18
CmpDate: 2026-11-18
Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratory.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Expanding access to Alzheimer's disease (AD) blood biomarker testing through capillary collection beyond clinic-based venipuncture could enable earlier biological triage, specialist referral, and timelier initiation of disease-modifying therapies. Prior attempts to measure phosphorylated tau at amino acid 217 (p-tau217) in capillary blood have not achieved the diagnostic accuracy required for triaging.
METHODS: This was a cross-sectional diagnostic validation study (January 2025-April 2026) across six US sites. Adults aged ≥ 50 years with cognitive concerns were recruited, including a community-based sample (N = 180) and specialty memory/research clinic sample with available amyloid positron emission tomography (PET; N = 64; total N = 244). Same-day paired capillary (Tasso upper-arm device) and venous samples were shipped ambient overnight and processed at a Clinical Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP)-certified laboratory via proprietary capillary-to-assay workflow. Samples were measured using the BD-pTau217 singleplex assay on the NULISA platform.
RESULTS: Among 244 participants (mean age 64.3 [standard deviation 11.9] years; 153 female [62.7%]; 51 Black [20.9%]), capillary and venous brain-derived p-tau217 (BD-p-tau217) correlated (R = 0.93, ρ = 0.73; both P < 0.001), with concentration-dependent bias on Bland-Altman analysis. In the PET-confirmed cohort (N = 64), capillary BD-p-tau217 yielded area under the curve (AUC) 0.959 (95.7% sensitivity, 83.3% specificity; positive predictive value [PPV] 93.6%, negative predictive value [NPV] 88.2%), meeting Global CEO Initiative on Alzheimer's Disease (CEOi) low-specificity and Alzheimer's Association guideline triage thresholds. Across the full cohort at 26% amyloid prevalence, against a composite reference standard, AUC was 0.959 (90.5% sensitivity, 89.0% specificity; PPV 74.0%, NPV 96.4%), meeting CEOi high-specificity triage thresholds.
DISCUSSION: Capillary BD-p-tau217 met clinical performance standards for remote AD triage, to our knowledge the first capillary p-tau217 test to meet these standards, suggesting it may support triage of patients for further diagnostic evaluation, including specialist referral and confirmatory testing.
Additional Links: PMID-43046597
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046597,
year = {2026},
author = {Thijssen, EH and Eghzawi, A and Gibellini, F and Ashton, NJ and Verberk, IMW and Khwaja, S and Chandramohan, L and Higgins, V and Alnachef, I and Mallick, Z and Barakat, M and Mielke, MM and Leahy, C and Bahk, K and Aburashed, R},
title = {Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratory.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43046597},
issn = {1552-5279},
support = {P30AG072947/AG/NIA NIH HHS/United States ; },
mesh = {Humans ; *Alzheimer Disease/diagnosis/pathology/blood ; *tau Proteins/blood/metabolism ; Female ; Male ; Cross-Sectional Studies ; Biomarkers/blood ; Aged ; Positron-Emission Tomography ; *Brain/metabolism ; Middle Aged ; Phosphorylation ; Capillaries ; *Triage ; Sensitivity and Specificity ; },
abstract = {INTRODUCTION: Expanding access to Alzheimer's disease (AD) blood biomarker testing through capillary collection beyond clinic-based venipuncture could enable earlier biological triage, specialist referral, and timelier initiation of disease-modifying therapies. Prior attempts to measure phosphorylated tau at amino acid 217 (p-tau217) in capillary blood have not achieved the diagnostic accuracy required for triaging.
METHODS: This was a cross-sectional diagnostic validation study (January 2025-April 2026) across six US sites. Adults aged ≥ 50 years with cognitive concerns were recruited, including a community-based sample (N = 180) and specialty memory/research clinic sample with available amyloid positron emission tomography (PET; N = 64; total N = 244). Same-day paired capillary (Tasso upper-arm device) and venous samples were shipped ambient overnight and processed at a Clinical Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP)-certified laboratory via proprietary capillary-to-assay workflow. Samples were measured using the BD-pTau217 singleplex assay on the NULISA platform.
RESULTS: Among 244 participants (mean age 64.3 [standard deviation 11.9] years; 153 female [62.7%]; 51 Black [20.9%]), capillary and venous brain-derived p-tau217 (BD-p-tau217) correlated (R = 0.93, ρ = 0.73; both P < 0.001), with concentration-dependent bias on Bland-Altman analysis. In the PET-confirmed cohort (N = 64), capillary BD-p-tau217 yielded area under the curve (AUC) 0.959 (95.7% sensitivity, 83.3% specificity; positive predictive value [PPV] 93.6%, negative predictive value [NPV] 88.2%), meeting Global CEO Initiative on Alzheimer's Disease (CEOi) low-specificity and Alzheimer's Association guideline triage thresholds. Across the full cohort at 26% amyloid prevalence, against a composite reference standard, AUC was 0.959 (90.5% sensitivity, 89.0% specificity; PPV 74.0%, NPV 96.4%), meeting CEOi high-specificity triage thresholds.
DISCUSSION: Capillary BD-p-tau217 met clinical performance standards for remote AD triage, to our knowledge the first capillary p-tau217 test to meet these standards, suggesting it may support triage of patients for further diagnostic evaluation, including specialist referral and confirmatory testing.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/diagnosis/pathology/blood
*tau Proteins/blood/metabolism
Female
Male
Cross-Sectional Studies
Biomarkers/blood
Aged
Positron-Emission Tomography
*Brain/metabolism
Middle Aged
Phosphorylation
Capillaries
*Triage
Sensitivity and Specificity
RevDate: 2026-11-18
CmpDate: 2026-11-18
Sleep-cognition associations change direction with proximity to dementia diagnosis.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Differentiating aspects of sleep health that are modifiable risk factors from prodromal symptoms or consequences of dementia can inform dementia prevention and/or clinical screening efforts, and temporal mapping of sleep-cognition associations can further inform mechanistic hypotheses regarding the role of sleep leading up to dementia diagnosis. We examined bidirectional associations between cognitive function and three modifiable sleep health features, and whether these associations vary by proximity to dementia diagnosis.
METHODS: 291 preclinical dementia participants (median initial age = 83 years, 73% female) and 281 matched cognitively unimpaired 'controls' from the Rush Memory and Aging Project completed up to 11 annual assessments of global cognition (composite of 19 neuropsychological measures) and actigraphy-derived measures of sleep amount, regularity, and timing. Linear mixed-effects models tested whether bidirectional sleep-cognition relationships differed by years-to-dementia diagnosis (preclinical dementia sample) or years-to-last follow-up (matched controls) after adjusting for sociodemographic and health covariates.
RESULTS: In the preclinical dementia sample, time-to-dementia modified the effects of sleep amount (both β = 0.02) and regularity (-0.04 < β < 0.02), but not timing, on next-year global cognition. Ten years before dementia diagnosis, longer and more irregular sleep predicted better next-year cognition; 1 year before diagnosis, these sleep patterns predicted worse next-year cognition. While sleep amount unidirectionally predicted subsequent cognition, sleep regularity-cognition associations were consistently bidirectional. These patterns were not observed in matched controls.
DISCUSSION: Changes in sleep-cognition associations over time may differentiate preclinical dementia from normal aging. Future research should investigate the driving mechanisms and modifiability of these sleep-cognition associations.
Additional Links: PMID-43046601
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046601,
year = {2026},
author = {Zaheed, AB and Oryshkewych, N and Yu, L and Buysse, DJ and Butters, MA and Hoepel, SJW and Barnes, LL and Lim, A and Wallace, ML},
title = {Sleep-cognition associations change direction with proximity to dementia diagnosis.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43046601},
issn = {1552-5279},
support = {RF1AG056331/AG/NIA NIH HHS/United States ; TL1TR001858/TR/NCATS NIH HHS/United States ; T32HL082610/HL/NHLBI NIH HHS/United States ; },
mesh = {Humans ; Female ; *Dementia/diagnosis/physiopathology ; *Sleep/physiology ; Male ; Aged, 80 and over ; Aged ; Actigraphy ; *Cognition/physiology ; Neuropsychological Tests/statistics & numerical data ; Sleep Duration ; Risk Factors ; },
abstract = {INTRODUCTION: Differentiating aspects of sleep health that are modifiable risk factors from prodromal symptoms or consequences of dementia can inform dementia prevention and/or clinical screening efforts, and temporal mapping of sleep-cognition associations can further inform mechanistic hypotheses regarding the role of sleep leading up to dementia diagnosis. We examined bidirectional associations between cognitive function and three modifiable sleep health features, and whether these associations vary by proximity to dementia diagnosis.
METHODS: 291 preclinical dementia participants (median initial age = 83 years, 73% female) and 281 matched cognitively unimpaired 'controls' from the Rush Memory and Aging Project completed up to 11 annual assessments of global cognition (composite of 19 neuropsychological measures) and actigraphy-derived measures of sleep amount, regularity, and timing. Linear mixed-effects models tested whether bidirectional sleep-cognition relationships differed by years-to-dementia diagnosis (preclinical dementia sample) or years-to-last follow-up (matched controls) after adjusting for sociodemographic and health covariates.
RESULTS: In the preclinical dementia sample, time-to-dementia modified the effects of sleep amount (both β = 0.02) and regularity (-0.04 < β < 0.02), but not timing, on next-year global cognition. Ten years before dementia diagnosis, longer and more irregular sleep predicted better next-year cognition; 1 year before diagnosis, these sleep patterns predicted worse next-year cognition. While sleep amount unidirectionally predicted subsequent cognition, sleep regularity-cognition associations were consistently bidirectional. These patterns were not observed in matched controls.
DISCUSSION: Changes in sleep-cognition associations over time may differentiate preclinical dementia from normal aging. Future research should investigate the driving mechanisms and modifiability of these sleep-cognition associations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
*Dementia/diagnosis/physiopathology
*Sleep/physiology
Male
Aged, 80 and over
Aged
Actigraphy
*Cognition/physiology
Neuropsychological Tests/statistics & numerical data
Sleep Duration
Risk Factors
RevDate: 2026-11-18
CmpDate: 2026-11-18
Network architecture of sleep, biomarkers, and cognition: Rapid eye movement sleep latency as a cross-domain connector.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Sleep disturbances are linked to Alzheimer's disease (AD) and related dementias (ADRD) pathology and cognitive decline, but how sleep architecture, biomarkers, and cognition are organized within a conditional dependence framework remains unclear.
METHODS: We studied 98 adults spanning normal cognition (NC; n = 21), mild cognitive impairment (MCI; n = 34), and clinically diagnosed AD dementia (n = 43) using overnight polysomnography, plasma phosphorylated tau181 (p-tau181), neurofilament light chain (NfL), brain-derived neurotrophic factor (BDNF), amyloid-β positron emission tomography (PET), and multidomain cognitive testing. A regularized Gaussian graphical model was used to characterize conditional associations and identify cross-domain connectivity among sleep, biomarkers, and cognition.
RESULTS: The 17-variable network contained 26 edges, with significantly denser within-domain than cross-domain connectivity (40.5% vs 9.6%; p < 0.001). Direct sleep-cognition connections were sparse. Rapid eye movement (REM) sleep latency had the highest bridge strength (0.387), directly connecting the sleep domain with NfL, amyloid-β PET, and BDNF. Plasma p-tau181 was the only biomarker directly connected to global cognition. Exploratory mediation analyses were consistent with indirect associations involving p-tau181 in three of five cognitive domains.
DISCUSSION: Sleep architecture and cognition were conditionally linked primarily through biomarker nodes. REM sleep latency and plasma p-tau181 may represent key cross-domain connectors linking sleep architecture, neurodegeneration, and cognition across the AD continuum.
Additional Links: PMID-43046619
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046619,
year = {2026},
author = {Chen, J and Reheman, P and Jin, J and Chen, H and Zhou, X and Gao, S and Peng, D and Leng, Y},
title = {Network architecture of sleep, biomarkers, and cognition: Rapid eye movement sleep latency as a cross-domain connector.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43046619},
issn = {1552-5279},
support = {2021ZD0201900//the Ministry of Science and Technology of the People's Republic of China/ ; 2021ZD0201902//the Ministry of Science and Technology of the People's Republic of China/ ; 2020ZD10//the National Health Commission's Key Project on Geriatric Health/ ; },
mesh = {Humans ; Biomarkers/blood ; Female ; *Alzheimer Disease/physiopathology ; Polysomnography ; Male ; *Cognition/physiology ; Aged ; *Cognitive Dysfunction/physiopathology ; Positron-Emission Tomography ; *Sleep, REM/physiology ; Amyloid beta-Peptides/metabolism ; tau Proteins/blood ; Brain-Derived Neurotrophic Factor/blood ; Middle Aged ; Brain/diagnostic imaging ; Neuropsychological Tests ; },
abstract = {INTRODUCTION: Sleep disturbances are linked to Alzheimer's disease (AD) and related dementias (ADRD) pathology and cognitive decline, but how sleep architecture, biomarkers, and cognition are organized within a conditional dependence framework remains unclear.
METHODS: We studied 98 adults spanning normal cognition (NC; n = 21), mild cognitive impairment (MCI; n = 34), and clinically diagnosed AD dementia (n = 43) using overnight polysomnography, plasma phosphorylated tau181 (p-tau181), neurofilament light chain (NfL), brain-derived neurotrophic factor (BDNF), amyloid-β positron emission tomography (PET), and multidomain cognitive testing. A regularized Gaussian graphical model was used to characterize conditional associations and identify cross-domain connectivity among sleep, biomarkers, and cognition.
RESULTS: The 17-variable network contained 26 edges, with significantly denser within-domain than cross-domain connectivity (40.5% vs 9.6%; p < 0.001). Direct sleep-cognition connections were sparse. Rapid eye movement (REM) sleep latency had the highest bridge strength (0.387), directly connecting the sleep domain with NfL, amyloid-β PET, and BDNF. Plasma p-tau181 was the only biomarker directly connected to global cognition. Exploratory mediation analyses were consistent with indirect associations involving p-tau181 in three of five cognitive domains.
DISCUSSION: Sleep architecture and cognition were conditionally linked primarily through biomarker nodes. REM sleep latency and plasma p-tau181 may represent key cross-domain connectors linking sleep architecture, neurodegeneration, and cognition across the AD continuum.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Biomarkers/blood
Female
*Alzheimer Disease/physiopathology
Polysomnography
Male
*Cognition/physiology
Aged
*Cognitive Dysfunction/physiopathology
Positron-Emission Tomography
*Sleep, REM/physiology
Amyloid beta-Peptides/metabolism
tau Proteins/blood
Brain-Derived Neurotrophic Factor/blood
Middle Aged
Brain/diagnostic imaging
Neuropsychological Tests
RevDate: 2026-11-18
CmpDate: 2026-11-18
Pericyte PDGFR-β deficiency contributes to Aβ pathology through impaired glymphatic transport and altered AQP-4 localization.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Pericyte platelet-derived growth factor receptor-β (PDGFR-β) signaling maintains neurovascular integrity, but its role in glymphatic function is unknown. We investigated whether pericyte PDGFR-β deficiency is associated with glymphatic dysfunction and altered aquaporin-4 (AQP-4) localization in Alzheimer's disease (AD).
METHODS: Glymphatic trafficking was assessed by fluorescent cerebrospinal fluid (CSF) tracer injection. Meningeal lymphatic drainage was blocked by deep cervical lymph node (dcLN) ligation. Pericyte coverage, AQP-4 expression/localization, and basement membrane components were analyzed by immunofluorescence and western blot. Pericyte-conditioned medium was used to examine the effects of pericyte-derived factors on astrocytic AQP-4. The AQP-4 facilitator TGN-073 was administered to assess functional rescue. Blood-brain barrier integrity, microvascular density, and cerebral blood flow were also evaluated.
RESULTS: DcLN ligation impaired amyloid beta clearance and spatial memory. Both APP/PS1 and Pdgfr-β+/- mice exhibited pericyte loss and glymphatic dysfunction, with Pdgfr-β+/- mice additionally showing reduced perivascular AQP-4 expression, accompanied by decreased laminin-α2/β1. In vitro, pericyte-derived factors promoted AQP-4 expression. TGN-073 partially improved small-molecule CSF tracer distribution in Pdgfr-β+/- mice. Pdgfr-β+/-/APP/PS1 mice displayed exacerbated AD-like pathology.
DISCUSSION: PDGFR-β deficiency compromises basement membrane integrity and AQP-4 localization, impairing glymphatic transport and accelerating AD pathogenesis. The PDGFR-β pathway may represent a novel therapeutic target for enhancing waste clearance.
Additional Links: PMID-43046622
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046622,
year = {2026},
author = {Chen, HC and Gao, FL and He, C and Yao, MH and Shi, YX and Zhou, SW and Zhang, XY and Li, CX and Gao, LP and Jing, YH},
title = {Pericyte PDGFR-β deficiency contributes to Aβ pathology through impaired glymphatic transport and altered AQP-4 localization.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43046622},
issn = {1552-5279},
support = {81870949//National Natural Science Foundation of China/ ; 21JR7RA452//Natural Science Foundation of Gansu Province/ ; lzuyxcx-2022-179//Lanzhou University Medical Research Innovation Capacity Enhancement Program/ ; 24JRRA817//Gansu Provincial Joint Funds/ ; 25JRRA691//Natural Science Foundation of Gansu Province-Gansu Provincial Young Science Fund/ ; 2024M751266//China Postdoctoral Science Foundation/ ; },
mesh = {Animals ; *Aquaporin 4/metabolism ; *Pericytes/metabolism/pathology ; *Receptor, Platelet-Derived Growth Factor beta/deficiency/genetics/metabolism ; *Glymphatic System/metabolism/pathology ; *Amyloid beta-Peptides/metabolism ; Mice ; *Alzheimer Disease/metabolism/pathology ; Mice, Transgenic ; Blood-Brain Barrier/metabolism ; Astrocytes/metabolism ; Humans ; Male ; },
abstract = {INTRODUCTION: Pericyte platelet-derived growth factor receptor-β (PDGFR-β) signaling maintains neurovascular integrity, but its role in glymphatic function is unknown. We investigated whether pericyte PDGFR-β deficiency is associated with glymphatic dysfunction and altered aquaporin-4 (AQP-4) localization in Alzheimer's disease (AD).
METHODS: Glymphatic trafficking was assessed by fluorescent cerebrospinal fluid (CSF) tracer injection. Meningeal lymphatic drainage was blocked by deep cervical lymph node (dcLN) ligation. Pericyte coverage, AQP-4 expression/localization, and basement membrane components were analyzed by immunofluorescence and western blot. Pericyte-conditioned medium was used to examine the effects of pericyte-derived factors on astrocytic AQP-4. The AQP-4 facilitator TGN-073 was administered to assess functional rescue. Blood-brain barrier integrity, microvascular density, and cerebral blood flow were also evaluated.
RESULTS: DcLN ligation impaired amyloid beta clearance and spatial memory. Both APP/PS1 and Pdgfr-β+/- mice exhibited pericyte loss and glymphatic dysfunction, with Pdgfr-β+/- mice additionally showing reduced perivascular AQP-4 expression, accompanied by decreased laminin-α2/β1. In vitro, pericyte-derived factors promoted AQP-4 expression. TGN-073 partially improved small-molecule CSF tracer distribution in Pdgfr-β+/- mice. Pdgfr-β+/-/APP/PS1 mice displayed exacerbated AD-like pathology.
DISCUSSION: PDGFR-β deficiency compromises basement membrane integrity and AQP-4 localization, impairing glymphatic transport and accelerating AD pathogenesis. The PDGFR-β pathway may represent a novel therapeutic target for enhancing waste clearance.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Aquaporin 4/metabolism
*Pericytes/metabolism/pathology
*Receptor, Platelet-Derived Growth Factor beta/deficiency/genetics/metabolism
*Glymphatic System/metabolism/pathology
*Amyloid beta-Peptides/metabolism
Mice
*Alzheimer Disease/metabolism/pathology
Mice, Transgenic
Blood-Brain Barrier/metabolism
Astrocytes/metabolism
Humans
Male
RevDate: 2026-11-18
Arts-based involvement is associated with positive perceptions of dementia in Singapore: an item-level perspective.
Arts & health [Epub ahead of print].
BACKGROUND: Arts-based programmes have shown promise in enhancing perceptions towards dementia, but research on such initiatives is scarce in the Asia-Pacific region. We investigated how involvement in an arts-based programme designed for persons living with dementia in Singapore is associated with attitudes towards dementia.
METHODS: A cross-sectional survey design was employed with 75 community members aged 19 to 68 (M = 42.07, SD = 13.77) with three levels of involvement in the programme: low involvement, high involvement, and newly inducted community members. Participants rated items on the Approaches to Dementia Questionnaire and Dementia Attitudes Scale. Quantitative data were analysed in R software.
RESULTS: Compared to community members with low involvement and those who are newly inducted, participants with high involvement reported significantly higher hope (ηp[2] = .18) and personhood (ηp[2] = .17). Arts-based involvement was positively associated with hope (rs = .40, p < .001), personhood (rs = .32, p = .005), and knowledge (rs = .28, p = .014), but not comfort (rs = .07, p = .528). Item-level analyses revealed that high involvement in the programme was associated with greater endorsement of flexible routine (ηp[2] = 0.09), hope (ηp[2] = .14), independent decision-making (ηp[2] = .12), and the importance of conversations (ηp[2] = .52).
CONCLUSIONS: Involvement in arts-based programmes is associated with viewing persons living with dementia through a more empowering lens - recognising their capacity for independent decision-making, valuing meaningful conversations, endorsing that dementia care need not be overly regimented, and holding greater hope for their dignity.
Additional Links: PMID-43046724
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046724,
year = {2026},
author = {Lim, XYH and Tan, WJ and Jiang, W and Koh, HJ and Yeo, D},
title = {Arts-based involvement is associated with positive perceptions of dementia in Singapore: an item-level perspective.},
journal = {Arts & health},
volume = {},
number = {},
pages = {1-17},
doi = {10.1080/17533015.2026.2765776},
pmid = {43046724},
issn = {1753-3023},
abstract = {BACKGROUND: Arts-based programmes have shown promise in enhancing perceptions towards dementia, but research on such initiatives is scarce in the Asia-Pacific region. We investigated how involvement in an arts-based programme designed for persons living with dementia in Singapore is associated with attitudes towards dementia.
METHODS: A cross-sectional survey design was employed with 75 community members aged 19 to 68 (M = 42.07, SD = 13.77) with three levels of involvement in the programme: low involvement, high involvement, and newly inducted community members. Participants rated items on the Approaches to Dementia Questionnaire and Dementia Attitudes Scale. Quantitative data were analysed in R software.
RESULTS: Compared to community members with low involvement and those who are newly inducted, participants with high involvement reported significantly higher hope (ηp[2] = .18) and personhood (ηp[2] = .17). Arts-based involvement was positively associated with hope (rs = .40, p < .001), personhood (rs = .32, p = .005), and knowledge (rs = .28, p = .014), but not comfort (rs = .07, p = .528). Item-level analyses revealed that high involvement in the programme was associated with greater endorsement of flexible routine (ηp[2] = 0.09), hope (ηp[2] = .14), independent decision-making (ηp[2] = .12), and the importance of conversations (ηp[2] = .52).
CONCLUSIONS: Involvement in arts-based programmes is associated with viewing persons living with dementia through a more empowering lens - recognising their capacity for independent decision-making, valuing meaningful conversations, endorsing that dementia care need not be overly regimented, and holding greater hope for their dignity.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Aβ42 induces selective degeneration in hippocampal cells of aged monkeys.
Zoological research, 47(6):2151-2167.
The hippocampus is one of the earliest and most severely affected brain regions in Alzheimer's disease (AD) and is critical for memory formation. However, the precise mechanisms through which AD disrupts hippocampal neurons remain poorly understood. To investigate the effects of Aβ42 in a model closer to humans, we performed stereotaxic injections of an adeno-associated virus serotype 9 (AAV9) vector encoding human Aβ42 into the hippocampus of young (7-year-old) and aged (>20-year-old) cynomolgus monkeys. We found that AAV9-mediated Aβ42 expression induced more severe neuropathology, reduced daytime activity, and increased sleep disturbances in aged monkeys compared to young controls. Single-nucleus RNA sequencing (snRNA-seq) revealed an age-dependent reduction in disease-associated microglia subtype II (DAM II) in the aged hippocampus. Furthermore, we identified a specific subtype of hippocampal pyramidal neurons (PCs) (TRPS1 [+] RELN [+]) that is selectively vulnerable to Aβ42 toxicity in aged monkeys. Our findings indicate that Aβ42 toxicity is exacerbated in the aged primate hippocampus due to a combination of microglial decline and the selective vulnerability of a distinct neuronal subtype (TRPS1 [+] RELN [+] PCs). This identified subtype represents a new potential therapeutic target for treating hippocampal dysfunction in AD.
Additional Links: PMID-43046728
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046728,
year = {2026},
author = {Chen, L and Zhang, J and Wang, Z and Ma, YH and Lin, Y and Song, X and Luo, X and Chen, K and Wang, L and Xu, H and Li, S and Yan, S and Wang, X and Wen, J and Yang, W and Li, B and Li, XJ},
title = {Aβ42 induces selective degeneration in hippocampal cells of aged monkeys.},
journal = {Zoological research},
volume = {47},
number = {6},
pages = {2151-2167},
doi = {10.24272/j.issn.2095-8137.2025.615},
pmid = {43046728},
issn = {2095-8137},
mesh = {Animals ; *Amyloid beta-Peptides/metabolism/toxicity/genetics ; *Hippocampus/pathology/cytology/drug effects ; *Aging/physiology ; *Macaca fascicularis ; *Peptide Fragments/metabolism/toxicity/genetics ; Male ; Dependovirus/genetics ; Neurons/drug effects ; },
abstract = {The hippocampus is one of the earliest and most severely affected brain regions in Alzheimer's disease (AD) and is critical for memory formation. However, the precise mechanisms through which AD disrupts hippocampal neurons remain poorly understood. To investigate the effects of Aβ42 in a model closer to humans, we performed stereotaxic injections of an adeno-associated virus serotype 9 (AAV9) vector encoding human Aβ42 into the hippocampus of young (7-year-old) and aged (>20-year-old) cynomolgus monkeys. We found that AAV9-mediated Aβ42 expression induced more severe neuropathology, reduced daytime activity, and increased sleep disturbances in aged monkeys compared to young controls. Single-nucleus RNA sequencing (snRNA-seq) revealed an age-dependent reduction in disease-associated microglia subtype II (DAM II) in the aged hippocampus. Furthermore, we identified a specific subtype of hippocampal pyramidal neurons (PCs) (TRPS1 [+] RELN [+]) that is selectively vulnerable to Aβ42 toxicity in aged monkeys. Our findings indicate that Aβ42 toxicity is exacerbated in the aged primate hippocampus due to a combination of microglial decline and the selective vulnerability of a distinct neuronal subtype (TRPS1 [+] RELN [+] PCs). This identified subtype represents a new potential therapeutic target for treating hippocampal dysfunction in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Amyloid beta-Peptides/metabolism/toxicity/genetics
*Hippocampus/pathology/cytology/drug effects
*Aging/physiology
*Macaca fascicularis
*Peptide Fragments/metabolism/toxicity/genetics
Male
Dependovirus/genetics
Neurons/drug effects
RevDate: 2026-11-18
CmpDate: 2026-11-18
Aβ Aggregate-Gated Ratiometric Probe Reveals Peri-Plaque Acidification Arising from Lysosomal Dysfunction in Alzheimer's Disease.
ACS chemical neuroscience, 17(22):3701-3714.
Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques surrounded by plaque-associated dystrophic neurites (PADNs), where dysfunctional autolysosomal vesicles accumulate abundantly. However, whether Aβ-induced autolysosomal dysfunction contributes to remodeling of the plaque microenvironment remains unclear. Herein, we developed DQ, an Aβ aggregate-gated ratiometric fluorescent probe in which recognition of fibrillar Aβ activates pH-responsive fluorescence. This target-triggered sensing strategy restricts pH reporting to the vicinity of Aβ aggregates, enabling selective visualization of local plaque-associated microenvironments with minimal background interference. DQ exhibited high selectivity toward fibrillar Aβ and enabled imaging of local pH changes in both cellular models and transgenic AD mice. Using DQ, we revealed progressive acidification surrounding plaques during AD progression and demonstrated an age-dependent increase in peri-plaque acidification. Furthermore, imaging analyses showed that local acidification was closely associated with lysosomal dysfunction within PADNs. Mechanistic studies further demonstrated that autolysosomal impairment within PADNs causes lysosomal proton leakage and microenvironmental acidification. Repair of lysosomal dysfunction alleviated multiple AD-associated pathological features, including plaque burden, neuroinflammation, synaptic loss, and cognitive impairment. Collectively, this work establishes a target-gated ratiometric sensing strategy for spatially resolved interrogation of plaque-associated microenvironments and identifies PADN-associated lysosomal proton dysregulation as an important pathological event in AD progression.
Additional Links: PMID-43046855
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046855,
year = {2026},
author = {Wang, H and Wang, X and Gong, H and Luo, H},
title = {Aβ Aggregate-Gated Ratiometric Probe Reveals Peri-Plaque Acidification Arising from Lysosomal Dysfunction in Alzheimer's Disease.},
journal = {ACS chemical neuroscience},
volume = {17},
number = {22},
pages = {3701-3714},
doi = {10.1021/acschemneuro.6c00498},
pmid = {43046855},
issn = {1948-7193},
support = {STI2030-Major Projects, 2021ZD0201001//National Programs for Brain Science and Brain-like Intelligence Technology of China/ ; 2021ZD0201004//National Programs for Brain Science and Brain-like Intelligence Technology of China/ ; },
mesh = {Animals ; *Alzheimer Disease/metabolism/pathology ; *Lysosomes/metabolism/pathology ; *Plaque, Amyloid/metabolism/pathology ; *Amyloid beta-Peptides/metabolism ; Mice, Transgenic ; Hydrogen-Ion Concentration ; Mice ; Humans ; Fluorescent Dyes ; Fluorescent Chemosensor Compounds ; },
abstract = {Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques surrounded by plaque-associated dystrophic neurites (PADNs), where dysfunctional autolysosomal vesicles accumulate abundantly. However, whether Aβ-induced autolysosomal dysfunction contributes to remodeling of the plaque microenvironment remains unclear. Herein, we developed DQ, an Aβ aggregate-gated ratiometric fluorescent probe in which recognition of fibrillar Aβ activates pH-responsive fluorescence. This target-triggered sensing strategy restricts pH reporting to the vicinity of Aβ aggregates, enabling selective visualization of local plaque-associated microenvironments with minimal background interference. DQ exhibited high selectivity toward fibrillar Aβ and enabled imaging of local pH changes in both cellular models and transgenic AD mice. Using DQ, we revealed progressive acidification surrounding plaques during AD progression and demonstrated an age-dependent increase in peri-plaque acidification. Furthermore, imaging analyses showed that local acidification was closely associated with lysosomal dysfunction within PADNs. Mechanistic studies further demonstrated that autolysosomal impairment within PADNs causes lysosomal proton leakage and microenvironmental acidification. Repair of lysosomal dysfunction alleviated multiple AD-associated pathological features, including plaque burden, neuroinflammation, synaptic loss, and cognitive impairment. Collectively, this work establishes a target-gated ratiometric sensing strategy for spatially resolved interrogation of plaque-associated microenvironments and identifies PADN-associated lysosomal proton dysregulation as an important pathological event in AD progression.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Alzheimer Disease/metabolism/pathology
*Lysosomes/metabolism/pathology
*Plaque, Amyloid/metabolism/pathology
*Amyloid beta-Peptides/metabolism
Mice, Transgenic
Hydrogen-Ion Concentration
Mice
Humans
Fluorescent Dyes
Fluorescent Chemosensor Compounds
RevDate: 2026-11-18
CmpDate: 2026-11-18
A Mito-CoQ10-TPP Nanocarrier Hybrid Enhances the Therapeutic Efficacy of Mitochondrial Transplantation in Alzheimer's Disease.
ACS chemical neuroscience, 17(22):3653-3667.
Mitochondrial dysfunction is an early pathological aspect of Alzheimer's disease (AD) that promotes oxidative stress, leading to amyloid β-plaque formation and neurofibrillary tangles. Thus, targeted mitochondrial therapy and mitochondrial transplantation have emerged as promising therapeutic strategies. However, excessive oxidative stress and neuroinflammation in the microenvironments of the AD brain limit the functional and stable integration of transplanted mitochondria. In this study, we have engineered a Mito-CoQ10-TPP hybrid nanocarrier by conjugating triphenylphosphonium (TPP), a lipophilic cation, with Coenzyme Q10 (CoQ10) and localized it to mitochondria isolated from healthy cortical brain cells. This nanocarrier hybrid was administered via a single intravenous (IV) dose to streptozotocin (STZ)-induced AD in mice. A comprehensive evaluation of mitochondrial function, amyloid burden, neuroinflammation, apoptosis, biogenesis, and behavior revealed that CoQ10-TPP conjugation significantly improved the mitochondrial transplantation efficacy in the amelioration of AD. Thus, conjugating the antioxidant CoQ10 with mitochondrial transplantation significantly improved the overall therapeutic efficacy, indicating the use of the Mito-CoQ10-TPP hybrid nanocarrier as a promising therapeutic strategy.
Additional Links: PMID-43046858
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046858,
year = {2026},
author = {Sindhu, N and Jain, S and Sharma, S and Paliwal, S},
title = {A Mito-CoQ10-TPP Nanocarrier Hybrid Enhances the Therapeutic Efficacy of Mitochondrial Transplantation in Alzheimer's Disease.},
journal = {ACS chemical neuroscience},
volume = {17},
number = {22},
pages = {3653-3667},
doi = {10.1021/acschemneuro.6c00379},
pmid = {43046858},
issn = {1948-7193},
support = {NIDHI-PRAYAS program in collaboration with AIC Ban//Department of Science and Technology/ ; },
mesh = {Animals ; *Alzheimer Disease/therapy/metabolism/pathology ; *Ubiquinone/analogs & derivatives/administration & dosage ; *Mitochondria/transplantation/metabolism ; Mice ; *Organophosphorus Compounds/administration & dosage ; Oxidative Stress/drug effects ; *Nanoparticles ; Male ; },
abstract = {Mitochondrial dysfunction is an early pathological aspect of Alzheimer's disease (AD) that promotes oxidative stress, leading to amyloid β-plaque formation and neurofibrillary tangles. Thus, targeted mitochondrial therapy and mitochondrial transplantation have emerged as promising therapeutic strategies. However, excessive oxidative stress and neuroinflammation in the microenvironments of the AD brain limit the functional and stable integration of transplanted mitochondria. In this study, we have engineered a Mito-CoQ10-TPP hybrid nanocarrier by conjugating triphenylphosphonium (TPP), a lipophilic cation, with Coenzyme Q10 (CoQ10) and localized it to mitochondria isolated from healthy cortical brain cells. This nanocarrier hybrid was administered via a single intravenous (IV) dose to streptozotocin (STZ)-induced AD in mice. A comprehensive evaluation of mitochondrial function, amyloid burden, neuroinflammation, apoptosis, biogenesis, and behavior revealed that CoQ10-TPP conjugation significantly improved the mitochondrial transplantation efficacy in the amelioration of AD. Thus, conjugating the antioxidant CoQ10 with mitochondrial transplantation significantly improved the overall therapeutic efficacy, indicating the use of the Mito-CoQ10-TPP hybrid nanocarrier as a promising therapeutic strategy.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Alzheimer Disease/therapy/metabolism/pathology
*Ubiquinone/analogs & derivatives/administration & dosage
*Mitochondria/transplantation/metabolism
Mice
*Organophosphorus Compounds/administration & dosage
Oxidative Stress/drug effects
*Nanoparticles
Male
RevDate: 2026-11-18
CmpDate: 2026-11-18
Functional impairment statistically mediates the association between hyperarousal neuropsychiatric symptoms and cognitive decline: a prospective cohort study.
Frontiers in aging neuroscience, 18:1968518.
INTRODUCTION: Neuropsychiatric symptoms (NPS) are prevalent in older adults and are associated with cognitive decline. This study investigated the association between hyperarousal NPS (HNPS) and cognitive progression, focusing on the mediating role of functional impairment and its link to Alzheimer's disease (AD) pathology.
METHODS: Using data from 1,657 non-demented participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), we evaluated the Hyperarousal Neuropsychiatric Inventory Questionnaire (HNPI-Q, comprising agitation, anxiety, and irritability), the Functional Activities Questionnaire (FAQ), APOE ε4 status, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores, regional brain volumes, and amyloid-β (Aβ) positron emission tomography (PET) Centiloid values. Analyses included Cox and linear regression, mediation analysis, and nomogram development.
RESULTS: HNPS predicted 5-year cognitive decline (HR = 1.14, p = 2.7 × 10[-4]), an association attenuated after adjusting for FAQ. HNPI-Q scores were longitudinally associated with functional and cognitive decline. Mediation analyses indicated that functional impairment statistically mediated the association between HNPS and cognition. Notably, the rate of functional decline was strongly correlated with the rate of Aβ accumulation, a coupling that was also evident in participants who progressed to cognitive deterioration. Predictive models based on HNPI-Q and FAQ showed excellent discrimination (AUC: 0.838 and 0.845) and calibration.
CONCLUSION: HNPS was associated with cognitive decline, an association that was statistically mediated by functional impairment, which itself co-varies with Aβ pathology. The HNPI-Q stratified the 5-year risk of cognitive deterioration in this cohort, and whether intervening on these symptoms or on functional decline alters the clinical course remains to be further investigated.
Additional Links: PMID-43047580
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047580,
year = {2026},
author = {Shi, X and Chen, G and Lu, F and Wang, X and Ma, R and Li, G and Guo, H},
title = {Functional impairment statistically mediates the association between hyperarousal neuropsychiatric symptoms and cognitive decline: a prospective cohort study.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {1968518},
pmid = {43047580},
issn = {1663-4365},
abstract = {INTRODUCTION: Neuropsychiatric symptoms (NPS) are prevalent in older adults and are associated with cognitive decline. This study investigated the association between hyperarousal NPS (HNPS) and cognitive progression, focusing on the mediating role of functional impairment and its link to Alzheimer's disease (AD) pathology.
METHODS: Using data from 1,657 non-demented participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), we evaluated the Hyperarousal Neuropsychiatric Inventory Questionnaire (HNPI-Q, comprising agitation, anxiety, and irritability), the Functional Activities Questionnaire (FAQ), APOE ε4 status, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores, regional brain volumes, and amyloid-β (Aβ) positron emission tomography (PET) Centiloid values. Analyses included Cox and linear regression, mediation analysis, and nomogram development.
RESULTS: HNPS predicted 5-year cognitive decline (HR = 1.14, p = 2.7 × 10[-4]), an association attenuated after adjusting for FAQ. HNPI-Q scores were longitudinally associated with functional and cognitive decline. Mediation analyses indicated that functional impairment statistically mediated the association between HNPS and cognition. Notably, the rate of functional decline was strongly correlated with the rate of Aβ accumulation, a coupling that was also evident in participants who progressed to cognitive deterioration. Predictive models based on HNPI-Q and FAQ showed excellent discrimination (AUC: 0.838 and 0.845) and calibration.
CONCLUSION: HNPS was associated with cognitive decline, an association that was statistically mediated by functional impairment, which itself co-varies with Aβ pathology. The HNPI-Q stratified the 5-year risk of cognitive deterioration in this cohort, and whether intervening on these symptoms or on functional decline alters the clinical course remains to be further investigated.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Artificial intelligence applications in fMRI-based disease diagnosis: A systematic review.
Digital health, 12:20552076261491584.
OBJECTIVE: The purpose of this study is to critically assess and thoroughly explore the use of artificial intelligence (AI) methods in functional magnetic resonance imaging (fMRI) for the diagnosis of neuropsychiatric and neurological conditions. Methodological variability, dataset features, validation techniques, repeatability transparency, and the clinical preparedness of AI-based diagnostic models are the main topics of the review.
METHODS: A thorough search for research published between 2010 and 2025 was conducted using PubMed, Scopus, Web of Science, and IEEE Xplore. The review was conducted in accordance with PRISMA 2020. The PICOS framework was used to define the eligibility requirements. Studies were included if they published quantitative performance metrics and used resting-state or task-based fMRI data in conjunction with machine learning or deep learning models for disease classification. A modified QUADAS-2 framework appropriate for AI-based diagnostic research was used to evaluate the methodological quality and bias risk. Because study designs, datasets, preprocessing pipelines, and evaluation metrics varied, the data were synthesized qualitatively.
RESULTS: After the PRISMA 2020 screening procedure, 80 studies in all satisfied the inclusion requirements. The majority of research concentrated on autistic spectrum disorder, Parkinson's disease, Alzheimer's disease, and major depressive disorder. While machine learning methods (especially support vector machines) and deep learning architectures like convolutional neural networks and graph neural networks were the most commonly used artificial intelligence techniques, resting-state fMRI was the most commonly used imaging modality. In general, reported categorization accuracy fell between 85% and 96%. Nonetheless, significant methodological variation was noted in model topologies, validation techniques, feature extraction techniques, and preprocessing pipelines. Concerns about the generalizability of the model and possible overfitting were highlighted by the frequent dependence on very small cohorts and the sparse use of external validation. Additionally, quality assessment revealed moderate to high risks of bias in several studies, especially in relation to validation and patient selection processes.
CONCLUSION: The use of AI to analyze fMRI data shows great promise for enhancing the diagnostic categorization of neurological and neuropsychiatric disorders. However, clinical translation is restricted by small sample sizes, inconsistent methods, and a lack of external validation. To improve repeatability and facilitate the incorporation of AI-driven fMRI analysis into clinical practice, standardized preprocessing procedures, bigger multi-site datasets, open reporting procedures, and stringent external validation are necessary.
Additional Links: PMID-43047603
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047603,
year = {2026},
author = {Almetwally, EM and Diab, LS and Ahmed, MA and Kamel, AR},
title = {Artificial intelligence applications in fMRI-based disease diagnosis: A systematic review.},
journal = {Digital health},
volume = {12},
number = {},
pages = {20552076261491584},
pmid = {43047603},
issn = {2055-2076},
abstract = {OBJECTIVE: The purpose of this study is to critically assess and thoroughly explore the use of artificial intelligence (AI) methods in functional magnetic resonance imaging (fMRI) for the diagnosis of neuropsychiatric and neurological conditions. Methodological variability, dataset features, validation techniques, repeatability transparency, and the clinical preparedness of AI-based diagnostic models are the main topics of the review.
METHODS: A thorough search for research published between 2010 and 2025 was conducted using PubMed, Scopus, Web of Science, and IEEE Xplore. The review was conducted in accordance with PRISMA 2020. The PICOS framework was used to define the eligibility requirements. Studies were included if they published quantitative performance metrics and used resting-state or task-based fMRI data in conjunction with machine learning or deep learning models for disease classification. A modified QUADAS-2 framework appropriate for AI-based diagnostic research was used to evaluate the methodological quality and bias risk. Because study designs, datasets, preprocessing pipelines, and evaluation metrics varied, the data were synthesized qualitatively.
RESULTS: After the PRISMA 2020 screening procedure, 80 studies in all satisfied the inclusion requirements. The majority of research concentrated on autistic spectrum disorder, Parkinson's disease, Alzheimer's disease, and major depressive disorder. While machine learning methods (especially support vector machines) and deep learning architectures like convolutional neural networks and graph neural networks were the most commonly used artificial intelligence techniques, resting-state fMRI was the most commonly used imaging modality. In general, reported categorization accuracy fell between 85% and 96%. Nonetheless, significant methodological variation was noted in model topologies, validation techniques, feature extraction techniques, and preprocessing pipelines. Concerns about the generalizability of the model and possible overfitting were highlighted by the frequent dependence on very small cohorts and the sparse use of external validation. Additionally, quality assessment revealed moderate to high risks of bias in several studies, especially in relation to validation and patient selection processes.
CONCLUSION: The use of AI to analyze fMRI data shows great promise for enhancing the diagnostic categorization of neurological and neuropsychiatric disorders. However, clinical translation is restricted by small sample sizes, inconsistent methods, and a lack of external validation. To improve repeatability and facilitate the incorporation of AI-driven fMRI analysis into clinical practice, standardized preprocessing procedures, bigger multi-site datasets, open reporting procedures, and stringent external validation are necessary.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Ganoderic Acid A Ameliorates Recognition Memory Deficits and Anxiety- and Depression-Like Behaviors in APP/PS1 Mice: Association With Histone Lactylation and Ferroptosis.
Food science & nutrition, 14(11):e72603.
Alzheimer's disease (AD) is a degenerative disorder of the central nervous system, characterized by core symptoms of memory and cognitive dysfunction. However, neuropsychiatric abnormalities such as anxiety and depression are commonly observed during the progression of AD. Aberrant histone lactylation is a key epigenetic mechanism that promotes AD progression. Ganoderic acid A (GAA), one of the major bioactive components in Ganoderma lucidum, has been shown to ameliorate AD; however, whether GAA ameliorates anxiety- and depression-like behaviors in AD, and whether it exerts neuroprotective effects through regulation of the histone lactylation-ferroptosis axis, remain unexplored. In this study, using APP/PS1 mice as a model, recognition memory as well as anxiety- and depression-like behaviors were evaluated. Furthermore, an AD cell model was established by treating HT22 cells with Aβ25-35 to investigate the mechanism of GAA in vitro. The results showed that GAA improved recognition memory, anxiety-, and depression-like behaviors in APP/PS1 mice and suppressed histone lactylation in the hippocampus. In AD cells, GAA treatment was accompanied by decreased LDH levels, reduced lactate contents, p300 downregulation, HDAC1 upregulation and reduced histone lactylation. Ferroptosis-related assays showed that GAA treatment downregulated TFR1, upregulated FTH1, decreased Fe[2+] levels, downregulated ACSL4, upregulated NRF2, SLC7A11, and GPX4, and decreased ROS and MDA levels, while increasing SOD and GSH levels and total antioxidant capacity. Collectively, these findings indicate that GAA effectively ameliorates recognition memory deficits and anxiety- and depression-like behaviors in APP/PS1 mice, possibly via the histone lactylation-ferroptosis axis, thereby exerting anti-AD effects. Our study suggests that GAA could be exploited as a novel functional food ingredient for the treatment or prevention of AD.
Additional Links: PMID-43047614
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047614,
year = {2026},
author = {Fang, Z and Yue, J and Lu, Q and Shao, N and Yang, R and Wang, Y and Liu, H and Cai, B and Wei, T},
title = {Ganoderic Acid A Ameliorates Recognition Memory Deficits and Anxiety- and Depression-Like Behaviors in APP/PS1 Mice: Association With Histone Lactylation and Ferroptosis.},
journal = {Food science & nutrition},
volume = {14},
number = {11},
pages = {e72603},
pmid = {43047614},
issn = {2048-7177},
abstract = {Alzheimer's disease (AD) is a degenerative disorder of the central nervous system, characterized by core symptoms of memory and cognitive dysfunction. However, neuropsychiatric abnormalities such as anxiety and depression are commonly observed during the progression of AD. Aberrant histone lactylation is a key epigenetic mechanism that promotes AD progression. Ganoderic acid A (GAA), one of the major bioactive components in Ganoderma lucidum, has been shown to ameliorate AD; however, whether GAA ameliorates anxiety- and depression-like behaviors in AD, and whether it exerts neuroprotective effects through regulation of the histone lactylation-ferroptosis axis, remain unexplored. In this study, using APP/PS1 mice as a model, recognition memory as well as anxiety- and depression-like behaviors were evaluated. Furthermore, an AD cell model was established by treating HT22 cells with Aβ25-35 to investigate the mechanism of GAA in vitro. The results showed that GAA improved recognition memory, anxiety-, and depression-like behaviors in APP/PS1 mice and suppressed histone lactylation in the hippocampus. In AD cells, GAA treatment was accompanied by decreased LDH levels, reduced lactate contents, p300 downregulation, HDAC1 upregulation and reduced histone lactylation. Ferroptosis-related assays showed that GAA treatment downregulated TFR1, upregulated FTH1, decreased Fe[2+] levels, downregulated ACSL4, upregulated NRF2, SLC7A11, and GPX4, and decreased ROS and MDA levels, while increasing SOD and GSH levels and total antioxidant capacity. Collectively, these findings indicate that GAA effectively ameliorates recognition memory deficits and anxiety- and depression-like behaviors in APP/PS1 mice, possibly via the histone lactylation-ferroptosis axis, thereby exerting anti-AD effects. Our study suggests that GAA could be exploited as a novel functional food ingredient for the treatment or prevention of AD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
GPR37 and GPR37L1-mediated neuroprotection: mechanisms and drug repurposing strategies for reducing neurological disorders.
Frontiers in aging neuroscience, 18:1947212.
Neurological disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, ischemic stroke, and neuropathic pain are major causes of long-term disability worldwide. The orphan G protein-coupled receptors GPR37 and GPR37L1 have gained considerable research attention as novel therapeutic targets. These receptors play critical roles in neuroprotection, neuroinflammation and tissue repair. GPR37 is primarily expressed in dopaminergic neurons and oligodendrocytes, whereas GPR37L1 is mainly expressed in astrocytes. These receptors modulate various cellular processes through Gi/o-coupled signaling, ERK/MAPK, and PI3K-Akt pathways. Both GPR37 and GPR37L1 affect neuronal survival, remyelination, oxidative stress, apoptosis, glial activation, and phagocytic clearance. Activation of GPR37 and GPR37L1 by their ligands, including prosaposin-derived peptides, neuroprotectin D1, and osteocalcin, regulates protective signaling and promotes functional recovery in the injured central nervous system. This review highlights recent progress in the cellular mechanisms regulating neuroprotection mediated by GPR37 and GPR37L1. This includes GPR37/GPR37L1 molecular characteristics and ligand signaling, mechanisms of proteostasis, ER stress, anti-apoptotic and survival signaling, modulation of oxidative stress, regulation of neuroinflammation, glial-mediated repair and remyelination, and synaptic and dopaminergic regulation. In addition, repurposed drugs targeting these receptors are also reviewed, along with a discussion on the clinical implications of GPR37/GPR37L1 in reducing neurological disorders. Despite these advances, a unified mechanistic framework linking receptor biology with therapeutic development remains lacking. This review proposes a conceptual framework that integrates receptor signaling, disease mechanisms, and drug repurposing strategies, while highlighting testable hypotheses on convergent neuroprotective pathways that warrant experimental validation. This systematic review was conducted in accordance with the PRISMA 2020 guidelines. By providing a translational perspective, this framework may facilitate biomarker discovery, prioritize therapeutic candidates, and accelerate the clinical development of GPR37/GPR37L1-targeted interventions for neurological disorders.
Additional Links: PMID-43047625
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047625,
year = {2026},
author = {Thiyagarajan, R and Muniyandi, V and Murugesan, A and Subbiah, R and Chandrabose, S and Kandhavelu, M},
title = {GPR37 and GPR37L1-mediated neuroprotection: mechanisms and drug repurposing strategies for reducing neurological disorders.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {1947212},
pmid = {43047625},
issn = {1663-4365},
abstract = {Neurological disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, ischemic stroke, and neuropathic pain are major causes of long-term disability worldwide. The orphan G protein-coupled receptors GPR37 and GPR37L1 have gained considerable research attention as novel therapeutic targets. These receptors play critical roles in neuroprotection, neuroinflammation and tissue repair. GPR37 is primarily expressed in dopaminergic neurons and oligodendrocytes, whereas GPR37L1 is mainly expressed in astrocytes. These receptors modulate various cellular processes through Gi/o-coupled signaling, ERK/MAPK, and PI3K-Akt pathways. Both GPR37 and GPR37L1 affect neuronal survival, remyelination, oxidative stress, apoptosis, glial activation, and phagocytic clearance. Activation of GPR37 and GPR37L1 by their ligands, including prosaposin-derived peptides, neuroprotectin D1, and osteocalcin, regulates protective signaling and promotes functional recovery in the injured central nervous system. This review highlights recent progress in the cellular mechanisms regulating neuroprotection mediated by GPR37 and GPR37L1. This includes GPR37/GPR37L1 molecular characteristics and ligand signaling, mechanisms of proteostasis, ER stress, anti-apoptotic and survival signaling, modulation of oxidative stress, regulation of neuroinflammation, glial-mediated repair and remyelination, and synaptic and dopaminergic regulation. In addition, repurposed drugs targeting these receptors are also reviewed, along with a discussion on the clinical implications of GPR37/GPR37L1 in reducing neurological disorders. Despite these advances, a unified mechanistic framework linking receptor biology with therapeutic development remains lacking. This review proposes a conceptual framework that integrates receptor signaling, disease mechanisms, and drug repurposing strategies, while highlighting testable hypotheses on convergent neuroprotective pathways that warrant experimental validation. This systematic review was conducted in accordance with the PRISMA 2020 guidelines. By providing a translational perspective, this framework may facilitate biomarker discovery, prioritize therapeutic candidates, and accelerate the clinical development of GPR37/GPR37L1-targeted interventions for neurological disorders.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Apolipoprotein ε4-allele as predictor of outcome in radiotherapy-treated childhood brain tumor survivors.
Neuro-oncology practice, 13(6):1089-1099.
BACKGROUND: Apolipoprotein E (APOE) is a polymorphic gene with three main alleles; the ε4-allele is a risk factor for distinct diseases, particularly for Alzheimer's disease. Radiotherapy-treated childhood brain tumor (BT) survivors face an increased risk of developing late-effects, especially cognitive impairment. Despite the similar treatment modality, the outcome varies considerably. Thus, we investigated the influence of ε4-allele on outcome in these survivors.
METHODS: A Finnish national cohort of radiotherapy-treated childhood BT survivors was investigated in a cross-sectional setting (median follow-up of 20 years). Survivors participated in the follow-up visit including neuropsychological and physical examinations, brain magnetic resonance imaging, and laboratory tests. BT and treatment-related information were collected from the patient files. APOE polymorphism was examined, and the results were compared to a previous study on the Finnish population. We also compared the late-effects between ε4-carriers and non-carriers.
RESULTS: Among 58 survivors [median age of 27 (range, 16-43) years], the observed frequencies of APOE genotypes were 78% (N = 45) for ε3ε3, 14% (N = 8) for ε3ε4, 7% (N = 4) for ε2ε3, and 2% (N = 1) for ε2ε4. The presence of ε4-allele was associated with poorer semantic, immediate, and delayed auditory memory. Since all ε4-carriers had ventriculoperitoneal shunt, we compared their results to those of non-carriers with ventriculoperitoneal shunt, which revealed that ε4-carriers had worse immediate and delayed auditory memory. E4-carriers exhibit higher total cholesterol and triglyceride levels than non-carriers.
CONCLUSIONS: APOE ε4-allele may impact the cognitive outcome and cholesterol levels in the radiotherapy-treated childhood BT survivors. E4-carrier survivors may especially benefit from healthy life-style interventions.
Additional Links: PMID-43047645
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047645,
year = {2026},
author = {Remes, TM and Ritari, N and Arikoski, PM and Koskenkorva, P and Lähteenmäki, PM and Ojaniemi, MK and Puosi, R and Sirkiä, KH and Suo-Palosaari, M and Sutela, A and Toiviainen-Salo, S and Rantala, HMJ and Harila, AH},
title = {Apolipoprotein ε4-allele as predictor of outcome in radiotherapy-treated childhood brain tumor survivors.},
journal = {Neuro-oncology practice},
volume = {13},
number = {6},
pages = {1089-1099},
pmid = {43047645},
issn = {2054-2577},
abstract = {BACKGROUND: Apolipoprotein E (APOE) is a polymorphic gene with three main alleles; the ε4-allele is a risk factor for distinct diseases, particularly for Alzheimer's disease. Radiotherapy-treated childhood brain tumor (BT) survivors face an increased risk of developing late-effects, especially cognitive impairment. Despite the similar treatment modality, the outcome varies considerably. Thus, we investigated the influence of ε4-allele on outcome in these survivors.
METHODS: A Finnish national cohort of radiotherapy-treated childhood BT survivors was investigated in a cross-sectional setting (median follow-up of 20 years). Survivors participated in the follow-up visit including neuropsychological and physical examinations, brain magnetic resonance imaging, and laboratory tests. BT and treatment-related information were collected from the patient files. APOE polymorphism was examined, and the results were compared to a previous study on the Finnish population. We also compared the late-effects between ε4-carriers and non-carriers.
RESULTS: Among 58 survivors [median age of 27 (range, 16-43) years], the observed frequencies of APOE genotypes were 78% (N = 45) for ε3ε3, 14% (N = 8) for ε3ε4, 7% (N = 4) for ε2ε3, and 2% (N = 1) for ε2ε4. The presence of ε4-allele was associated with poorer semantic, immediate, and delayed auditory memory. Since all ε4-carriers had ventriculoperitoneal shunt, we compared their results to those of non-carriers with ventriculoperitoneal shunt, which revealed that ε4-carriers had worse immediate and delayed auditory memory. E4-carriers exhibit higher total cholesterol and triglyceride levels than non-carriers.
CONCLUSIONS: APOE ε4-allele may impact the cognitive outcome and cholesterol levels in the radiotherapy-treated childhood BT survivors. E4-carrier survivors may especially benefit from healthy life-style interventions.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Targeting the cGAS-STING axis in Alzheimer's disease: neuroinflammation-centric therapeutic strategies and perspectives.
Frontiers in pharmacology, 17:1983598.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder traditionally characterized by amyloid-β (Aβ) plaques and tau neurofibrillary tangles. However, the limited clinical efficacy of Aβ/tau-targeted therapies has redefined neuroinflammation as an active driver of AD pathogenesis. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis acts as a central hub connecting aberrant cytosolic nucleic acid sensing particularly mitochondrial DNA leakage induced by Aβ and tau pathologies to chronic innate immune activation. This review comprehensively elucidates the pathogenic mechanisms of the cGAS-STING axis in AD, detailing its cell-type-specific activation in microglia, astrocytes, and neurons, and its downstream propagation via type I interferons, NF-κB, and NLRP3 inflammasome signaling, which collectively drive synaptic damage and neuronal loss. We critically evaluate emerging therapeutic strategies, including covalent/non-covalent small-molecule inhibitors (e.g., RU.521, H-151, PF-06928215, SN-011), PROTAC degraders, RNA-based therapies, and immunomodulatory natural products/traditional Chinese medicines (e.g., icariin, tetrahydroxy stilbene glucoside, compound danshen dripping pills). Furthermore, we explore clinical translation prospects, emphasizing cerebrospinal fluid cGAMP and exosomal phosphorylated STING as minimally invasive biomarkers, while addressing key hurdles in blood-brain barrier penetration, and off-target risks. Finally, we highlight future directions involving organoid-microfluidic chip models and precision medicine frameworks to facilitate personalized cGAS-STING-targeted immunotherapy for AD.
Additional Links: PMID-43047654
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047654,
year = {2026},
author = {Liu, J and Shan, X and Li, S and Li, X and Wang, C and Gu, L and Zhang, X},
title = {Targeting the cGAS-STING axis in Alzheimer's disease: neuroinflammation-centric therapeutic strategies and perspectives.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1983598},
pmid = {43047654},
issn = {1663-9812},
abstract = {Alzheimer's disease (AD) is a progressive neurodegenerative disorder traditionally characterized by amyloid-β (Aβ) plaques and tau neurofibrillary tangles. However, the limited clinical efficacy of Aβ/tau-targeted therapies has redefined neuroinflammation as an active driver of AD pathogenesis. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis acts as a central hub connecting aberrant cytosolic nucleic acid sensing particularly mitochondrial DNA leakage induced by Aβ and tau pathologies to chronic innate immune activation. This review comprehensively elucidates the pathogenic mechanisms of the cGAS-STING axis in AD, detailing its cell-type-specific activation in microglia, astrocytes, and neurons, and its downstream propagation via type I interferons, NF-κB, and NLRP3 inflammasome signaling, which collectively drive synaptic damage and neuronal loss. We critically evaluate emerging therapeutic strategies, including covalent/non-covalent small-molecule inhibitors (e.g., RU.521, H-151, PF-06928215, SN-011), PROTAC degraders, RNA-based therapies, and immunomodulatory natural products/traditional Chinese medicines (e.g., icariin, tetrahydroxy stilbene glucoside, compound danshen dripping pills). Furthermore, we explore clinical translation prospects, emphasizing cerebrospinal fluid cGAMP and exosomal phosphorylated STING as minimally invasive biomarkers, while addressing key hurdles in blood-brain barrier penetration, and off-target risks. Finally, we highlight future directions involving organoid-microfluidic chip models and precision medicine frameworks to facilitate personalized cGAS-STING-targeted immunotherapy for AD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
SoniNet: an AI framework for enhancing voice features in speech-based health monitoring.
Frontiers in aging neuroscience, 18:1977352.
Deep learning based speech embeddings learned from large-scale speech corpora have achieved strong performance across a range of speech analysis tasks. However, handcrafted acoustic features, such as prosodic, spectral, and voice-quality descriptors, remain widely used in clinical speech analysis because of their established role in characterizing vocal behavior. Despite this, these features often struggle to generalize across variations in speech dynamics, recording duration, and recording conditions. This paper introduces SoniNet, a framework that enhances the discriminative power of handcrafted acoustic features by learning data-driven temporal representations from large-scale speech data. SoniNet captures the temporal evolution of acoustic descriptors across speech recordings of variable length while maintaining compatibility with established acoustic feature sets used in clinical speech analysis. We evaluate SoniNet on benchmark speech data sets and demonstrate consistent improvements in classification performance across clinical speech assessment tasks, outperforming conventional acoustic modeling approaches in 22 out of 24 feature-task combinations. These findings highlight the potential of SoniNet as a robust framework for speech-based health monitoring, affect recognition, and computational behavioral analysis.
Additional Links: PMID-43047669
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047669,
year = {2026},
author = {Haider, F and De La Fuente Garcia, S and Luz, S},
title = {SoniNet: an AI framework for enhancing voice features in speech-based health monitoring.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {1977352},
pmid = {43047669},
issn = {1663-4365},
abstract = {Deep learning based speech embeddings learned from large-scale speech corpora have achieved strong performance across a range of speech analysis tasks. However, handcrafted acoustic features, such as prosodic, spectral, and voice-quality descriptors, remain widely used in clinical speech analysis because of their established role in characterizing vocal behavior. Despite this, these features often struggle to generalize across variations in speech dynamics, recording duration, and recording conditions. This paper introduces SoniNet, a framework that enhances the discriminative power of handcrafted acoustic features by learning data-driven temporal representations from large-scale speech data. SoniNet captures the temporal evolution of acoustic descriptors across speech recordings of variable length while maintaining compatibility with established acoustic feature sets used in clinical speech analysis. We evaluate SoniNet on benchmark speech data sets and demonstrate consistent improvements in classification performance across clinical speech assessment tasks, outperforming conventional acoustic modeling approaches in 22 out of 24 feature-task combinations. These findings highlight the potential of SoniNet as a robust framework for speech-based health monitoring, affect recognition, and computational behavioral analysis.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Dementia in individuals with intellectual disabilities: An exploratory study of prevalence and mortality risk using Dutch routine care and population data.
Alzheimer's & dementia (Amsterdam, Netherlands), 18(4):e70542.
INTRODUCTION: Improvements in care for individuals with intellectual disabilities (ID) have increased life expectancy, but have also brought an increase in age-related conditions such as dementia. While Alzheimer's Dementia in Down syndrome is well-documented, data on overall dementia prevalence and related mortality across the broader ID population are limited.
METHODS: Exploratory analyzes were performed, using dementia data from a large regional Dutch primary care database and the national Dutch mortality registry. Descriptive statistics, odds ratios, and hazard ratios were calculated.
RESULTS: People with ID showed higher dementia prevalence at younger ages compared to those without ID and a higher risk of dementia-related mortality.
DISCUSSION: These findings suggest individuals with ID are diagnosed with dementia at younger ages than in the general population. There is a need for greater awareness of dementia in individuals with ID among health care providers, and increased knowledge on the distinct clinical characteristics in this population.
Additional Links: PMID-43047819
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047819,
year = {2026},
author = {Cuypers, M and Celik, A and Dimmendaal, M and Duits, F and Boot, E and van Eeghen, AM},
title = {Dementia in individuals with intellectual disabilities: An exploratory study of prevalence and mortality risk using Dutch routine care and population data.},
journal = {Alzheimer's & dementia (Amsterdam, Netherlands)},
volume = {18},
number = {4},
pages = {e70542},
pmid = {43047819},
issn = {2352-8729},
abstract = {INTRODUCTION: Improvements in care for individuals with intellectual disabilities (ID) have increased life expectancy, but have also brought an increase in age-related conditions such as dementia. While Alzheimer's Dementia in Down syndrome is well-documented, data on overall dementia prevalence and related mortality across the broader ID population are limited.
METHODS: Exploratory analyzes were performed, using dementia data from a large regional Dutch primary care database and the national Dutch mortality registry. Descriptive statistics, odds ratios, and hazard ratios were calculated.
RESULTS: People with ID showed higher dementia prevalence at younger ages compared to those without ID and a higher risk of dementia-related mortality.
DISCUSSION: These findings suggest individuals with ID are diagnosed with dementia at younger ages than in the general population. There is a need for greater awareness of dementia in individuals with ID among health care providers, and increased knowledge on the distinct clinical characteristics in this population.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Disulfidptosis in neurological disorders: from disulfide stress to actin cytoskeletal collapse.
Frontiers in aging neuroscience, 18:2003656.
The mechanisms driving irreversible neural cell loss in neurodegenerative diseases remain elusive. The collapse of cellular redox balance has unveiled a complex network of emerging metabolic cell death modalities that extend far beyond classical apoptosis. Disulfidptosis, a newly identified form of regulated cell death driven by disulfide stress and uniquely marked by actin cytoskeletal collapse, adds a critical dimension to this network. This review establishes an integrative framework-from sulfur metabolic imbalance to cytoskeletal collapse-for understanding this lethal pathway specifically within the nervous system. we focus on three features that are distinctive to neural tissue: the neuron-glia metabolic coupling that dictates which cell type is most vulnerable; the contrast between chronic disulfide stress dynamics in neurodegeneration and acute stress dynamics in ischemic stroke; and the blood-brain barrier (BBB) and cellular heterogeneity constraints that shape translational strategies. We first establish the cystine/cysteine cycle as the central hub of sulfur metabolism, revealing how it transforms from an antioxidant defense into a lethal driver of disulfide stress upon crossing a critical threshold. We then systematically dissect the molecular machinery of disulfidptosis, centered on NADPH depletion, the SLC7A11 bidirectional paradox, and aberrant cytoskeletal crosslinking. By systematically comparing disulfidptosis with ferroptosis and cuproptosis, we identify the SLC7A11-cystine-NADPH axis as a shared regulatory node. We further discuss how this mechanism may converge to contribute to neural cell injury across chronic neurodegenerative and acute neurological conditions, including Alzheimer's disease and Parkinson's disease, and may also extend to acute neurological conditions such as ischemic stroke. Finally, we propose a dual neuroprotective strategy targeting disulfidptosis and highlight its biomarker potential. Collectively, this review offers a new paradigm for understanding metabolic cell death in neurodegenerative diseases and lays a theoretical foundation for neuroprotective strategies targeting disulfide homeostasis.
Additional Links: PMID-43047855
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047855,
year = {2026},
author = {Qi, C and Gu, Y and Lei, J and Jiang, L and Li, J and Bai, B and Jiang, X},
title = {Disulfidptosis in neurological disorders: from disulfide stress to actin cytoskeletal collapse.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {2003656},
pmid = {43047855},
issn = {1663-4365},
abstract = {The mechanisms driving irreversible neural cell loss in neurodegenerative diseases remain elusive. The collapse of cellular redox balance has unveiled a complex network of emerging metabolic cell death modalities that extend far beyond classical apoptosis. Disulfidptosis, a newly identified form of regulated cell death driven by disulfide stress and uniquely marked by actin cytoskeletal collapse, adds a critical dimension to this network. This review establishes an integrative framework-from sulfur metabolic imbalance to cytoskeletal collapse-for understanding this lethal pathway specifically within the nervous system. we focus on three features that are distinctive to neural tissue: the neuron-glia metabolic coupling that dictates which cell type is most vulnerable; the contrast between chronic disulfide stress dynamics in neurodegeneration and acute stress dynamics in ischemic stroke; and the blood-brain barrier (BBB) and cellular heterogeneity constraints that shape translational strategies. We first establish the cystine/cysteine cycle as the central hub of sulfur metabolism, revealing how it transforms from an antioxidant defense into a lethal driver of disulfide stress upon crossing a critical threshold. We then systematically dissect the molecular machinery of disulfidptosis, centered on NADPH depletion, the SLC7A11 bidirectional paradox, and aberrant cytoskeletal crosslinking. By systematically comparing disulfidptosis with ferroptosis and cuproptosis, we identify the SLC7A11-cystine-NADPH axis as a shared regulatory node. We further discuss how this mechanism may converge to contribute to neural cell injury across chronic neurodegenerative and acute neurological conditions, including Alzheimer's disease and Parkinson's disease, and may also extend to acute neurological conditions such as ischemic stroke. Finally, we propose a dual neuroprotective strategy targeting disulfidptosis and highlight its biomarker potential. Collectively, this review offers a new paradigm for understanding metabolic cell death in neurodegenerative diseases and lays a theoretical foundation for neuroprotective strategies targeting disulfide homeostasis.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Ketogenic diet and ketone body metabolism in Alzheimer's disease: mechanisms, clinical evidence, and emerging perspectives.
Frontiers in nutrition, 13:1971568.
Alzheimer's disease (AD), the most common neurodegenerative disorder, is associated with progressive cognitive impairment, β-amyloid (Aβ) aggregation, and tau hyperphosphorylation, while currently available treatments provide only partial symptomatic relief or modestly slow disease progression. Cerebral glucose hypometabolism and neuronal energy deficiency can occur early in AD, making metabolic dysfunction a potential therapeutic target. The ketogenic diet (KD) restricts carbohydrate intake to stimulate hepatic ketogenesis and increase the availability of ketone bodies; its principal circulating metabolite, β-hydroxybutyrate (BHB), may influence AD-related processes through metabolic, epigenetic, and immunomodulatory pathways. This review summarizes proposed mechanisms and clinical evidence for ketogenic dietary interventions and exogenous ketone strategies in AD and mild cognitive impairment (MCI). BHB may provide an alternative oxidative substrate, influence mitochondrial and autophagy-related signaling, serve as a substrate for β-hydroxybutyrylation (Kbhb), inhibit selected histone deacetylases (HDACs), and modulate inflammatory pathways involving GPR109A and the NLRP3 inflammasome. These mechanisms are supported mainly by preclinical studies and have not been jointly validated in clinical trials. Human studies remain limited by small samples, heterogeneous interventions, short follow-up, and variable blinding and adherence. We therefore discuss safety, methodological limitations, and priorities for biomarker-informed clinical studies, while emphasizing that the clinical relevance of the proposed mechanisms remains to be established.
Additional Links: PMID-43047907
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047907,
year = {2026},
author = {Deng, Y and Hu, B},
title = {Ketogenic diet and ketone body metabolism in Alzheimer's disease: mechanisms, clinical evidence, and emerging perspectives.},
journal = {Frontiers in nutrition},
volume = {13},
number = {},
pages = {1971568},
pmid = {43047907},
issn = {2296-861X},
abstract = {Alzheimer's disease (AD), the most common neurodegenerative disorder, is associated with progressive cognitive impairment, β-amyloid (Aβ) aggregation, and tau hyperphosphorylation, while currently available treatments provide only partial symptomatic relief or modestly slow disease progression. Cerebral glucose hypometabolism and neuronal energy deficiency can occur early in AD, making metabolic dysfunction a potential therapeutic target. The ketogenic diet (KD) restricts carbohydrate intake to stimulate hepatic ketogenesis and increase the availability of ketone bodies; its principal circulating metabolite, β-hydroxybutyrate (BHB), may influence AD-related processes through metabolic, epigenetic, and immunomodulatory pathways. This review summarizes proposed mechanisms and clinical evidence for ketogenic dietary interventions and exogenous ketone strategies in AD and mild cognitive impairment (MCI). BHB may provide an alternative oxidative substrate, influence mitochondrial and autophagy-related signaling, serve as a substrate for β-hydroxybutyrylation (Kbhb), inhibit selected histone deacetylases (HDACs), and modulate inflammatory pathways involving GPR109A and the NLRP3 inflammasome. These mechanisms are supported mainly by preclinical studies and have not been jointly validated in clinical trials. Human studies remain limited by small samples, heterogeneous interventions, short follow-up, and variable blinding and adherence. We therefore discuss safety, methodological limitations, and priorities for biomarker-informed clinical studies, while emphasizing that the clinical relevance of the proposed mechanisms remains to be established.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.
The journal of medicine access, 10:27550834261495456.
BACKGROUND: Neurological disorders are diseases or conditions that affect the brain, spinal cord, and nerves. Without understanding the magnitude and burden, it will be difficult to design evidence-based interventions. Therefore, this study will fill the information gap by analyzing the magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.
METHODS: A retrospective, systematic analysis of secondary data was conducted. Estimates of age-standardized incidence, prevalence, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) were extracted. Percentage change was also used to assess trends in all metrics between 1990 and 2023. Each metric was estimated to be per 100,000 populations with a 95% uncertainty interval. The analysis included Level 2 and specific Level 3 cause categories, adhering to the GATHER guidelines for transparency.
RESULTS: In 2023, the overall age-standardized incidence rate of neurological disorders in Ethiopia was 7,588 per 100,000 population (95% UI: 6,659, 8,490) and the prevalence rate was 25,346 per 100,000 population (95%UI: 23,005, 27,886). While overall rates showed a slight, statistically significant decline, Parkinson's disease showed a significant increase in incidence of 14% (95% UI: 7%, 21%) and prevalence of 35% (95% UI: 25%, 45%). Headache disorders (tension-type headache and migraine) were the main drivers of YLDs, whereas idiopathic epilepsy and Alzheimer's disease were the leading contributors to YLLs and DALYs. The burden increases sharply after age 55. Notably, Parkinson's, motor neuron, and other neurological disorders exhibited significant increments across all primary burden metrics (DALYs, YLLs, and YLDs). Gender disparities were observed, with females bearing a higher burden of Alzheimer's and migraine, while males were more affected by Parkinson's disease.
CONCLUSION: The observed trends reflect a demographic transition toward an aging population. The slight decline in magnitude and insignificant change in burden likely reflect underdiagnosis and limited healthcare access rather than true epidemiological stability. These findings underscore the urgent need for targeted public health programs, including integrating neurological care into primary healthcare, developing age-specific and gender-responsive care strategies, and improving surveillance systems to monitor the rising burden in Ethiopia.
Additional Links: PMID-43047934
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047934,
year = {2026},
author = {Tadesse, S and Gebremariam, AG and Jemal, M and Areru, HA and Mersha, A and Zewudie, A and Dube, GN},
title = {Magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.},
journal = {The journal of medicine access},
volume = {10},
number = {},
pages = {27550834261495456},
pmid = {43047934},
issn = {2755-0834},
abstract = {BACKGROUND: Neurological disorders are diseases or conditions that affect the brain, spinal cord, and nerves. Without understanding the magnitude and burden, it will be difficult to design evidence-based interventions. Therefore, this study will fill the information gap by analyzing the magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.
METHODS: A retrospective, systematic analysis of secondary data was conducted. Estimates of age-standardized incidence, prevalence, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) were extracted. Percentage change was also used to assess trends in all metrics between 1990 and 2023. Each metric was estimated to be per 100,000 populations with a 95% uncertainty interval. The analysis included Level 2 and specific Level 3 cause categories, adhering to the GATHER guidelines for transparency.
RESULTS: In 2023, the overall age-standardized incidence rate of neurological disorders in Ethiopia was 7,588 per 100,000 population (95% UI: 6,659, 8,490) and the prevalence rate was 25,346 per 100,000 population (95%UI: 23,005, 27,886). While overall rates showed a slight, statistically significant decline, Parkinson's disease showed a significant increase in incidence of 14% (95% UI: 7%, 21%) and prevalence of 35% (95% UI: 25%, 45%). Headache disorders (tension-type headache and migraine) were the main drivers of YLDs, whereas idiopathic epilepsy and Alzheimer's disease were the leading contributors to YLLs and DALYs. The burden increases sharply after age 55. Notably, Parkinson's, motor neuron, and other neurological disorders exhibited significant increments across all primary burden metrics (DALYs, YLLs, and YLDs). Gender disparities were observed, with females bearing a higher burden of Alzheimer's and migraine, while males were more affected by Parkinson's disease.
CONCLUSION: The observed trends reflect a demographic transition toward an aging population. The slight decline in magnitude and insignificant change in burden likely reflect underdiagnosis and limited healthcare access rather than true epidemiological stability. These findings underscore the urgent need for targeted public health programs, including integrating neurological care into primary healthcare, developing age-specific and gender-responsive care strategies, and improving surveillance systems to monitor the rising burden in Ethiopia.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Pseudolaric Acid A and Pseudolaric Acid B Exert Dual Neuroprotection: Inhibiting Aβ-Induced PC12 Apoptosis and Neuroinflammation with Therapeutic Potential in Alzheimer's Disease Mice.
ACS pharmacology & translational science, 9(11):3264-3276.
OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disorder with no effective prevention strategy. This study explored the neuroprotective effects of pseudolaric acid A (PAA) and pseudolaric acid B (PAB) against Aβ25-35-induced PC12 cell apoptosis and their anti-inflammatory roles in macrophages/microglia. We also assessed PAB's therapeutic potential in an AD mouse model.
METHOD: To dissect the potential antiapoptotic and anti-inflammatory mechanisms of PAA and PAB, we established distinct in vitro models, including the Aβ25-35-induced PC12 apoptosis model and LPS-stimulated BV2 microglia/RAW264.7 macrophage inflammatory models. The effects of PAA and PAB on cell viability, apoptosis, inflammation, migration, NO release, ROS levels, miRNA-155 expression, and related protein expression were investigated in vitro. Subsequently, the AlCl3-induced AD mouse model was established, and the effects of PAB on spatial learning/memory abilities and hippocampal neurons were evaluated by the Morris water maze and HE staining.
RESULT: Our in vitro results showed that PAA and PAB could inhibit the apoptosis of PC12 cells induced by Aβ25-35 by regulating the expression of IRS-1, p-Akt, and p-GSK-3β. In parallel, PAA and PAB could alleviate the inflammatory response of macrophages and microglia induced by LPS by regulating the expression of P-Iκ-Bα/Iκ-Bα, TNF-α, and TGF-β1. Furthermore, behavioral tests showed that PAB had a certain therapeutic effect on AD model mice, as evidenced by improved spatial learning and memory.
CONCLUSION: Our in vitro findings indicate that PAA and PAB exert neuroprotective effects via two distinct mechanisms: inhibiting apoptosis through PI3K/Akt signaling and attenuating neuroinflammation through NF-κB/miR-155 modulation. In vivo, PAB improved cognitive function in AD model mice. Although further validation is required to confirm these mechanisms in vivo, these results support the therapeutic potential of PAA and PAB for AD.
Additional Links: PMID-43047984
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047984,
year = {2026},
author = {Wang, D and Liu, L and Sun, T and Guan, Q and Qiu, T and Zhao, M and Meng, X},
title = {Pseudolaric Acid A and Pseudolaric Acid B Exert Dual Neuroprotection: Inhibiting Aβ-Induced PC12 Apoptosis and Neuroinflammation with Therapeutic Potential in Alzheimer's Disease Mice.},
journal = {ACS pharmacology & translational science},
volume = {9},
number = {11},
pages = {3264-3276},
pmid = {43047984},
issn = {2575-9108},
abstract = {OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disorder with no effective prevention strategy. This study explored the neuroprotective effects of pseudolaric acid A (PAA) and pseudolaric acid B (PAB) against Aβ25-35-induced PC12 cell apoptosis and their anti-inflammatory roles in macrophages/microglia. We also assessed PAB's therapeutic potential in an AD mouse model.
METHOD: To dissect the potential antiapoptotic and anti-inflammatory mechanisms of PAA and PAB, we established distinct in vitro models, including the Aβ25-35-induced PC12 apoptosis model and LPS-stimulated BV2 microglia/RAW264.7 macrophage inflammatory models. The effects of PAA and PAB on cell viability, apoptosis, inflammation, migration, NO release, ROS levels, miRNA-155 expression, and related protein expression were investigated in vitro. Subsequently, the AlCl3-induced AD mouse model was established, and the effects of PAB on spatial learning/memory abilities and hippocampal neurons were evaluated by the Morris water maze and HE staining.
RESULT: Our in vitro results showed that PAA and PAB could inhibit the apoptosis of PC12 cells induced by Aβ25-35 by regulating the expression of IRS-1, p-Akt, and p-GSK-3β. In parallel, PAA and PAB could alleviate the inflammatory response of macrophages and microglia induced by LPS by regulating the expression of P-Iκ-Bα/Iκ-Bα, TNF-α, and TGF-β1. Furthermore, behavioral tests showed that PAB had a certain therapeutic effect on AD model mice, as evidenced by improved spatial learning and memory.
CONCLUSION: Our in vitro findings indicate that PAA and PAB exert neuroprotective effects via two distinct mechanisms: inhibiting apoptosis through PI3K/Akt signaling and attenuating neuroinflammation through NF-κB/miR-155 modulation. In vivo, PAB improved cognitive function in AD model mice. Although further validation is required to confirm these mechanisms in vivo, these results support the therapeutic potential of PAA and PAB for AD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Glymphatic dysfunction and amyloid-β clearance in Alzheimer's disease: mechanistic insights and therapeutic potential of traditional Chinese medicine.
Frontiers in aging neuroscience, 18:1996143.
The glymphatic system supports cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange and extracellular solute transport, and its dysfunction may contribute to amyloid-β (Aβ) accumulation in Alzheimer's disease (AD). This narrative review examines mechanisms linking impaired brain fluid transport to Aβ retention, focusing on altered perivascular aquaporin-4 (AQP4) polarization, vascular and paravascular remodeling, impaired cerebrovascular dynamics, astrocyte dysfunction, neuroinflammation, and sleep and circadian disturbances. It also evaluates preclinical evidence for Chinese herbal interventions. Preclinical studies have reported changes in CSF tracer influx or distribution, parenchymal solute efflux, meningeal lymphatic tracer transport, AQP4 localization, and lymphatic vessel morphology, often accompanied by reduced Aβ burden and improved cognitive performance. Other studies primarily report changes in cellular Aβ handling, inflammation, or sleep and therefore provide only indirect support for glymphatic involvement. Glymphatic exchange, intramural periarterial drainage, and meningeal lymphatic outflow are anatomically distinct processes with different experimental readouts; reduced tissue Aβ alone does not establish enhanced clearance. Major limitations include heterogeneity in experimental models and tracer methods, limited pathway-specific causal validation, and a lack of clinical evidence directly supporting these mechanisms of action. Dynamic transport measurements, pathway-specific perturbations, and standardized formulations are needed to determine whether enhancement of brain fluid and solute clearance represents a clinically translatable mechanism of Chinese herbal interventions in AD.
Additional Links: PMID-43048073
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048073,
year = {2026},
author = {Wang, B and Luo, L and Ying, C and Yang, J and Zhang, Y},
title = {Glymphatic dysfunction and amyloid-β clearance in Alzheimer's disease: mechanistic insights and therapeutic potential of traditional Chinese medicine.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {1996143},
pmid = {43048073},
issn = {1663-4365},
abstract = {The glymphatic system supports cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange and extracellular solute transport, and its dysfunction may contribute to amyloid-β (Aβ) accumulation in Alzheimer's disease (AD). This narrative review examines mechanisms linking impaired brain fluid transport to Aβ retention, focusing on altered perivascular aquaporin-4 (AQP4) polarization, vascular and paravascular remodeling, impaired cerebrovascular dynamics, astrocyte dysfunction, neuroinflammation, and sleep and circadian disturbances. It also evaluates preclinical evidence for Chinese herbal interventions. Preclinical studies have reported changes in CSF tracer influx or distribution, parenchymal solute efflux, meningeal lymphatic tracer transport, AQP4 localization, and lymphatic vessel morphology, often accompanied by reduced Aβ burden and improved cognitive performance. Other studies primarily report changes in cellular Aβ handling, inflammation, or sleep and therefore provide only indirect support for glymphatic involvement. Glymphatic exchange, intramural periarterial drainage, and meningeal lymphatic outflow are anatomically distinct processes with different experimental readouts; reduced tissue Aβ alone does not establish enhanced clearance. Major limitations include heterogeneity in experimental models and tracer methods, limited pathway-specific causal validation, and a lack of clinical evidence directly supporting these mechanisms of action. Dynamic transport measurements, pathway-specific perturbations, and standardized formulations are needed to determine whether enhancement of brain fluid and solute clearance represents a clinically translatable mechanism of Chinese herbal interventions in AD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Alzheimer's disease as a multilevel pathological network: mechanisms, heterogeneity, and therapeutic translation.
Frontiers in aging neuroscience, 18:1987345.
Amyloid-β (Aβ) plaques and Alzheimer-type tau pathology are the neuropathological hallmarks of Alzheimer's disease, but their burden does not fully explain variation in vulnerability, symptoms or progression. This structured narrative review presents a multilevel conceptual framework for comparing how protein pathology relates to synaptic and network dysfunction, cellular maintenance, glial responses and systemic conditions. Its contribution is a set of relationship-specific appraisal rules: a driver, mediator, amplifier or modifier role must be supported for a defined outcome, biological setting and stage, with human associations distinguished from experimental causal tests. Roles remain unassigned when evidence cannot discriminate among causal contributions, responses and compensation. Threshold, topography and tempo organize heterogeneity without defining validated subtypes. Measurements must match the biological process and intended use; biomarker change cannot by itself establish clinical benefit. Therapeutic reasoning considers stage, co-pathology, safety, delivery conditions and patient priorities. Four provisional predictions concern post-onset complement inhibition in a tauopathy model, frailty-related modification of pathology-clinical coupling, the predictive value of complementary measurements and incremental clinical benefit from a conditional combination strategy. Each specifies the comparison and findings that would weaken the proposed relationship or use. The framework is an evidence map rather than a quantitative network or validated treatment algorithm. Its narrative evidence base and uneven human causal support limit generalization; prospective evaluation is required to establish added explanatory, predictive or clinical value.
Additional Links: PMID-43048080
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048080,
year = {2026},
author = {Feng, J and Huang, X and Shi, Y and Gao, Y and Chen, J and Song, Z and Mao, X and Niu, S and Li, J and Li, J},
title = {Alzheimer's disease as a multilevel pathological network: mechanisms, heterogeneity, and therapeutic translation.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {1987345},
pmid = {43048080},
issn = {1663-4365},
abstract = {Amyloid-β (Aβ) plaques and Alzheimer-type tau pathology are the neuropathological hallmarks of Alzheimer's disease, but their burden does not fully explain variation in vulnerability, symptoms or progression. This structured narrative review presents a multilevel conceptual framework for comparing how protein pathology relates to synaptic and network dysfunction, cellular maintenance, glial responses and systemic conditions. Its contribution is a set of relationship-specific appraisal rules: a driver, mediator, amplifier or modifier role must be supported for a defined outcome, biological setting and stage, with human associations distinguished from experimental causal tests. Roles remain unassigned when evidence cannot discriminate among causal contributions, responses and compensation. Threshold, topography and tempo organize heterogeneity without defining validated subtypes. Measurements must match the biological process and intended use; biomarker change cannot by itself establish clinical benefit. Therapeutic reasoning considers stage, co-pathology, safety, delivery conditions and patient priorities. Four provisional predictions concern post-onset complement inhibition in a tauopathy model, frailty-related modification of pathology-clinical coupling, the predictive value of complementary measurements and incremental clinical benefit from a conditional combination strategy. Each specifies the comparison and findings that would weaken the proposed relationship or use. The framework is an evidence map rather than a quantitative network or validated treatment algorithm. Its narrative evidence base and uneven human causal support limit generalization; prospective evaluation is required to establish added explanatory, predictive or clinical value.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Aberrant Interregional Brain Connectivity During Different Memory Processes in a Mouse Model of Alzheimer's Disease.
Neuroscience insights, 21:26331055261496260.
Reduced working memory is a hallmark of Alzheimer's disease (AD). Analyzing local field potentials (LFPs) across neural networks provides crucial insights into the mechanisms underlying these cognitive deficits. Standard LFP studies often rely on spontaneous exploration, while we designed a novel Y-maze paradigm with aversive voltage feedback. This paradigm enable precise time-locked temporal subdivision of trials (first choice vs. second choice, correct vs. incorrect decisionst) to compare memory-related electrophysiology between AD and normal mice. Our analysis reveals four key findings: (1) LFP exhibit task-specific lateralization, suggesting the right hemisphere is prominently engaged during this specific spatial navigation context; (2) correct behavioral outcomes correlate with pre-decision neural states, highlighting distinct network encoding mechanisms compared to error processing; (3) causal connectivity suggests a disrupted functional balance between the cingulate gyrus and hippocampus in AD mice, it may reflect early network compensation; (4) AD mice display widespread oscillatory and directional connectivity disruptions during memory process, which strongly correlate with spatial memory failures. These findings characterize AD memory impairment as a dynamic network disconnectivity syndrome and highlight cingulate gyrus-hippocampal interactions as potential biomarkers to improve memory dysfunction in AD.
Additional Links: PMID-43048114
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048114,
year = {2026},
author = {Wu, L and Li, S and Liang, L and Yin, S and Zhou, P and Lu, Z and Li, B and Wang, P and Lv, S},
title = {Aberrant Interregional Brain Connectivity During Different Memory Processes in a Mouse Model of Alzheimer's Disease.},
journal = {Neuroscience insights},
volume = {21},
number = {},
pages = {26331055261496260},
pmid = {43048114},
issn = {2633-1055},
abstract = {Reduced working memory is a hallmark of Alzheimer's disease (AD). Analyzing local field potentials (LFPs) across neural networks provides crucial insights into the mechanisms underlying these cognitive deficits. Standard LFP studies often rely on spontaneous exploration, while we designed a novel Y-maze paradigm with aversive voltage feedback. This paradigm enable precise time-locked temporal subdivision of trials (first choice vs. second choice, correct vs. incorrect decisionst) to compare memory-related electrophysiology between AD and normal mice. Our analysis reveals four key findings: (1) LFP exhibit task-specific lateralization, suggesting the right hemisphere is prominently engaged during this specific spatial navigation context; (2) correct behavioral outcomes correlate with pre-decision neural states, highlighting distinct network encoding mechanisms compared to error processing; (3) causal connectivity suggests a disrupted functional balance between the cingulate gyrus and hippocampus in AD mice, it may reflect early network compensation; (4) AD mice display widespread oscillatory and directional connectivity disruptions during memory process, which strongly correlate with spatial memory failures. These findings characterize AD memory impairment as a dynamic network disconnectivity syndrome and highlight cingulate gyrus-hippocampal interactions as potential biomarkers to improve memory dysfunction in AD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Atomoxetine and risk of Alzheimer's disease in older adults.
Alzheimer's & dementia (New York, N. Y.), 12(4):e70345.
INTRODUCTION: Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's disease (AD). Its association with incident AD is unclear.
METHODS: This non-concurrent prospective study emulated a target trial among Medicare beneficiaries (January 1, 2007-December 31, 2023). The primary outcome was AD, determined using a validated algorithm. We estimated 5- and 10-year risk ratios (RRs) and risk differences (RDs). Analyses were examined overall and by indication.
RESULTS: This study included 70,367 person-trials (74.6% ≥70 years; 59.5% female; 86.7% non-Hispanic White). Initiation of atomoxetine versus no initiation was not associated with 5- or 10-year risk of AD but was associated with lower risk of AD-free death. In indication-specific analyses, atomoxetine was associated with lower 5-year risk of AD and AD-free death among individuals with depression.
DISCUSSION: Initiation of atomoxetine was not associated with lower risk of AD later in life. The lower risk of AD among people with depression warrants further study.
Additional Links: PMID-43048136
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048136,
year = {2026},
author = {Bress, AP and Xu, Y and Marcum, ZA and Davis, M and LaCroix, AZ and Feldman, HH and Shadyab, AH},
title = {Atomoxetine and risk of Alzheimer's disease in older adults.},
journal = {Alzheimer's & dementia (New York, N. Y.)},
volume = {12},
number = {4},
pages = {e70345},
pmid = {43048136},
issn = {2352-8737},
abstract = {INTRODUCTION: Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's disease (AD). Its association with incident AD is unclear.
METHODS: This non-concurrent prospective study emulated a target trial among Medicare beneficiaries (January 1, 2007-December 31, 2023). The primary outcome was AD, determined using a validated algorithm. We estimated 5- and 10-year risk ratios (RRs) and risk differences (RDs). Analyses were examined overall and by indication.
RESULTS: This study included 70,367 person-trials (74.6% ≥70 years; 59.5% female; 86.7% non-Hispanic White). Initiation of atomoxetine versus no initiation was not associated with 5- or 10-year risk of AD but was associated with lower risk of AD-free death. In indication-specific analyses, atomoxetine was associated with lower 5-year risk of AD and AD-free death among individuals with depression.
DISCUSSION: Initiation of atomoxetine was not associated with lower risk of AD later in life. The lower risk of AD among people with depression warrants further study.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer's disease: emerging roles in astrocyte activation and pathological signaling.
Frontiers in immunology, 17:1978082.
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau pathology, and persistent neuroinflammation. Although therapeutic strategies targeting Aβ and Tau have significantly advanced our understanding of AD pathogenesis, growing attention has been directed toward the role of immune dysregulation in AD progression, highlighting the need to identify immune regulators that contribute to AD-associated pathological mechanisms. Interferon-induced transmembrane protein 3 (IFITM3), an interferon-responsive membrane protein involved in innate immune responses, has recently emerged as a potential regulator of AD-associated pathological processes. Experimental and transcriptomic studies suggest that IFITM3 modulates γ-secretase activity, amyloidogenic processing, inflammatory activation, and membrane trafficking pathways. Notably, IFITM3 is enriched in reactive astrocyte populations, raising the possibility that astrocytic IFITM3 contributes to the regulation of interferon-associated glial responses and neuroinflammatory signaling. In this review, we summarize current evidence regarding the role of IFITM3 in AD, focusing on astrocyte-associated mechanisms, including inflammatory regulation, endo-lysosomal dysfunction, and extracellular vesicle-mediated communication. We further discuss IFITM3-related signaling across astrocytes, neurons, microglia, vascular cells, and peripheral immune compartments, as well as emerging therapeutic approaches targeting IFITM3-associated pathways. Collectively, current evidence suggests that IFITM3 may serve as a potential regulatory interface connecting interferon activation, neuroimmune dysregulation, amyloid metabolism, and neuroinflammatory signaling, providing new perspectives on astrocyte-mediated mechanisms and therapeutic intervention in AD.
Additional Links: PMID-43048173
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048173,
year = {2026},
author = {Zhang, T and Huang, J and Wang, H and Li, J and Han, X and Yuan, Y},
title = {Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer's disease: emerging roles in astrocyte activation and pathological signaling.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1978082},
pmid = {43048173},
issn = {1664-3224},
mesh = {Humans ; *Alzheimer Disease/immunology/metabolism/pathology ; *Astrocytes/metabolism/immunology/pathology ; *Membrane Proteins/metabolism/immunology/genetics ; Animals ; Signal Transduction/immunology ; *RNA-Binding Proteins/metabolism/immunology/genetics ; *Neuroimmunomodulation ; Immunity, Innate ; },
abstract = {Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau pathology, and persistent neuroinflammation. Although therapeutic strategies targeting Aβ and Tau have significantly advanced our understanding of AD pathogenesis, growing attention has been directed toward the role of immune dysregulation in AD progression, highlighting the need to identify immune regulators that contribute to AD-associated pathological mechanisms. Interferon-induced transmembrane protein 3 (IFITM3), an interferon-responsive membrane protein involved in innate immune responses, has recently emerged as a potential regulator of AD-associated pathological processes. Experimental and transcriptomic studies suggest that IFITM3 modulates γ-secretase activity, amyloidogenic processing, inflammatory activation, and membrane trafficking pathways. Notably, IFITM3 is enriched in reactive astrocyte populations, raising the possibility that astrocytic IFITM3 contributes to the regulation of interferon-associated glial responses and neuroinflammatory signaling. In this review, we summarize current evidence regarding the role of IFITM3 in AD, focusing on astrocyte-associated mechanisms, including inflammatory regulation, endo-lysosomal dysfunction, and extracellular vesicle-mediated communication. We further discuss IFITM3-related signaling across astrocytes, neurons, microglia, vascular cells, and peripheral immune compartments, as well as emerging therapeutic approaches targeting IFITM3-associated pathways. Collectively, current evidence suggests that IFITM3 may serve as a potential regulatory interface connecting interferon activation, neuroimmune dysregulation, amyloid metabolism, and neuroinflammatory signaling, providing new perspectives on astrocyte-mediated mechanisms and therapeutic intervention in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/immunology/metabolism/pathology
*Astrocytes/metabolism/immunology/pathology
*Membrane Proteins/metabolism/immunology/genetics
Animals
Signal Transduction/immunology
*RNA-Binding Proteins/metabolism/immunology/genetics
*Neuroimmunomodulation
Immunity, Innate
RevDate: 2026-11-18
CmpDate: 2026-11-18
Mechanistic roles and therapeutic potential of gut microbiota-neuroimmune crosstalk in the development and progression of Alzheimer's disease.
Frontiers in microbiology, 17:1958902.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and distinct neuropathological and biological alterations, including amyloid-β (Aβ) deposition, tau pathology, synaptic dysfunction, and neuronal loss. Increasing evidence suggests that dysregulated neuroimmune responses are closely associated with AD progression and may provide an important interface through which the gut microbiota influences brain homeostasis. Gut microbial dysbiosis and alterations in microbial functional output have been reported in patients with AD and mild cognitive impairment, although current human evidence remains predominantly associative. Experimental and animal studies further suggest that microbial structural components, microbiota-derived metabolites, and long-distance communication signals, including bacterial extracellular vesicles and microbial nucleic acids, may modulate intestinal barrier integrity, peripheral immunity, cerebrovascular interfaces, and central glial responses, thereby potentially influencing Aβ clearance, tau pathology, and synaptic function. Conversely, AD-associated alterations in neuroimmune regulation, autonomic signaling, neuroendocrine function, and mucosal immunity may reshape the intestinal ecological niche and further modify microbial composition and function, supporting a bidirectional gut microbiota-neuroimmune regulatory network. In this review, we integrate these interactions within a stage-oriented conceptual framework encompassing disease susceptibility, pathological initiation, amplification, and chronic progression, while emphasizing that these stages represent overlapping biological processes rather than established clinical categories. We also evaluate microbiota-based interventions, including dietary strategies, prebiotics, probiotics, psychobiotics, postbiotics, fecal microbiota transplantation, next-generation probiotics, engineered microorganisms, and metabolite-targeted approaches, with explicit consideration of their distinct evidence bases, translational limitations, and safety concerns. Overall, gut microbiota-neuroimmune crosstalk provides an integrative framework for understanding systemic contributions to AD pathophysiology, but establishing causal relevance in humans will require longitudinal studies, mechanistic validation, and population-stratified clinical trials.
Additional Links: PMID-43048367
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048367,
year = {2026},
author = {Fang, X and Xi, O and Yang, R and Tang, S and Wu, J and Dong, X},
title = {Mechanistic roles and therapeutic potential of gut microbiota-neuroimmune crosstalk in the development and progression of Alzheimer's disease.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1958902},
pmid = {43048367},
issn = {1664-302X},
abstract = {Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and distinct neuropathological and biological alterations, including amyloid-β (Aβ) deposition, tau pathology, synaptic dysfunction, and neuronal loss. Increasing evidence suggests that dysregulated neuroimmune responses are closely associated with AD progression and may provide an important interface through which the gut microbiota influences brain homeostasis. Gut microbial dysbiosis and alterations in microbial functional output have been reported in patients with AD and mild cognitive impairment, although current human evidence remains predominantly associative. Experimental and animal studies further suggest that microbial structural components, microbiota-derived metabolites, and long-distance communication signals, including bacterial extracellular vesicles and microbial nucleic acids, may modulate intestinal barrier integrity, peripheral immunity, cerebrovascular interfaces, and central glial responses, thereby potentially influencing Aβ clearance, tau pathology, and synaptic function. Conversely, AD-associated alterations in neuroimmune regulation, autonomic signaling, neuroendocrine function, and mucosal immunity may reshape the intestinal ecological niche and further modify microbial composition and function, supporting a bidirectional gut microbiota-neuroimmune regulatory network. In this review, we integrate these interactions within a stage-oriented conceptual framework encompassing disease susceptibility, pathological initiation, amplification, and chronic progression, while emphasizing that these stages represent overlapping biological processes rather than established clinical categories. We also evaluate microbiota-based interventions, including dietary strategies, prebiotics, probiotics, psychobiotics, postbiotics, fecal microbiota transplantation, next-generation probiotics, engineered microorganisms, and metabolite-targeted approaches, with explicit consideration of their distinct evidence bases, translational limitations, and safety concerns. Overall, gut microbiota-neuroimmune crosstalk provides an integrative framework for understanding systemic contributions to AD pathophysiology, but establishing causal relevance in humans will require longitudinal studies, mechanistic validation, and population-stratified clinical trials.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Alzheimer's disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study.
Therapeutic advances in neurological disorders, 19:17562864261490439.
BACKGROUND: Olfactory dysfunction (OD) is a common and important symptom at the early stage of Alzheimer's disease (AD). Growing evidence has showed that abnormal iron metabolism played important roles on the development and progression of AD. However, the specific roles and potential mechanisms of abnormal iron metabolism in AD with OD (AD-OD) patients are still unclear.
OBJECTIVES: To explore the iron metabolism changes in brain and the potential neuroinflammatory and neuropathological mechanisms of OD in AD patients.
DESIGN: A cross-sectional study of AD-OD and AD with no OD (AD-nOD) patients with measurements of cerebrospinal fluid (CSF) biomarkers, including iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers.
METHODS: AD patients were divided into AD-OD and AD-nOD groups according to the overall olfactory function assessed by Sniffin' Sticks test. The levels of iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers in CSF were measured.
RESULTS: CSF levels of ferritin, tumor necrosis factor-α (TNF-α) and phosphorylated tau 199 (P-tau199) in AD-OD group were significantly higher than those in AD-nOD group. Overall olfactory function was significantly and negatively correlated with CSF levels of ferritin, TNF-α and P-tau199 in AD patients. CSF levels of ferritin, TNF-α and P-tau199 were significantly and positively correlated with each other in AD-OD group. TNF-α mediated 29.6% of the effect of ferritin on P-tau199 in CSF.
CONCLUSION: AD-OD is correlated with the elevated CSF levels of ferritin, TNF-α and P-tau199. CSF Ferritin, TNF-α and P-tau199 levels are associated with each other and collectively correlated with OD in AD patients. TNF-α partially mediates the effect of ferritin on P-tau199 in CSF.
Additional Links: PMID-43048402
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048402,
year = {2026},
author = {Wang, R and Lian, T and Li, J and Guo, P and Li, J and Luo, D and Zhang, Y and Rong, L and He, M and Qi, J and Yue, H and Zheng, Z and Zhang, F and Liu, Z and Meng, Y and Zhang, W},
title = {Alzheimer's disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study.},
journal = {Therapeutic advances in neurological disorders},
volume = {19},
number = {},
pages = {17562864261490439},
pmid = {43048402},
issn = {1756-2856},
abstract = {BACKGROUND: Olfactory dysfunction (OD) is a common and important symptom at the early stage of Alzheimer's disease (AD). Growing evidence has showed that abnormal iron metabolism played important roles on the development and progression of AD. However, the specific roles and potential mechanisms of abnormal iron metabolism in AD with OD (AD-OD) patients are still unclear.
OBJECTIVES: To explore the iron metabolism changes in brain and the potential neuroinflammatory and neuropathological mechanisms of OD in AD patients.
DESIGN: A cross-sectional study of AD-OD and AD with no OD (AD-nOD) patients with measurements of cerebrospinal fluid (CSF) biomarkers, including iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers.
METHODS: AD patients were divided into AD-OD and AD-nOD groups according to the overall olfactory function assessed by Sniffin' Sticks test. The levels of iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers in CSF were measured.
RESULTS: CSF levels of ferritin, tumor necrosis factor-α (TNF-α) and phosphorylated tau 199 (P-tau199) in AD-OD group were significantly higher than those in AD-nOD group. Overall olfactory function was significantly and negatively correlated with CSF levels of ferritin, TNF-α and P-tau199 in AD patients. CSF levels of ferritin, TNF-α and P-tau199 were significantly and positively correlated with each other in AD-OD group. TNF-α mediated 29.6% of the effect of ferritin on P-tau199 in CSF.
CONCLUSION: AD-OD is correlated with the elevated CSF levels of ferritin, TNF-α and P-tau199. CSF Ferritin, TNF-α and P-tau199 levels are associated with each other and collectively correlated with OD in AD patients. TNF-α partially mediates the effect of ferritin on P-tau199 in CSF.},
}
RevDate: 2026-11-18
Case-cohort designs to improve efficiency for detecting effect modification.
Statistics in biosciences [Epub ahead of print].
In analyses of time-to-event outcomes, we may utilize efficient sampling designs to save effort, cost, and valuable specimens. The originally proposed case-cohort design is one such design, and performs analysis on a random sample selected from the full cohort supplemented with unsampled individuals who experienced an event. In Alzheimer's disease biomarker discovery, such cost-savings is important as samples that contain biomarker measurements can be very limited due to high burden and cost. Furthermore, quantifying differences across subgroups and ensuring that diagnostic biomarker effects can be well powered and well understood across subpopulations is an increasingly important goal. This ability to quantify subgroup differences is required in efforts to minimize health disparities and achieve precision medicine. In this paper, we emphasize the importance of such considerations and propose using a stratified case-cohort estimator to sample a subcohort with balanced subgroups across the proposed effect modifier. We provide inverse-probability-of-sampling-based estimates that consistently estimate covariate effects in the population while improving precision for assessing differences across rare subpopulations. Simulation results are presented to illustrate power gains for testing effect modification, especially as a population subgroup becomes increasingly rare, and show minimal bias for marginal covariate effect estimates. We apply this method to data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to better assess potential heterogeneity of phosphorylated tau as a biomarker for AD progression across ethnoracial and genetic status subpopulations.
Additional Links: PMID-43048665
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048665,
year = {2026},
author = {Xu, Y and Grill, JD and Gillen, DL},
title = {Case-cohort designs to improve efficiency for detecting effect modification.},
journal = {Statistics in biosciences},
volume = {},
number = {},
pages = {},
pmid = {43048665},
issn = {1867-1764},
abstract = {In analyses of time-to-event outcomes, we may utilize efficient sampling designs to save effort, cost, and valuable specimens. The originally proposed case-cohort design is one such design, and performs analysis on a random sample selected from the full cohort supplemented with unsampled individuals who experienced an event. In Alzheimer's disease biomarker discovery, such cost-savings is important as samples that contain biomarker measurements can be very limited due to high burden and cost. Furthermore, quantifying differences across subgroups and ensuring that diagnostic biomarker effects can be well powered and well understood across subpopulations is an increasingly important goal. This ability to quantify subgroup differences is required in efforts to minimize health disparities and achieve precision medicine. In this paper, we emphasize the importance of such considerations and propose using a stratified case-cohort estimator to sample a subcohort with balanced subgroups across the proposed effect modifier. We provide inverse-probability-of-sampling-based estimates that consistently estimate covariate effects in the population while improving precision for assessing differences across rare subpopulations. Simulation results are presented to illustrate power gains for testing effect modification, especially as a population subgroup becomes increasingly rare, and show minimal bias for marginal covariate effect estimates. We apply this method to data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to better assess potential heterogeneity of phosphorylated tau as a biomarker for AD progression across ethnoracial and genetic status subpopulations.},
}
RevDate: 2026-11-18
Comparison of Personal and General Views on Aging Between UK Dementia Caregivers and Non-Caregivers.
Journal of applied gerontology : the official journal of the Southern Gerontological Society [Epub ahead of print].
IntroductionAlthough positive Views on Aging (VoA) are important for the well-being of dementia caregivers, maintaining them while being in frequent/constant contact with a person with significant cognitive and physical decline may be difficult. This cross-sectional study investigated the associations of caregiving status with VoA and the moderating roles of age and sex.MethodsParticipants were 259 family dementia caregivers matched with 548 non-caregivers (1:2 matching for 229 participants and 1:3 matching for 30 participants). Indicators of VoA were Felt Age, Awareness of Age-Related Change, Non-Essentialist Beliefs about Aging, and Expectations Regarding Aging.ResultsCompared to non-caregivers, caregivers had an older felt age, perceived fewer age-related gains, perceived more age-related losses, and reported more essentialist beliefs about aging.DiscussionFamily dementia caregivers may be at risk of negative VoA. Because this may have negative consequences on caregivers' well-being, the support offered to caregivers should address, among other things, their VoA.
Additional Links: PMID-43048774
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048774,
year = {2026},
author = {Sabatini, S and Rupprecht, FS and Tischler, V and Stephan, BCM},
title = {Comparison of Personal and General Views on Aging Between UK Dementia Caregivers and Non-Caregivers.},
journal = {Journal of applied gerontology : the official journal of the Southern Gerontological Society},
volume = {},
number = {},
pages = {7334648261506279},
doi = {10.1177/07334648261506279},
pmid = {43048774},
issn = {1552-4523},
abstract = {IntroductionAlthough positive Views on Aging (VoA) are important for the well-being of dementia caregivers, maintaining them while being in frequent/constant contact with a person with significant cognitive and physical decline may be difficult. This cross-sectional study investigated the associations of caregiving status with VoA and the moderating roles of age and sex.MethodsParticipants were 259 family dementia caregivers matched with 548 non-caregivers (1:2 matching for 229 participants and 1:3 matching for 30 participants). Indicators of VoA were Felt Age, Awareness of Age-Related Change, Non-Essentialist Beliefs about Aging, and Expectations Regarding Aging.ResultsCompared to non-caregivers, caregivers had an older felt age, perceived fewer age-related gains, perceived more age-related losses, and reported more essentialist beliefs about aging.DiscussionFamily dementia caregivers may be at risk of negative VoA. Because this may have negative consequences on caregivers' well-being, the support offered to caregivers should address, among other things, their VoA.},
}
RevDate: 2026-11-18
Microvascular Oxygen Delivery Dysfunction as a Contributory Neurovascular-Metabolic Mechanism in Alzheimer's Disease.
Current Alzheimer research pii:CAR-EPUB-159796 [Epub ahead of print].
Alzheimer's disease (AD) is characterized by amyloid-β and tau pathology, neuroinflammation, synaptic dysfunction, and progressive neurodegeneration. Increasing evidence indicates that vascular dysfunction, impaired neurovascular coupling, blood-brain barrier disruption, and altered cerebral perfusion may contribute to disease vulnerability. However, the physiological mechanisms linking microvascular dysfunction to regional metabolic stress and established AD pathology remain incompletely defined. This article proposes a neurovascular-metabolic framework in which impaired cerebral microvascular oxygen delivery contributes to regional metabolic stress and may contribute to disease vulnerability and progression of Alzheimer-related pathological processes in susceptible individuals. The framework emphasizes capillary flow heterogeneity, neurovascular uncoupling, impaired oxygen extraction, pericyte-mediated capillary dysfunction, and neurovascular- unit abnormalities that may occur even in the absence of severe large-vessel ischemia. Rather than replacing amyloid- or tau-based models, the proposed framework places microvascular oxygen-delivery dysfunction within a broader network of interacting vascular, metabolic, inflammatory, and proteostatic processes. These disturbances may influence amyloidogenic processing, tau pathology, neuroinflammation, glymphatic clearance, and selective vulnerability of metabolically demanding regions such as the hippocampus and entorhinal cortex. The framework generates testable predictions involving regional oxygen extraction, microvascular flow, neurovascular coupling, and hypoxia-related signaling. If validated, interventions targeting cerebral microcirculation, neurovascular integrity, and metabolic homeostasis could complement established disease-modifying approaches.
Additional Links: PMID-43048831
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048831,
year = {2026},
author = {Gabbay, U},
title = {Microvascular Oxygen Delivery Dysfunction as a Contributory Neurovascular-Metabolic Mechanism in Alzheimer's Disease.},
journal = {Current Alzheimer research},
volume = {},
number = {},
pages = {},
doi = {10.2174/0115672050521798261029101323},
pmid = {43048831},
issn = {1875-5828},
abstract = {Alzheimer's disease (AD) is characterized by amyloid-β and tau pathology, neuroinflammation, synaptic dysfunction, and progressive neurodegeneration. Increasing evidence indicates that vascular dysfunction, impaired neurovascular coupling, blood-brain barrier disruption, and altered cerebral perfusion may contribute to disease vulnerability. However, the physiological mechanisms linking microvascular dysfunction to regional metabolic stress and established AD pathology remain incompletely defined. This article proposes a neurovascular-metabolic framework in which impaired cerebral microvascular oxygen delivery contributes to regional metabolic stress and may contribute to disease vulnerability and progression of Alzheimer-related pathological processes in susceptible individuals. The framework emphasizes capillary flow heterogeneity, neurovascular uncoupling, impaired oxygen extraction, pericyte-mediated capillary dysfunction, and neurovascular- unit abnormalities that may occur even in the absence of severe large-vessel ischemia. Rather than replacing amyloid- or tau-based models, the proposed framework places microvascular oxygen-delivery dysfunction within a broader network of interacting vascular, metabolic, inflammatory, and proteostatic processes. These disturbances may influence amyloidogenic processing, tau pathology, neuroinflammation, glymphatic clearance, and selective vulnerability of metabolically demanding regions such as the hippocampus and entorhinal cortex. The framework generates testable predictions involving regional oxygen extraction, microvascular flow, neurovascular coupling, and hypoxia-related signaling. If validated, interventions targeting cerebral microcirculation, neurovascular integrity, and metabolic homeostasis could complement established disease-modifying approaches.},
}
RevDate: 2026-11-18
Circular RNAs as emerging multi-pathway blood-based biomarkers for Alzheimer's disease: Clinical need, biological rationale, and translational considerations.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
Alzheimer's disease (AD) remains underdiagnosed in its earliest and most modifiable stages. Most patients present in primary care with mild cognitive concerns, yet diagnostic pathways are fragmented, specialist-dependent, and poorly optimized for scalable early detection, while specialists face rising referral volume and limited capacity. Positron emission tomography, cerebrospinal fluid biomarkers, and blood-based biomarkers (BBMs) are constrained by accessibility, reimbursement, indeterminate results, and inconsistent performance across populations and disease stages. This narrative review summarizes clinical and system-level barriers across primary and specialty care and highlights emerging biomarker strategies supporting earlier diagnosis. Within the expanded A/T/N/X framework, biomarkers capturing upstream, multi-domain signals may enable earlier, more comprehensive detection. Circular RNAs (circRNAs), a novel class of BBMs, are highly stable, brain-enriched, and detectable in peripheral blood, enabling minimally invasive testing. Specific circRNAs have been shown to be altered in AD and associated with core AD mechanistic processes, including circHOMER1 in synaptic function, circAβ-a and circPSEN1 in amyloid processing, circTau6 in tau pathology, and circTREM2 in neuroinflammation. In the largest blood-based circRNA study to date, a 34-circRNA signature classified biomarker-confirmed AD with an area under the curve of 0.945 versus 0.877 for plasma p-tau217, predicted progression to symptomatic AD more strongly than p-tau217 (hazard ratio 2.92 versus 1.81), showed low predictive power in non-AD dementias, and changed 2-4 years before symptom onset. These features position circRNAs as candidates for next-generation blood-based diagnosis that could streamline triage and reduce reliance on confirmatory testing. Prospective validation, assay standardization, and health economic evidence remain essential.
Additional Links: PMID-43048885
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048885,
year = {2026},
author = {DeHart, J and Song, SS and Janve, VA and Hohman, TJ and Mellios, N},
title = {Circular RNAs as emerging multi-pathway blood-based biomarkers for Alzheimer's disease: Clinical need, biological rationale, and translational considerations.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261509410},
doi = {10.1177/13872877261509410},
pmid = {43048885},
issn = {1875-8908},
abstract = {Alzheimer's disease (AD) remains underdiagnosed in its earliest and most modifiable stages. Most patients present in primary care with mild cognitive concerns, yet diagnostic pathways are fragmented, specialist-dependent, and poorly optimized for scalable early detection, while specialists face rising referral volume and limited capacity. Positron emission tomography, cerebrospinal fluid biomarkers, and blood-based biomarkers (BBMs) are constrained by accessibility, reimbursement, indeterminate results, and inconsistent performance across populations and disease stages. This narrative review summarizes clinical and system-level barriers across primary and specialty care and highlights emerging biomarker strategies supporting earlier diagnosis. Within the expanded A/T/N/X framework, biomarkers capturing upstream, multi-domain signals may enable earlier, more comprehensive detection. Circular RNAs (circRNAs), a novel class of BBMs, are highly stable, brain-enriched, and detectable in peripheral blood, enabling minimally invasive testing. Specific circRNAs have been shown to be altered in AD and associated with core AD mechanistic processes, including circHOMER1 in synaptic function, circAβ-a and circPSEN1 in amyloid processing, circTau6 in tau pathology, and circTREM2 in neuroinflammation. In the largest blood-based circRNA study to date, a 34-circRNA signature classified biomarker-confirmed AD with an area under the curve of 0.945 versus 0.877 for plasma p-tau217, predicted progression to symptomatic AD more strongly than p-tau217 (hazard ratio 2.92 versus 1.81), showed low predictive power in non-AD dementias, and changed 2-4 years before symptom onset. These features position circRNAs as candidates for next-generation blood-based diagnosis that could streamline triage and reduce reliance on confirmatory testing. Prospective validation, assay standardization, and health economic evidence remain essential.},
}
RevDate: 2026-11-18
Insulin resistance is associated with lower cerebral myelin content in cognitively unimpaired women across the adult lifespan.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundInsulin resistance (IR) has been implicated in brain aging and Alzheimer's disease (AD), yet its relationship with cerebral myelin content in cognitively unimpaired adults remains unclear, particularly regarding sex differences.ObjectiveTo investigate whether peripheral IR is associated with white matter (WM) myelin content and microstructural integrity in cognitively unimpaired adults, and whether these associations differ by sex.MethodsWe used multicomponent relaxometry (n = 125) and diffusion tensor imaging (n = 116) to obtain myelin water fraction (MWF), longitudinal relaxation rate (R1), transverse relaxation rate (R2), and diffusion measures of WM microstructure. Multiple linear regression models adjusted for age, age[2], sex, and IR-by-sex interactions across fifteen WM regions.ResultsHigher IR was associated with lower MWF across widespread WM regions, including frontal, temporal, and parietal lobes, corpus callosum, internal capsule, and thalamic radiation. Similar but weaker negative trends were observed for R1, R2, and fractional anisotropy, whereas diffusivity metrics showed opposite but nonsignificant trends. Significant IR-by-sex interactions indicated stronger inverse associations between IR and MWF in women, in whom higher IR was consistently associated with lower MWF across most regions. However, the dynamic range of IR for men was limited.ConclusionsHigher peripheral IR is associated with lower myelin-sensitive WM MRI measures in cognitively unimpaired adults, with stronger associations in women. These findings identify WM myelin alterations as a potential neurobiological correlate of metabolic dysfunction and provide evidence linking peripheral metabolic dysfunction to brain changes relevant to AD pathophysiology. The findings highlight a potential sex-dependent pathway linking metabolic dysfunction to WM alterations associated with AD risk.
Additional Links: PMID-43048889
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048889,
year = {2026},
author = {Zhang, N and Fox, NY and De Rouen, A and Taranath, A and Bae, J and Guo, A and Ferrucci, L and Egan, JM and Gong, Z and Bouhrara, M},
title = {Insulin resistance is associated with lower cerebral myelin content in cognitively unimpaired women across the adult lifespan.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507268},
doi = {10.1177/13872877261507268},
pmid = {43048889},
issn = {1875-8908},
abstract = {BackgroundInsulin resistance (IR) has been implicated in brain aging and Alzheimer's disease (AD), yet its relationship with cerebral myelin content in cognitively unimpaired adults remains unclear, particularly regarding sex differences.ObjectiveTo investigate whether peripheral IR is associated with white matter (WM) myelin content and microstructural integrity in cognitively unimpaired adults, and whether these associations differ by sex.MethodsWe used multicomponent relaxometry (n = 125) and diffusion tensor imaging (n = 116) to obtain myelin water fraction (MWF), longitudinal relaxation rate (R1), transverse relaxation rate (R2), and diffusion measures of WM microstructure. Multiple linear regression models adjusted for age, age[2], sex, and IR-by-sex interactions across fifteen WM regions.ResultsHigher IR was associated with lower MWF across widespread WM regions, including frontal, temporal, and parietal lobes, corpus callosum, internal capsule, and thalamic radiation. Similar but weaker negative trends were observed for R1, R2, and fractional anisotropy, whereas diffusivity metrics showed opposite but nonsignificant trends. Significant IR-by-sex interactions indicated stronger inverse associations between IR and MWF in women, in whom higher IR was consistently associated with lower MWF across most regions. However, the dynamic range of IR for men was limited.ConclusionsHigher peripheral IR is associated with lower myelin-sensitive WM MRI measures in cognitively unimpaired adults, with stronger associations in women. These findings identify WM myelin alterations as a potential neurobiological correlate of metabolic dysfunction and provide evidence linking peripheral metabolic dysfunction to brain changes relevant to AD pathophysiology. The findings highlight a potential sex-dependent pathway linking metabolic dysfunction to WM alterations associated with AD risk.},
}
RevDate: 2026-11-18
Sex-specific cognitive predictors of conversion from mild cognitive impairment to Alzheimer's disease.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundMild cognitive impairment (MCI) involves cognitive decline without impaired daily functioning. Although it increases risk for Alzheimer's disease (AD), many remain stable or revert to normal cognition. Identifying those most likely to convert is essential for early intervention. Despite women comprising two-thirds of AD cases, sex differences in cognitive predictors of MCI conversion remain underexplored.ObjectiveTo identify baseline neuropsychological and sociodemographic factors associated with progression from MCI to AD and determine whether these conversion predictors differ by sex.MethodsUsing baseline data from the ADNI cohort and longitudinal follow-up to determine clinical outcomes, we compared baseline profiles of 435 MCI non converter individuals and 328 MCI converters, who later converted to AD, using linear regression and classification approaches, including sex effects and sex-stratified analyses.ResultsConverters had greater baseline impairments not only in episodic memory and executive function, but also language. Significant, but small, sex-by-conversion interactions in memory indicated slightly more pronounced conversion-related decline among women. Machine learning classifier achieved a mean bootstrap accuracy of 74.0% in distinguishing converters from non-converters, slightly improving in sex-specific models for women (76.2%) but not for men (71.4%). Predictive features differed by sex: memory (recognition), global cognition and executive function were most informative in men, while functional ability, memory (encoding), demographics and language were stronger predictors in women.ConclusionsThese findings highlight the value of neuropsychological assessments for predicting progression from MCI to AD and underscore the importance of incorporating sex-specific approaches to improve the clinical relevance of dementia risk prediction.
Additional Links: PMID-43048890
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048890,
year = {2026},
author = {Lajoie, X and Boutin, S and Clarke, N and Houzé, B and Brambati, SM and , },
title = {Sex-specific cognitive predictors of conversion from mild cognitive impairment to Alzheimer's disease.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261506461},
doi = {10.1177/13872877261506461},
pmid = {43048890},
issn = {1875-8908},
abstract = {BackgroundMild cognitive impairment (MCI) involves cognitive decline without impaired daily functioning. Although it increases risk for Alzheimer's disease (AD), many remain stable or revert to normal cognition. Identifying those most likely to convert is essential for early intervention. Despite women comprising two-thirds of AD cases, sex differences in cognitive predictors of MCI conversion remain underexplored.ObjectiveTo identify baseline neuropsychological and sociodemographic factors associated with progression from MCI to AD and determine whether these conversion predictors differ by sex.MethodsUsing baseline data from the ADNI cohort and longitudinal follow-up to determine clinical outcomes, we compared baseline profiles of 435 MCI non converter individuals and 328 MCI converters, who later converted to AD, using linear regression and classification approaches, including sex effects and sex-stratified analyses.ResultsConverters had greater baseline impairments not only in episodic memory and executive function, but also language. Significant, but small, sex-by-conversion interactions in memory indicated slightly more pronounced conversion-related decline among women. Machine learning classifier achieved a mean bootstrap accuracy of 74.0% in distinguishing converters from non-converters, slightly improving in sex-specific models for women (76.2%) but not for men (71.4%). Predictive features differed by sex: memory (recognition), global cognition and executive function were most informative in men, while functional ability, memory (encoding), demographics and language were stronger predictors in women.ConclusionsThese findings highlight the value of neuropsychological assessments for predicting progression from MCI to AD and underscore the importance of incorporating sex-specific approaches to improve the clinical relevance of dementia risk prediction.},
}
RevDate: 2026-11-18
Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundNeuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies.ObjectiveWe sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways.MethodsWe identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than -2.0, a false-discovery rate corrected p-value less than 0.05, and evidence in transgenic mouse models or AD clinical trials.ResultsWe found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models.ConclusionsWe provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.
Additional Links: PMID-43048891
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048891,
year = {2026},
author = {Cammann, D and Cummings, JL and Zhou, Y and Cheng, F and Chen, J},
title = {Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507113},
doi = {10.1177/13872877261507113},
pmid = {43048891},
issn = {1875-8908},
abstract = {BackgroundNeuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies.ObjectiveWe sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways.MethodsWe identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than -2.0, a false-discovery rate corrected p-value less than 0.05, and evidence in transgenic mouse models or AD clinical trials.ResultsWe found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models.ConclusionsWe provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.},
}
RevDate: 2026-11-18
Piloting an integrated assessment tool for measuring cognitive, affective, sensory, and social resources in dementia care settings.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundPerson-centered dementia care, for example for persons with Alzheimer's disease, requires holistic assessment tools, but traditional methods focus mainly on cognition, neglecting well-being, sensory functions, and social skills. The newly developed Person-Centered Modular Assessment Tool (PCMAT) aims to evaluate cognitive, affective, sensory, and social capacities in people with dementia.ObjectiveDesigned for both stationary and ambulatory nursing contexts, the aim was to pilot a preliminary screening tool to assess multi-domain resources, ensuring a more comprehensive approach applicable to dementia care.MethodsThe present paper presents the PCMAT and reports on pilot data from 21 persons with dementia and 22 healthy older adults, also presenting comparative data from single-domain scales targeting the PCMAT modules. Most module scores showed medium-to-large differences between the two samples with lower scores in the clinical sample.ResultsIn both samples, the results provided preliminary support for feasibility and selected validity indicators. Correlational analyses of the PCMAT modules indicated that the different areas of resources were assessed independently. In the clinical sample, evidence for preliminary convergent validity was found for the cognition module and the Montreal Cognitive Assessment score, in the healthy sample, data suggested preliminary convergent validity for the module on affective states.ConclusionsThese initial results demonstrated that assessing cognitive, affective, sensory and social capacities with the PCMAT seems feasible among individuals with dementia in early to moderate stages. The preliminary evidence further indicates the potential and suitability of the tool for the care context.
Additional Links: PMID-43048895
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048895,
year = {2026},
author = {Hering, A and Bassal, C and Haas, M and Kliegel, M and Aschwanden, D},
title = {Piloting an integrated assessment tool for measuring cognitive, affective, sensory, and social resources in dementia care settings.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261506208},
doi = {10.1177/13872877261506208},
pmid = {43048895},
issn = {1875-8908},
abstract = {BackgroundPerson-centered dementia care, for example for persons with Alzheimer's disease, requires holistic assessment tools, but traditional methods focus mainly on cognition, neglecting well-being, sensory functions, and social skills. The newly developed Person-Centered Modular Assessment Tool (PCMAT) aims to evaluate cognitive, affective, sensory, and social capacities in people with dementia.ObjectiveDesigned for both stationary and ambulatory nursing contexts, the aim was to pilot a preliminary screening tool to assess multi-domain resources, ensuring a more comprehensive approach applicable to dementia care.MethodsThe present paper presents the PCMAT and reports on pilot data from 21 persons with dementia and 22 healthy older adults, also presenting comparative data from single-domain scales targeting the PCMAT modules. Most module scores showed medium-to-large differences between the two samples with lower scores in the clinical sample.ResultsIn both samples, the results provided preliminary support for feasibility and selected validity indicators. Correlational analyses of the PCMAT modules indicated that the different areas of resources were assessed independently. In the clinical sample, evidence for preliminary convergent validity was found for the cognition module and the Montreal Cognitive Assessment score, in the healthy sample, data suggested preliminary convergent validity for the module on affective states.ConclusionsThese initial results demonstrated that assessing cognitive, affective, sensory and social capacities with the PCMAT seems feasible among individuals with dementia in early to moderate stages. The preliminary evidence further indicates the potential and suitability of the tool for the care context.},
}
RevDate: 2026-11-18
Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundAlzheimer's disease (AD) features amyloid-β (Aβ) deposition and tau pathology, with microglial dysfunction and neuroinflammation increasingly implicated. Soluble triggering receptor expressed on myeloid cells-2 (sTREM2) and progranulin (PGRN) regulate microglial function and lysosomal homeostasis, but their dynamics across the AD continuum remain unclear.ObjectiveTo investigate cerebrospinal fluid (CSF) sTREM2 and PGRN in the early diagnosis and progression monitoring of AD, and their associations with Aβ pathology and other biomarkers.MethodsData were from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Based on CSF Aβ42 and Clinical Dementia Rating (CDR) scores, subjects were categorized into Aβ-CN (n = 196), Aβ+CN (n = 101), Aβ+MCI (n = 378), and Aβ+AD (n = 96). Baseline demographics, neuropsychological assessments, imaging indices, and CSF biomarkers were compared. Spearman correlation, ROC curve analysis, and linear mixed-effects models (n = 255) were used.ResultsBaseline CSF sTREM2 was lower in Aβ+CN than Aβ-CN. PGRN was lower in Aβ+CN and Aβ+MCI than Aβ-CN. Over 2 years, sTREM2 increased most in Aβ+MCI and moderately in Aβ+CN, while PGRN declined in Aβ-CN, Aβ+MCI, and Aβ+AD. Both biomarkers correlated with CSF tau and p-tau in Aβ+ individuals.ConclusionsBaseline CSF sTREM2 and PGRN have limited cross-sectional diagnostic value for AD. However, their longitudinal trajectories raise the possibility that they may reflect the microglia-lysosome axis. Combined biomarker strategies and multi-targeted therapeutic interventions warrant further investigation.
Additional Links: PMID-43048900
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048900,
year = {2026},
author = {Gong, X and Khalid, MU and Long, J and Zhou, Z and Li, J and Bai, K and Li, X and , },
title = {Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507326},
doi = {10.1177/13872877261507326},
pmid = {43048900},
issn = {1875-8908},
abstract = {BackgroundAlzheimer's disease (AD) features amyloid-β (Aβ) deposition and tau pathology, with microglial dysfunction and neuroinflammation increasingly implicated. Soluble triggering receptor expressed on myeloid cells-2 (sTREM2) and progranulin (PGRN) regulate microglial function and lysosomal homeostasis, but their dynamics across the AD continuum remain unclear.ObjectiveTo investigate cerebrospinal fluid (CSF) sTREM2 and PGRN in the early diagnosis and progression monitoring of AD, and their associations with Aβ pathology and other biomarkers.MethodsData were from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Based on CSF Aβ42 and Clinical Dementia Rating (CDR) scores, subjects were categorized into Aβ-CN (n = 196), Aβ+CN (n = 101), Aβ+MCI (n = 378), and Aβ+AD (n = 96). Baseline demographics, neuropsychological assessments, imaging indices, and CSF biomarkers were compared. Spearman correlation, ROC curve analysis, and linear mixed-effects models (n = 255) were used.ResultsBaseline CSF sTREM2 was lower in Aβ+CN than Aβ-CN. PGRN was lower in Aβ+CN and Aβ+MCI than Aβ-CN. Over 2 years, sTREM2 increased most in Aβ+MCI and moderately in Aβ+CN, while PGRN declined in Aβ-CN, Aβ+MCI, and Aβ+AD. Both biomarkers correlated with CSF tau and p-tau in Aβ+ individuals.ConclusionsBaseline CSF sTREM2 and PGRN have limited cross-sectional diagnostic value for AD. However, their longitudinal trajectories raise the possibility that they may reflect the microglia-lysosome axis. Combined biomarker strategies and multi-targeted therapeutic interventions warrant further investigation.},
}
RevDate: 2026-11-18
Distinguishing Major Forms of Dementia Through Neuropsychological Performances: A Systematic Review With Structured Narrative Synthesis.
Journal of geriatric psychiatry and neurology [Epub ahead of print].
ObjectiveMajor dementia subtypes show characteristic neurocognitive profiles, but findings vary across neuropsychological tests, diagnostic frameworks, disease severity, and assessment languages. This systematic review examined whether subtype-level profiles remain consistent despite methodological and clinical heterogeneity.MethodsWeb of Science, PubMed, Scopus, and APA PsycArticles were searched on December 31, 2025, for English-language articles published from 2015 onward comparing AD, bvFTD, DLB, or VaD with non-dementia controls using validated neuropsychological tests. Effect sizes were synthesized across general intelligence, executive function, social cognition, attention/processing-speed, verbal function, visuospatial function, and episodic memory.ResultsOf 14 175 records, 116 studies were included. Effect size magnitude varied according to task demands and scoring methods and was discussed in the context of methodological and clinical sources of heterogeneity.ConclusionSynthesizing effect sizes enabled comparison across diverse neuropsychological tests, demonstrating that domain-level cognitive profiles were more robust than individual test findings, supporting profile-based neuropsychological interpretation.
Additional Links: PMID-43049085
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049085,
year = {2026},
author = {Yap, KH and Tan, JK and Chin, HL and Ng, LTE and Tan, MM and Zaman Huri, S and Goh, HT and Yeo, DHH and Lua, CT and Teoh, ZB and Chung, SY and Jairom, P and Woon, YX and Tan, MP},
title = {Distinguishing Major Forms of Dementia Through Neuropsychological Performances: A Systematic Review With Structured Narrative Synthesis.},
journal = {Journal of geriatric psychiatry and neurology},
volume = {},
number = {},
pages = {8919887261503011},
doi = {10.1177/08919887261503011},
pmid = {43049085},
issn = {1552-5708},
abstract = {ObjectiveMajor dementia subtypes show characteristic neurocognitive profiles, but findings vary across neuropsychological tests, diagnostic frameworks, disease severity, and assessment languages. This systematic review examined whether subtype-level profiles remain consistent despite methodological and clinical heterogeneity.MethodsWeb of Science, PubMed, Scopus, and APA PsycArticles were searched on December 31, 2025, for English-language articles published from 2015 onward comparing AD, bvFTD, DLB, or VaD with non-dementia controls using validated neuropsychological tests. Effect sizes were synthesized across general intelligence, executive function, social cognition, attention/processing-speed, verbal function, visuospatial function, and episodic memory.ResultsOf 14 175 records, 116 studies were included. Effect size magnitude varied according to task demands and scoring methods and was discussed in the context of methodological and clinical sources of heterogeneity.ConclusionSynthesizing effect sizes enabled comparison across diverse neuropsychological tests, demonstrating that domain-level cognitive profiles were more robust than individual test findings, supporting profile-based neuropsychological interpretation.},
}
RevDate: 2026-11-18
The hippocampus as a latent diffusion engine for memory, perception and cognitive dysfunction.
Brain : a journal of neurology pii:9016667 [Epub ahead of print].
The hippocampus is a central cognitive hub whose dysfunction contributes to most neurodegenerative dementias. Despite extensive knowledge of its anatomy, physiology and circuitry, a unifying account that links hippocampal dynamics to cognition and clinical syndromes remains lacking. Drawing on systems neuroscience and recent advances in generative artificial intelligence, we conceptualize the hippocampus as a latent diffusion engine that compresses sensory, interoceptive and cognitive inputs into low-dimensional representations and regenerates percepts, episodic memories and imagined scenes for cortical integration. Travelling waves of cortico-hippocampal oscillations, aligned with large-scale functional gradients, schedule and structure this generative process and organize distributed neural activity into coherent, semantically grounded constructs. We formalize this proposal as stochastic latent oscillatory diffusion (SLOD), a biologically grounded framework that maps hippocampal-cortical computations onto specific anatomical substrates and dynamical processes. While we do not suggest that the hippocampus implements diffusion algorithms per se, we show that its computations can be decomposed into homologous operations including compression, stochastic exploration, conditioning and reconstruction, whose formal structure closely parallels that of latent diffusion models. Finally, we demonstrate how major neurodegenerative dementias, including the Alzheimer's disease spectrum, dementia with Lewy bodies and frontotemporal dementia, can be understood as selective breakdowns of distinct components of this generative architecture.
Additional Links: PMID-43049192
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049192,
year = {2026},
author = {Jones, DT and Breakspear, M},
title = {The hippocampus as a latent diffusion engine for memory, perception and cognitive dysfunction.},
journal = {Brain : a journal of neurology},
volume = {},
number = {},
pages = {},
doi = {10.1093/brain/awag325},
pmid = {43049192},
issn = {1460-2156},
support = {U01-AG082350/NH/NIH HHS/United States ; P30-AG062677-07/NH/NIH HHS/United States ; APP2008612//National Health and Medical Research Council/ ; APP115262//National Health and Medical Research Council/ ; },
abstract = {The hippocampus is a central cognitive hub whose dysfunction contributes to most neurodegenerative dementias. Despite extensive knowledge of its anatomy, physiology and circuitry, a unifying account that links hippocampal dynamics to cognition and clinical syndromes remains lacking. Drawing on systems neuroscience and recent advances in generative artificial intelligence, we conceptualize the hippocampus as a latent diffusion engine that compresses sensory, interoceptive and cognitive inputs into low-dimensional representations and regenerates percepts, episodic memories and imagined scenes for cortical integration. Travelling waves of cortico-hippocampal oscillations, aligned with large-scale functional gradients, schedule and structure this generative process and organize distributed neural activity into coherent, semantically grounded constructs. We formalize this proposal as stochastic latent oscillatory diffusion (SLOD), a biologically grounded framework that maps hippocampal-cortical computations onto specific anatomical substrates and dynamical processes. While we do not suggest that the hippocampus implements diffusion algorithms per se, we show that its computations can be decomposed into homologous operations including compression, stochastic exploration, conditioning and reconstruction, whose formal structure closely parallels that of latent diffusion models. Finally, we demonstrate how major neurodegenerative dementias, including the Alzheimer's disease spectrum, dementia with Lewy bodies and frontotemporal dementia, can be understood as selective breakdowns of distinct components of this generative architecture.},
}
RevDate: 2026-11-18
Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial.
JAMA neurology pii:2856813 [Epub ahead of print].
IMPORTANCE: Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being.
OBJECTIVE: To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being.
The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included.
INTERVENTIONS: Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality.
MAIN OUTCOMES AND MEASURES: Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins.
RESULTS: A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority.
CONCLUSIONS AND RELEVANCE: Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06459583.
Additional Links: PMID-43049195
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049195,
year = {2026},
author = {Langbaum, JB and Erickson, CM and Langlois, CM and Wood, EM and Egleston, BL and Harkins, K and Mim, R and John, S and Brown, C and Brown, S and Howe, S and Cacioppo, C and Eppelmann, L and Enos, J and Salata, H and De Santiago, D and Largent, EA and Reiman, EM and Denkinger, MN and Ashton, NJ and Roberts, JS and Karlawish, J and Bradbury, AR},
title = {Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial.},
journal = {JAMA neurology},
volume = {},
number = {},
pages = {},
doi = {10.1001/jamaneurol.2026.4279},
pmid = {43049195},
issn = {2168-6157},
abstract = {IMPORTANCE: Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being.
OBJECTIVE: To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being.
The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included.
INTERVENTIONS: Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality.
MAIN OUTCOMES AND MEASURES: Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins.
RESULTS: A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority.
CONCLUSIONS AND RELEVANCE: Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06459583.},
}
RevDate: 2026-11-18
Bdnf mRNA-LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Epub ahead of print].
Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.
Additional Links: PMID-43049235
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049235,
year = {2026},
author = {Bergamasco, M and Scarborough, H and Ponta, A and Clark, T and Cohen, SB and Loo, L and Fujikake, K and Carr, R and Holsinger, RMD and Neely, GG},
title = {Bdnf mRNA-LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models.},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
volume = {},
number = {},
pages = {},
pmid = {43049235},
issn = {2198-3844},
support = {GNT2019264//National Health and Medical Research council (NHMRC)/ ; GNT2020532//National Health and Medical Research council (NHMRC)/ ; GNT1185002//National Health and Medical Research council (NHMRC)/ ; GNT1107514//National Health and Medical Research council (NHMRC)/ ; GNT1158164//National Health and Medical Research council (NHMRC)/ ; GNT1158165//National Health and Medical Research council (NHMRC)/ ; GNT1046090//National Health and Medical Research council (NHMRC)/ ; GNT1111940//National Health and Medical Research council (NHMRC)/ ; },
abstract = {Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Extracellular Vesicle Derived Biomarkers for the Diagnosis of Neurodegenerative Diseases.
BioMed research international, 2026(1):.
Liquid biopsy, a noninvasive method analyzing biofluids such as blood and cerebrospinal fluid, has transformed early detection and monitoring of neurodegenerative diseases. Small extracellular vesicles (sEVs) (30-150 nm) secreted by cells are pivotal because of their ability to cross the blood-brain barrier and carry disease-specific cargos like proteins and microRNAs. This review synthesizes recent advancements in EV-based liquid biopsy for diagnosing NDDs, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Following PRISMA guidelines, we analyzed 113 studies from databases like PubMed and Scopus, highlighting EV-associated biomarkers' diagnostic potential. These vesicles offer a minimally invasive approach to detect proteinopathies and genetic markers, reflecting central nervous system pathology. Despite their promise, challenges such as standardized isolation protocols and clinical validation remain. This review discusses current trends, methodologies, and future directions for integrating EV-based diagnostics into clinical practice, emphasizing precision medicine for NDDs.
Additional Links: PMID-43049247
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049247,
year = {2026},
author = {Gupta, BP and Agarwal, S and Prasad, S},
title = {Extracellular Vesicle Derived Biomarkers for the Diagnosis of Neurodegenerative Diseases.},
journal = {BioMed research international},
volume = {2026},
number = {1},
pages = {},
pmid = {43049247},
issn = {2314-6141},
mesh = {Humans ; *Neurodegenerative Diseases/diagnosis/metabolism ; *Extracellular Vesicles/metabolism ; *Biomarkers/metabolism ; Liquid Biopsy/methods ; MicroRNAs ; },
abstract = {Liquid biopsy, a noninvasive method analyzing biofluids such as blood and cerebrospinal fluid, has transformed early detection and monitoring of neurodegenerative diseases. Small extracellular vesicles (sEVs) (30-150 nm) secreted by cells are pivotal because of their ability to cross the blood-brain barrier and carry disease-specific cargos like proteins and microRNAs. This review synthesizes recent advancements in EV-based liquid biopsy for diagnosing NDDs, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Following PRISMA guidelines, we analyzed 113 studies from databases like PubMed and Scopus, highlighting EV-associated biomarkers' diagnostic potential. These vesicles offer a minimally invasive approach to detect proteinopathies and genetic markers, reflecting central nervous system pathology. Despite their promise, challenges such as standardized isolation protocols and clinical validation remain. This review discusses current trends, methodologies, and future directions for integrating EV-based diagnostics into clinical practice, emphasizing precision medicine for NDDs.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Neurodegenerative Diseases/diagnosis/metabolism
*Extracellular Vesicles/metabolism
*Biomarkers/metabolism
Liquid Biopsy/methods
MicroRNAs
RevDate: 2026-11-18
CmpDate: 2026-11-18
Neurotransmitter and Transcriptomic Basis of Gray Matter Volume Abnormalities in Alzheimer's Disease: A Meta-Analysis.
Human brain mapping, 47(17):.
Alzheimer's disease (AD), the commonest neurodegenerative disorder, is characterized by progressive cognitive decline. However, much remains unclear about brain morphological alterations in AD and the underlying molecular mechanisms. We conducted a whole-brain voxel-wise meta-analysis using Seed-based d Mapping with Permutation of Subject Images to identify consistent gray matter volume (GMV) alterations in AD. Significant clusters were assigned to AAL regions and Yeo 7 functional networks and further annotated via Neurosynth. Spatial correspondence between the meta-analysis results and 29 neurotransmitter maps was assessed with JuSpace. Transcriptional associations were assessed using Allen Human Brain Atlas data with partial least squares regression and gene enrichment analysis. The meta-analysis included 70 voxel-based morphometry studies, reporting 2628 AD patients and 2508 healthy controls. AD patients had lower GMV than controls in the bilateral hippocampus, bilateral parahippocampal gyrus and bilateral amygdala (p < 0.05, FWE corrected), regions mainly involved in the default mode network, ventral attention network and the limbic network. Sensitivity analyses indicated high robustness, with low heterogeneity. Neurosynth decoding found the regions of lower GMV to be related to emotional processing and facial expression recognition. Neurotransmitter mapping revealed multiple spatial correlations, notably with the dopaminergic and serotonergic systems (p < 0.001, FDR corrected). Genes associated with the lower-GMV regions were enriched mainly in cytoplasmic translation, ribosomal subunits, cadherin-mediated cell adhesion, and ligand-gated ion channel activity. These findings suggest that GMV alterations in AD predominantly affect temporal regions within specific functional networks and are associated with neurotransmitter systems and molecular pathways.
Additional Links: PMID-43049552
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049552,
year = {2026},
author = {Jian, K and Zhang, P and Xu, H and Liu, W and Li, Y and Kemp, GJ and Gong, Q},
title = {Neurotransmitter and Transcriptomic Basis of Gray Matter Volume Abnormalities in Alzheimer's Disease: A Meta-Analysis.},
journal = {Human brain mapping},
volume = {47},
number = {17},
pages = {},
pmid = {43049552},
issn = {1097-0193},
support = {82672621//National Natural Science Foundation of China/ ; },
mesh = {Humans ; *Alzheimer Disease/pathology/diagnostic imaging/metabolism/genetics ; *Gray Matter/pathology/diagnostic imaging/metabolism ; *Transcriptome/physiology ; *Neurotransmitter Agents/metabolism ; *Brain/pathology/diagnostic imaging/metabolism ; Magnetic Resonance Imaging ; },
abstract = {Alzheimer's disease (AD), the commonest neurodegenerative disorder, is characterized by progressive cognitive decline. However, much remains unclear about brain morphological alterations in AD and the underlying molecular mechanisms. We conducted a whole-brain voxel-wise meta-analysis using Seed-based d Mapping with Permutation of Subject Images to identify consistent gray matter volume (GMV) alterations in AD. Significant clusters were assigned to AAL regions and Yeo 7 functional networks and further annotated via Neurosynth. Spatial correspondence between the meta-analysis results and 29 neurotransmitter maps was assessed with JuSpace. Transcriptional associations were assessed using Allen Human Brain Atlas data with partial least squares regression and gene enrichment analysis. The meta-analysis included 70 voxel-based morphometry studies, reporting 2628 AD patients and 2508 healthy controls. AD patients had lower GMV than controls in the bilateral hippocampus, bilateral parahippocampal gyrus and bilateral amygdala (p < 0.05, FWE corrected), regions mainly involved in the default mode network, ventral attention network and the limbic network. Sensitivity analyses indicated high robustness, with low heterogeneity. Neurosynth decoding found the regions of lower GMV to be related to emotional processing and facial expression recognition. Neurotransmitter mapping revealed multiple spatial correlations, notably with the dopaminergic and serotonergic systems (p < 0.001, FDR corrected). Genes associated with the lower-GMV regions were enriched mainly in cytoplasmic translation, ribosomal subunits, cadherin-mediated cell adhesion, and ligand-gated ion channel activity. These findings suggest that GMV alterations in AD predominantly affect temporal regions within specific functional networks and are associated with neurotransmitter systems and molecular pathways.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/pathology/diagnostic imaging/metabolism/genetics
*Gray Matter/pathology/diagnostic imaging/metabolism
*Transcriptome/physiology
*Neurotransmitter Agents/metabolism
*Brain/pathology/diagnostic imaging/metabolism
Magnetic Resonance Imaging
RevDate: 2026-11-18
Late-Life Cognitive Disparities at the Intersection of Race, Sex, and Education: a Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy.
Neuroepidemiology pii:9089977 [Epub ahead of print].
INTRODUCTION: Prior research demonstrates significant race-, sex-, and education-related disparities in Alzheimer's and related dementias (ADRD). However, these social determinants are often examined in isolation from one another. An intersectional approach, however, may reveal whether they influence cognition in an additive or multiplicative way.
METHODS: This study uses data from the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol (HCAP) substudy (N=3,496), to examine intersectional inequalities in general cognitive performance (GCP) as well as sub-domains of memory, executive functioning, and language/fluency among a population-representative sample of older adults in the U.S. We implement a multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIHDA) which nests individuals in 18 strata based on race/ethnicity, sex, and education. We quantify the variation that exists between and within strata and determine if there is intersectional interaction shaping cognitive performance.
RESULTS: We find that a substantial portion of the variation in cognition is at the intersectional level, ranging from 24% for GCP, 13.6% for memory, 30% for executive functioning, and 9.9% for language/fluency. The majority of this variation however was accounted for by additive effects: 100% for memory and language/fluency, and around 98.9% for GCP and 98.03% for executive functioning. We did not find statistically significant evidence of unexpected intersectional advantage or disadvantage within any specific strata.
CONCLUSION: Cognitive performance in later life is marked by a high degree of inequality across social strata. Important social determinants of ADRD such as race, sex, and education combine primarily in an additive manner to shape cognitive performance.
Additional Links: PMID-43049740
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049740,
year = {2026},
author = {Rios Casas, F and Erving, C and Farina, MP},
title = {Late-Life Cognitive Disparities at the Intersection of Race, Sex, and Education: a Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy.},
journal = {Neuroepidemiology},
volume = {},
number = {},
pages = {},
doi = {10.1159/ned/adwag073},
pmid = {43049740},
issn = {1423-0208},
abstract = {INTRODUCTION: Prior research demonstrates significant race-, sex-, and education-related disparities in Alzheimer's and related dementias (ADRD). However, these social determinants are often examined in isolation from one another. An intersectional approach, however, may reveal whether they influence cognition in an additive or multiplicative way.
METHODS: This study uses data from the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol (HCAP) substudy (N=3,496), to examine intersectional inequalities in general cognitive performance (GCP) as well as sub-domains of memory, executive functioning, and language/fluency among a population-representative sample of older adults in the U.S. We implement a multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIHDA) which nests individuals in 18 strata based on race/ethnicity, sex, and education. We quantify the variation that exists between and within strata and determine if there is intersectional interaction shaping cognitive performance.
RESULTS: We find that a substantial portion of the variation in cognition is at the intersectional level, ranging from 24% for GCP, 13.6% for memory, 30% for executive functioning, and 9.9% for language/fluency. The majority of this variation however was accounted for by additive effects: 100% for memory and language/fluency, and around 98.9% for GCP and 98.03% for executive functioning. We did not find statistically significant evidence of unexpected intersectional advantage or disadvantage within any specific strata.
CONCLUSION: Cognitive performance in later life is marked by a high degree of inequality across social strata. Important social determinants of ADRD such as race, sex, and education combine primarily in an additive manner to shape cognitive performance.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
[1]H, [13]C, and [15]N chemical shift assignments of monomorphic Aβ1-40 at 100 kHz MAS in a diamond rotor.
Biomolecular NMR assignments, 20(1):.
Amyloid-β (Aβ) fibrils are the principal component of the senile plaques that characterize Alzheimer's disease, and fibrils formed from the Aβ1-40 alloform are strongly polymorphic, which has long complicated their structural characterization. We recently reported a reproducible, unseeded, monomorphic Aβ1-40 fibril grown at neutral pH from supersaturated monomer, together with its atomic-resolution structure and its [13]C and [15]N chemical shift assignments (PDB 12GB; BMRB 31300). Here we extend that reference to [1]H. From a 3D [1]H-detected hCCH (RFDR) experiment and a 2D hNH experiment recorded at 18.8 T and ωr/2π = 100 kHz on approximately 0.5 mg of hydrated fibrils packed in a home-built 0.7 mm single-crystal diamond rotor, we assign 122 [1]H resonances, corresponding to close to 83% of the distinct [1]H sites of the rigid core (residues Q15→V40), together with sixteen [1]H of the dynamic N-terminal segment. The [1]H-detected data additionally yield six previously unassigned [13]C and three previously unassigned [15]N resonances, predominantly in aromatic side chains and in the mobile N-terminus, and nine [1]H-[13]C and twenty [1]H-[15]N inter-residue contacts that are consistent with the published structure. These assignments (BMRB 54013) provide a residue-level reference for fingerprinting Aβ1-40 polymorphs and for mapping the binding of antibodies, chaperones and small molecules to this fibril.
Additional Links: PMID-43049823
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049823,
year = {2026},
author = {Matthey, NL and Palani, RS and Liu, J and Bahri, S and Silvers, R and Michael, B and Gershenfeld, N and Linse, S and Griffin, RG},
title = {[1]H, [13]C, and [15]N chemical shift assignments of monomorphic Aβ1-40 at 100 kHz MAS in a diamond rotor.},
journal = {Biomolecular NMR assignments},
volume = {20},
number = {1},
pages = {},
pmid = {43049823},
issn = {1874-270X},
support = {GM142912/GM/NIGMS NIH HHS/United States ; GM139055/GM/NIGMS NIH HHS/United States ; GM132997/GM/NIGMS NIH HHS/United States ; VR2015-00143//Swedish Research Council/ ; AG058504/AG/NIA NIH HHS/United States ; },
mesh = {*Nuclear Magnetic Resonance, Biomolecular ; *Amyloid beta-Peptides/chemistry ; *Peptide Fragments/chemistry ; Nitrogen Isotopes ; *Diamond ; Carbon Isotopes ; },
abstract = {Amyloid-β (Aβ) fibrils are the principal component of the senile plaques that characterize Alzheimer's disease, and fibrils formed from the Aβ1-40 alloform are strongly polymorphic, which has long complicated their structural characterization. We recently reported a reproducible, unseeded, monomorphic Aβ1-40 fibril grown at neutral pH from supersaturated monomer, together with its atomic-resolution structure and its [13]C and [15]N chemical shift assignments (PDB 12GB; BMRB 31300). Here we extend that reference to [1]H. From a 3D [1]H-detected hCCH (RFDR) experiment and a 2D hNH experiment recorded at 18.8 T and ωr/2π = 100 kHz on approximately 0.5 mg of hydrated fibrils packed in a home-built 0.7 mm single-crystal diamond rotor, we assign 122 [1]H resonances, corresponding to close to 83% of the distinct [1]H sites of the rigid core (residues Q15→V40), together with sixteen [1]H of the dynamic N-terminal segment. The [1]H-detected data additionally yield six previously unassigned [13]C and three previously unassigned [15]N resonances, predominantly in aromatic side chains and in the mobile N-terminus, and nine [1]H-[13]C and twenty [1]H-[15]N inter-residue contacts that are consistent with the published structure. These assignments (BMRB 54013) provide a residue-level reference for fingerprinting Aβ1-40 polymorphs and for mapping the binding of antibodies, chaperones and small molecules to this fibril.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Nuclear Magnetic Resonance, Biomolecular
*Amyloid beta-Peptides/chemistry
*Peptide Fragments/chemistry
Nitrogen Isotopes
*Diamond
Carbon Isotopes
RevDate: 2026-11-18
CmpDate: 2026-11-18
Incretin-Based Therapies and the Gut-Brain Axis in Neurodegenerative Diseases.
Molecular neurobiology, 63(1):.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for metabolic disorders, remain under active investigation as potential therapeutic candidates for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, with clinical trials to date reporting both positive and negative findings. This scoping review critically synthesizes evidence from preclinical and clinical studies (n = 99), with a focus on the molecular pharmacodynamics of semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide, together with tirzepatide, a dual GLP-1/GIP receptor agonist (GLP-1/GIP RA) discussed separately given its distinct receptor pharmacology. In preclinical models, GLP-1 receptor activation has been associated with engagement of intracellular signaling pathways, including PI3K/Akt/GSK-3β, cAMP/PKA/CREB, and AMPK/SIRT1, and several studies report reduced neuroinflammation, oxidative stress, and amyloid-β or α-synuclein accumulation. These findings are not uniform: recent studies in preventive and established Alzheimer's disease mouse models found no benefit of semaglutide or tirzepatide, and the phase 3 EVOKE/EVOKE+ trials of oral semaglutide in early Alzheimer's disease did not slow clinical progression. GLP-1 RAs are also frequently associated with shifts in gut microbiota composition, including enrichment of short-chain fatty acid-producing taxa, which supports a biologically plausible gut-brain axis interaction. However, microbiota responses are heterogeneous and context-dependent, and no included study used causal designs such as germ-free models or fecal microbiota transplantation. Whether neuroprotective effects arise from direct central receptor engagement, from peripheral metabolic effects, or from microbiota remodeling therefore remains unresolved, and microbiota changes may be a secondary consequence of metabolic improvement rather than a mediator of therapeutic effect.
Additional Links: PMID-43049829
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049829,
year = {2026},
author = {Lázaro, Á and Mohammed, V and Bridgeman, L and Frangiamone, M},
title = {Incretin-Based Therapies and the Gut-Brain Axis in Neurodegenerative Diseases.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43049829},
issn = {1559-1182},
mesh = {Humans ; Animals ; *Neurodegenerative Diseases/drug therapy/metabolism ; *Incretins/therapeutic use/pharmacology ; *Brain-Gut Axis/drug effects/physiology ; Glucagon-Like Peptide-1 Receptor Agonists ; Semaglutide ; Tirzepatide ; },
abstract = {Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for metabolic disorders, remain under active investigation as potential therapeutic candidates for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, with clinical trials to date reporting both positive and negative findings. This scoping review critically synthesizes evidence from preclinical and clinical studies (n = 99), with a focus on the molecular pharmacodynamics of semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide, together with tirzepatide, a dual GLP-1/GIP receptor agonist (GLP-1/GIP RA) discussed separately given its distinct receptor pharmacology. In preclinical models, GLP-1 receptor activation has been associated with engagement of intracellular signaling pathways, including PI3K/Akt/GSK-3β, cAMP/PKA/CREB, and AMPK/SIRT1, and several studies report reduced neuroinflammation, oxidative stress, and amyloid-β or α-synuclein accumulation. These findings are not uniform: recent studies in preventive and established Alzheimer's disease mouse models found no benefit of semaglutide or tirzepatide, and the phase 3 EVOKE/EVOKE+ trials of oral semaglutide in early Alzheimer's disease did not slow clinical progression. GLP-1 RAs are also frequently associated with shifts in gut microbiota composition, including enrichment of short-chain fatty acid-producing taxa, which supports a biologically plausible gut-brain axis interaction. However, microbiota responses are heterogeneous and context-dependent, and no included study used causal designs such as germ-free models or fecal microbiota transplantation. Whether neuroprotective effects arise from direct central receptor engagement, from peripheral metabolic effects, or from microbiota remodeling therefore remains unresolved, and microbiota changes may be a secondary consequence of metabolic improvement rather than a mediator of therapeutic effect.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Animals
*Neurodegenerative Diseases/drug therapy/metabolism
*Incretins/therapeutic use/pharmacology
*Brain-Gut Axis/drug effects/physiology
Glucagon-Like Peptide-1 Receptor Agonists
Semaglutide
Tirzepatide
RevDate: 2026-11-18
The chronobiology of brain waste clearance: Sleep-wake and circadian regulation of glymphatic function.
Chronobiology international [Epub ahead of print].
The glymphatic system - a glia-dependent perivascular network mediating cerebrospinal fluid and interstitial fluid exchange - has emerged as a key determinant of restorative sleep, with its efficiency governed by both sleep-wake state and the circadian clock. Its activity peaks during NREM slow-wave sleep and is essential for clearing neurotoxic proteins including amyloid-β and hyperphosphorylated tau, whose accumulation underlies Alzheimer's disease and related neurodegenerative proteinopathies. This activity is itself under circadian control, with aquaporin-4 expression, CSF production, and perivascular flow exhibiting diurnal rhythmicity driven by the suprachiasmatic clock and peripheral clock genes. Recent work identifying synchronized norepinephrine oscillations from the locus coeruleus as the primary driver of glymphatic vasomotion has reframed the system's mechanistic architecture and raised questions about sedative-hypnotics and circadian disruption, both of which suppress this oscillatory pattern. This review synthesizes mechanistic, biomarker, and therapeutic evidence into a chronobiological framework positioning glymphatic efficiency as a distinct dimension of sleep quality - one that conventional EEG-based staging fails to capture. We examine disruption of glymphatic function by circadian misalignment, aging, sleep fragmentation, and neurodegeneration, and evaluate emerging biomarkers - including DTI-ALPS and plasma markers of waste accumulation - appraising their validity and limitations. Drawing on a broad literature survey and publication-trend analysis, we identify emerging perspectives to inform targeted therapeutic strategies. The therapeutic landscape is assessed across non-pharmacological, chronotherapeutic, pharmacological, and vascular and meningeal lymphatic interventions. We identify a translational gap between preclinical and human evidence, and propose that glymphatic biomarker endpoints be incorporated into sleep and chronobiology trials as a scientific priority.
Additional Links: PMID-43049879
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049879,
year = {2026},
author = {Koynova-Tenchov, R},
title = {The chronobiology of brain waste clearance: Sleep-wake and circadian regulation of glymphatic function.},
journal = {Chronobiology international},
volume = {},
number = {},
pages = {1-40},
doi = {10.1080/07420528.2026.2765308},
pmid = {43049879},
issn = {1525-6073},
abstract = {The glymphatic system - a glia-dependent perivascular network mediating cerebrospinal fluid and interstitial fluid exchange - has emerged as a key determinant of restorative sleep, with its efficiency governed by both sleep-wake state and the circadian clock. Its activity peaks during NREM slow-wave sleep and is essential for clearing neurotoxic proteins including amyloid-β and hyperphosphorylated tau, whose accumulation underlies Alzheimer's disease and related neurodegenerative proteinopathies. This activity is itself under circadian control, with aquaporin-4 expression, CSF production, and perivascular flow exhibiting diurnal rhythmicity driven by the suprachiasmatic clock and peripheral clock genes. Recent work identifying synchronized norepinephrine oscillations from the locus coeruleus as the primary driver of glymphatic vasomotion has reframed the system's mechanistic architecture and raised questions about sedative-hypnotics and circadian disruption, both of which suppress this oscillatory pattern. This review synthesizes mechanistic, biomarker, and therapeutic evidence into a chronobiological framework positioning glymphatic efficiency as a distinct dimension of sleep quality - one that conventional EEG-based staging fails to capture. We examine disruption of glymphatic function by circadian misalignment, aging, sleep fragmentation, and neurodegeneration, and evaluate emerging biomarkers - including DTI-ALPS and plasma markers of waste accumulation - appraising their validity and limitations. Drawing on a broad literature survey and publication-trend analysis, we identify emerging perspectives to inform targeted therapeutic strategies. The therapeutic landscape is assessed across non-pharmacological, chronotherapeutic, pharmacological, and vascular and meningeal lymphatic interventions. We identify a translational gap between preclinical and human evidence, and propose that glymphatic biomarker endpoints be incorporated into sleep and chronobiology trials as a scientific priority.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Thirteen-month real-world effectiveness and safety of lecanemab in Chinese patients with Alzheimer's disease: integrating objective clinical outcomes and caregiver-reported experiences.
Journal of neurology, 273(12):.
BACKGROUND: The longer-term real-world effectiveness of lecanemab and predictors of treatment response remain unclear in Chinese patients with Alzheimer's disease (AD).
METHODS: This prospective multicenter cohort enrolled patients receiving lecanemab (10 mg/kg biweekly) across nine medical centers in Southwest China. Longitudinal cognition, 13-month amyloid-β positron emission tomography/computed tomography (Aβ-PET/CT), safety, treatment discontinuation, and caregiver-reported Clinical Global Impression (CGI) outcomes were assessed. Cognitive trajectories were compared with propensity score-matched local controls and an external Alzheimer's disease Neuroimaging Initiative (ADNI) natural-history cohort.
RESULTS: Among 122 lecanemab-treated patients, 38.52% had mild cognitive impairment due to AD and 40.98% had mild AD dementia. Linear mixed-effects models incorporating 222 follow-up visits demonstrated generally stable cognitive performance, with modest favorable changes in cognitive scores at certain follow-up time points. At 13 months, 84.00% maintained or improved Clinical Dementia Rating stage, and 66.67% achieved amyloid-negative conversion, defined as a Centiloid value < 12. Lecanemab-treated patients showed more favorable longitudinal cognitive trajectories than matched ADNI and local natural-history controls. Amyloid reduction was not robustly associated with cognitive improvement, and routine baseline clinical variables did not reliably predict treatment response. CGI assessments indicated clinical improvement or stability in 77.55% of participants. Amyloid-related imaging abnormalities and infusion-related reactions occurred in 10.66% and 5.74% of patients, respectively, while treatment discontinuation was most commonly driven by the inconvenience of repeated infusions rather than safety concerns.
CONCLUSION: Lecanemab was associated with favorable longitudinal cognitive trajectories, substantial amyloid clearance, and acceptable safety in Chinese patients with AD. However, amyloid reduction and routine baseline clinical characteristics did not reliably predict treatment response.
Additional Links: PMID-43049898
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049898,
year = {2026},
author = {Chen, S and Gao, X and Li, F and Ou, R and Wei, Q and Li, C and Song, W and Zhao, B and Yang, J and Fu, J and Ma, Y and Wang, X and Fang, D and Hu, T and Xiao, L and Zhang, S and Huang, R and Guo, X and Feng, F and Chen, X and Shang, H and , },
title = {Thirteen-month real-world effectiveness and safety of lecanemab in Chinese patients with Alzheimer's disease: integrating objective clinical outcomes and caregiver-reported experiences.},
journal = {Journal of neurology},
volume = {273},
number = {12},
pages = {},
pmid = {43049898},
issn = {1432-1459},
support = {No.2025-108//the Sichuan Provincial Cadre Healthcare Research Project/ ; No.2022ZD0211605//the Sci-Tech Innovation 2023 "Brain Science and Brain-like Research/ ; Grant No. SYYHZX20250401//the Sichuan Preventive Medicine Association/ ; },
mesh = {Humans ; *Alzheimer Disease/drug therapy/diagnostic imaging ; Female ; Male ; Aged ; Caregivers ; Treatment Outcome ; Prospective Studies ; Aged, 80 and over ; China ; Positron Emission Tomography Computed Tomography ; Amyloid beta-Peptides/metabolism ; Middle Aged ; Follow-Up Studies ; Cognitive Dysfunction/drug therapy/diagnostic imaging ; East Asian People ; },
abstract = {BACKGROUND: The longer-term real-world effectiveness of lecanemab and predictors of treatment response remain unclear in Chinese patients with Alzheimer's disease (AD).
METHODS: This prospective multicenter cohort enrolled patients receiving lecanemab (10 mg/kg biweekly) across nine medical centers in Southwest China. Longitudinal cognition, 13-month amyloid-β positron emission tomography/computed tomography (Aβ-PET/CT), safety, treatment discontinuation, and caregiver-reported Clinical Global Impression (CGI) outcomes were assessed. Cognitive trajectories were compared with propensity score-matched local controls and an external Alzheimer's disease Neuroimaging Initiative (ADNI) natural-history cohort.
RESULTS: Among 122 lecanemab-treated patients, 38.52% had mild cognitive impairment due to AD and 40.98% had mild AD dementia. Linear mixed-effects models incorporating 222 follow-up visits demonstrated generally stable cognitive performance, with modest favorable changes in cognitive scores at certain follow-up time points. At 13 months, 84.00% maintained or improved Clinical Dementia Rating stage, and 66.67% achieved amyloid-negative conversion, defined as a Centiloid value < 12. Lecanemab-treated patients showed more favorable longitudinal cognitive trajectories than matched ADNI and local natural-history controls. Amyloid reduction was not robustly associated with cognitive improvement, and routine baseline clinical variables did not reliably predict treatment response. CGI assessments indicated clinical improvement or stability in 77.55% of participants. Amyloid-related imaging abnormalities and infusion-related reactions occurred in 10.66% and 5.74% of patients, respectively, while treatment discontinuation was most commonly driven by the inconvenience of repeated infusions rather than safety concerns.
CONCLUSION: Lecanemab was associated with favorable longitudinal cognitive trajectories, substantial amyloid clearance, and acceptable safety in Chinese patients with AD. However, amyloid reduction and routine baseline clinical characteristics did not reliably predict treatment response.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/drug therapy/diagnostic imaging
Female
Male
Aged
Caregivers
Treatment Outcome
Prospective Studies
Aged, 80 and over
China
Positron Emission Tomography Computed Tomography
Amyloid beta-Peptides/metabolism
Middle Aged
Follow-Up Studies
Cognitive Dysfunction/drug therapy/diagnostic imaging
East Asian People
RevDate: 2026-11-18
Estimating Prevalence of Early Symptomatic Alzheimer's Disease and the Demand for amyloid-targeting therapies in China: A Meta-analysis and Modelling Study.
Advances in therapy [Epub ahead of print].
INTRODUCTION: Amyloid-targeting therapies provide disease-modifying treatment for early symptomatic Alzheimer's disease (AD), but the number of individuals potentially eligible for treatment in China remains uncertain. We aimed to synthesize the prevalence of mild cognitive impairment (MCI) and AD among older adults in China and quantify the population potentially eligible for amyloid-targeting therapies.
METHODS: PubMed, Web of Science, SinoMed, and China National Knowledge Infrastructure were searched from January 1, 2020 through August 6, 2026. Population-based observational studies reporting MCI or AD prevalence among adults aged ≥ 60 years in mainland China were included; studies restricted to selected disease subgroups and non-primary reports were excluded. Methodological quality was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies. Prevalence estimates were synthesized using random-effects meta-analysis and incorporated into a stepwise funnel model accounting for healthcare consultation, clinical diagnosis, biomarker testing, and amyloid positivity. Scenario and probabilistic sensitivity analyses assessed uncertainty.
RESULTS: Twenty-seven studies involving 312,204 participants were included; most were of moderate quality. Pooled prevalence was 21.21% [95% confidence interval (CI) 17.41-25.01%; I[2] = 99.7%] for MCI and 4.72% (95% CI 3.13-6.31%; I[2] = 99.8%) for AD. Under current healthcare consultation, diagnostic, and biomarker testing conditions, an estimated 39,825 individuals were potentially eligible for amyloid-targeting therapies. When these constraints were removed, the estimated potentially eligible population increased to 14.17 million. Study heterogeneity was substantial, and age-stratified evidence was limited.
CONCLUSION: China has a substantial population potentially eligible for amyloid-targeting therapies, but current healthcare consultation, diagnostic, and biomarker testing constraints markedly limit treatment access. These estimates can inform diagnostic capacity planning, resource allocation, treatment access, and reimbursement decisions.
Additional Links: PMID-43050111
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050111,
year = {2026},
author = {Lian, D and Zhao, J and Liu, L and Yu, J and Chen, Y and Liu, S},
title = {Estimating Prevalence of Early Symptomatic Alzheimer's Disease and the Demand for amyloid-targeting therapies in China: A Meta-analysis and Modelling Study.},
journal = {Advances in therapy},
volume = {},
number = {},
pages = {},
pmid = {43050111},
issn = {1865-8652},
abstract = {INTRODUCTION: Amyloid-targeting therapies provide disease-modifying treatment for early symptomatic Alzheimer's disease (AD), but the number of individuals potentially eligible for treatment in China remains uncertain. We aimed to synthesize the prevalence of mild cognitive impairment (MCI) and AD among older adults in China and quantify the population potentially eligible for amyloid-targeting therapies.
METHODS: PubMed, Web of Science, SinoMed, and China National Knowledge Infrastructure were searched from January 1, 2020 through August 6, 2026. Population-based observational studies reporting MCI or AD prevalence among adults aged ≥ 60 years in mainland China were included; studies restricted to selected disease subgroups and non-primary reports were excluded. Methodological quality was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies. Prevalence estimates were synthesized using random-effects meta-analysis and incorporated into a stepwise funnel model accounting for healthcare consultation, clinical diagnosis, biomarker testing, and amyloid positivity. Scenario and probabilistic sensitivity analyses assessed uncertainty.
RESULTS: Twenty-seven studies involving 312,204 participants were included; most were of moderate quality. Pooled prevalence was 21.21% [95% confidence interval (CI) 17.41-25.01%; I[2] = 99.7%] for MCI and 4.72% (95% CI 3.13-6.31%; I[2] = 99.8%) for AD. Under current healthcare consultation, diagnostic, and biomarker testing conditions, an estimated 39,825 individuals were potentially eligible for amyloid-targeting therapies. When these constraints were removed, the estimated potentially eligible population increased to 14.17 million. Study heterogeneity was substantial, and age-stratified evidence was limited.
CONCLUSION: China has a substantial population potentially eligible for amyloid-targeting therapies, but current healthcare consultation, diagnostic, and biomarker testing constraints markedly limit treatment access. These estimates can inform diagnostic capacity planning, resource allocation, treatment access, and reimbursement decisions.},
}
RevDate: 2026-11-18
Decoding neurodegeneration: RNA therapeutics in Alzheimer's and Parkinson's diseases.
Acta neurologica Belgica [Epub ahead of print].
Neurodegenerative conditions like Alzheimer disease and Parkinson disease are of major global health concern considering that they are progressive and not curable. The standard therapeutic methods mainly aim at the treatment of the symptoms, and they do not treat the molecular processes that contribute to the pathogenesis of the disease. Over the last few years, RNA-based therapeutics have emerged as a promising approach to precisely target disease-specific genes and pathways at the molecular level. This review examines the involvement of the use of different RNA-based methods such as small interfering RNA (siRNA), microRNA (miRNA), messenger RNA (mRNA) and antisense oligonucleotides (ASOs) in the management of Alzheimer's and Parkinson's disease. The article emphasises the ability of these therapies to regulate gene expression that relates to some of the major pathological phenotypes, including amyloid-beta deposition, hyperphosphorylation of the tau protein, and alpha-synuclein aggregation. In addition to that, it also talks about the progress in delivery systems to address limitations such as the blood-brain barrier, making RNA therapeutics more clinically applicable. The existing evidence of research shows that there is great potential to slow the progression of disease and improve the functioning of neurons. In spite of these developments, there are still some issues such as the problems of stability, off-target effects, and mass production. On the whole, RNA-based therapeutics is an innovative solution that can potentially turn the face of neurodegenerative diseases treatment. These innovations should be translated to effective therapeutic interventions, which can only be achieved through further research and clinical validation.
Additional Links: PMID-43050133
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050133,
year = {2026},
author = {Seal, R and Mandal, D and Ghosh, I and Rahaman, A and Sridhar, SB and Bhui, U and Sen, S and Pal, R},
title = {Decoding neurodegeneration: RNA therapeutics in Alzheimer's and Parkinson's diseases.},
journal = {Acta neurologica Belgica},
volume = {},
number = {},
pages = {},
pmid = {43050133},
issn = {2240-2993},
abstract = {Neurodegenerative conditions like Alzheimer disease and Parkinson disease are of major global health concern considering that they are progressive and not curable. The standard therapeutic methods mainly aim at the treatment of the symptoms, and they do not treat the molecular processes that contribute to the pathogenesis of the disease. Over the last few years, RNA-based therapeutics have emerged as a promising approach to precisely target disease-specific genes and pathways at the molecular level. This review examines the involvement of the use of different RNA-based methods such as small interfering RNA (siRNA), microRNA (miRNA), messenger RNA (mRNA) and antisense oligonucleotides (ASOs) in the management of Alzheimer's and Parkinson's disease. The article emphasises the ability of these therapies to regulate gene expression that relates to some of the major pathological phenotypes, including amyloid-beta deposition, hyperphosphorylation of the tau protein, and alpha-synuclein aggregation. In addition to that, it also talks about the progress in delivery systems to address limitations such as the blood-brain barrier, making RNA therapeutics more clinically applicable. The existing evidence of research shows that there is great potential to slow the progression of disease and improve the functioning of neurons. In spite of these developments, there are still some issues such as the problems of stability, off-target effects, and mass production. On the whole, RNA-based therapeutics is an innovative solution that can potentially turn the face of neurodegenerative diseases treatment. These innovations should be translated to effective therapeutic interventions, which can only be achieved through further research and clinical validation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Multicomponent Lifestyle Intervention and Brain Aging: A Secondary Analysis of a Randomized Clinical Trial.
JAMA network open, 9(11):e2644426 pii:2856772.
IMPORTANCE: Multicomponent lifestyle interventions show promise for promoting cognitive health, but their effects on clinically established brain aging markers among individuals with amnestic mild cognitive impairment (aMCI) are unclear. Intervention adherence may influence intervention efficacy.
OBJECTIVES: To evaluate the association of combined aerobic exercise and cognitive training (ACT) with brain aging markers and to explore the role of intervention adherence.
This secondary analysis of a phase 2, single-blind, 2 × 2 factorial randomized clinical trial with data collection lasting up to 18 months per participant was conducted at 3 academic research facilities between April 1, 2018, and July 17, 2024. Among 911 individuals screened, 146 participants with aMCI were randomized. Data were analyzed from October 10, 2025, to January 8, 2026.
INTERVENTIONS: The ACT intervention was compared with 3 other intervention arms during a 6-month period, including speed-of-processing training (SOP), cycling, and mental leisure activities plus stretching (MS).
MAIN OUTCOMES AND MEASURES: Alzheimer disease signature for cortical thickness (ADSCT) and natural log-transformed white matter hyperintensity (ln-WMH) were assessed at baseline, post intervention, and at the 12- and 18-month follow-ups. Outcome-specific modified intention-to-treat analyses used 100 forward-only multiple imputations and age-, sex-, and site-adjusted linear mixed-effects models with a participant random intercept. Visit-specific complete-case and attendance analyses used participants observed at baseline and the relevant follow-up.
RESULTS: Among 146 randomized participants (mean [SD] age, 73.8 [5.7] years), 75 (51.4%) were male. A total of 144 participants had baseline ADSCT and 141 had baseline ln-WMH measurements. In primary analyses, compared with ACT, SOP was associated with greater worsening in 18-month ADSCT change (B = -0.060 [95% CI, -0.117 to -0.004] mm; P = .04), and MS was associated with greater 12-month worsening (B = -0.066 [95% CI, -0.122 to -0.011] mm; P = .02). No primary ln-WMH contrast was significant. In visit-specific complete cases, cycling was associated with greater 18-month ln-WMH progression than ACT (B = 0.452 [95% CI, 0.131-0.772] natural log units; P = .006). Exploratory within-ACT analyses linked each of 10 additional sessions to greater postintervention ADSCT change (B = 0.022 [95% CI, 0.002-0.042] mm; P = .03), but not ln-WMH change.
CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial of older adults with aMCI, ACT was associated with more favorable ADSCT change than SOP at 18 months and MS at 12 months. No primary ln-WMH contrast was significant. Attendance findings were post randomization and exploratory. Larger confirmatory trials are needed to verify these findings.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03313895.
Additional Links: PMID-43050189
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050189,
year = {2026},
author = {Vankee-Lin, F and Ai, M and Zhuang, Y and Heffner, KL and Salisbury, D and Li, D and Jack, CR and Yu, F},
title = {Multicomponent Lifestyle Intervention and Brain Aging: A Secondary Analysis of a Randomized Clinical Trial.},
journal = {JAMA network open},
volume = {9},
number = {11},
pages = {e2644426},
doi = {10.1001/jamanetworkopen.2026.44426},
pmid = {43050189},
issn = {2574-3805},
mesh = {Humans ; Female ; Aged ; Male ; Single-Blind Method ; Cognitive Training ; *Cognitive Dysfunction/therapy ; *Aging/physiology ; *Life Style ; *Brain/diagnostic imaging ; Magnetic Resonance Imaging ; *Exercise ; Aged, 80 and over ; Cognitive Enhancement ; },
abstract = {IMPORTANCE: Multicomponent lifestyle interventions show promise for promoting cognitive health, but their effects on clinically established brain aging markers among individuals with amnestic mild cognitive impairment (aMCI) are unclear. Intervention adherence may influence intervention efficacy.
OBJECTIVES: To evaluate the association of combined aerobic exercise and cognitive training (ACT) with brain aging markers and to explore the role of intervention adherence.
This secondary analysis of a phase 2, single-blind, 2 × 2 factorial randomized clinical trial with data collection lasting up to 18 months per participant was conducted at 3 academic research facilities between April 1, 2018, and July 17, 2024. Among 911 individuals screened, 146 participants with aMCI were randomized. Data were analyzed from October 10, 2025, to January 8, 2026.
INTERVENTIONS: The ACT intervention was compared with 3 other intervention arms during a 6-month period, including speed-of-processing training (SOP), cycling, and mental leisure activities plus stretching (MS).
MAIN OUTCOMES AND MEASURES: Alzheimer disease signature for cortical thickness (ADSCT) and natural log-transformed white matter hyperintensity (ln-WMH) were assessed at baseline, post intervention, and at the 12- and 18-month follow-ups. Outcome-specific modified intention-to-treat analyses used 100 forward-only multiple imputations and age-, sex-, and site-adjusted linear mixed-effects models with a participant random intercept. Visit-specific complete-case and attendance analyses used participants observed at baseline and the relevant follow-up.
RESULTS: Among 146 randomized participants (mean [SD] age, 73.8 [5.7] years), 75 (51.4%) were male. A total of 144 participants had baseline ADSCT and 141 had baseline ln-WMH measurements. In primary analyses, compared with ACT, SOP was associated with greater worsening in 18-month ADSCT change (B = -0.060 [95% CI, -0.117 to -0.004] mm; P = .04), and MS was associated with greater 12-month worsening (B = -0.066 [95% CI, -0.122 to -0.011] mm; P = .02). No primary ln-WMH contrast was significant. In visit-specific complete cases, cycling was associated with greater 18-month ln-WMH progression than ACT (B = 0.452 [95% CI, 0.131-0.772] natural log units; P = .006). Exploratory within-ACT analyses linked each of 10 additional sessions to greater postintervention ADSCT change (B = 0.022 [95% CI, 0.002-0.042] mm; P = .03), but not ln-WMH change.
CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial of older adults with aMCI, ACT was associated with more favorable ADSCT change than SOP at 18 months and MS at 12 months. No primary ln-WMH contrast was significant. Attendance findings were post randomization and exploratory. Larger confirmatory trials are needed to verify these findings.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03313895.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Aged
Male
Single-Blind Method
Cognitive Training
*Cognitive Dysfunction/therapy
*Aging/physiology
*Life Style
*Brain/diagnostic imaging
Magnetic Resonance Imaging
*Exercise
Aged, 80 and over
Cognitive Enhancement
RevDate: 2026-11-18
Blood-Based Biomarker Testing for Alzheimer Disease in US Clinical Practice.
JAMA pii:2856893 [Epub ahead of print].
Additional Links: PMID-43050206
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050206,
year = {2026},
author = {Fu, M and Andersen, M and Ramachandran, R and Berg, KM and Ross, JS},
title = {Blood-Based Biomarker Testing for Alzheimer Disease in US Clinical Practice.},
journal = {JAMA},
volume = {},
number = {},
pages = {},
doi = {10.1001/jama.2026.23534},
pmid = {43050206},
issn = {1538-3598},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing.
Proceedings of the National Academy of Sciences of the United States of America, 123(47):e2625362123.
Neuroinflammation is a hallmark of Alzheimer's disease (AD), yet the molecular mechanisms linking microglial dysfunction to amyloid-β (Aβ) pathology remain incompletely understood. Here, we identify galectin-3 (Gal3) as a regulator of plaque-associated microglial responses, linking Aβ aggregation, lysosomal function, and neuritic pathology. Using postmortem brain tissue from AD patients, we found that Gal3[+] microglia preferentially associate with cored plaques and correlate with increased LAMP1[+] dystrophic neurites. Gal3 was also detected in microglial lysosomal compartments, extramicroglial dystrophic structures, and in association with extracellular amyloid fibrils, suggesting roles in both intracellular and extracellular Aβ processing. In APP mice, Gal3 deficiency reduced plaque burden and neuritic dystrophy, increased plaque compaction, and enhanced TREM2 coverage around amyloid plaques. Mechanistically, in vitro microglial experiments showed that Gal3 modulates Aβ uptake and lysosomal processing, whereas lysosomal dysfunction promoted the accumulation of fibrillar Aβ from initially monomeric species, particularly in Gal3-deficient cells. Cell-free assays demonstrated that Gal3 preferentially binds fibrillar Aβ, inhibits secondary nucleation, and alters fibril morphology, while Gal3-modified fibrillar Aβ reduces N2a neuronal cell number. Finally, in silico structural analyses identified candidate Gal3 interactors enriched in leucine-rich-repeat and immunoglobulin-like proteins, supporting a role for this lectin in immune receptor regulation. Complementary in vivo transcriptomic profiling showed that Gal3 deletion suppresses type I interferon and microglial neurodegenerative transcriptional signatures. Together, these findings position Gal3 at the interface between Aβ remodeling, lysosomal homeostasis, and plaque-associated microglial responses in AD.
Additional Links: PMID-43050315
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050315,
year = {2026},
author = {Camprubí-Ferrer, L and Soldán-Hidalgo, J and Axell, E and Dell'Eva, M and García-Cruzado, M and García-Revilla, J and Yang, Y and Fernández-Calle, R and Larlham, L and Chouhan, B and Talaverón, R and Paulus, A and Danielson, L and Gomez-Arboledas, A and Klementieva, O and Gutierrez, A and Vitorica, J and Wennström, M and Gouras, GK and Frontiñán-Rubio, J and Boza-Serrano, A and Rabinovich, GA and Venero, JL and Deierborg, T},
title = {Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing.},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
volume = {123},
number = {47},
pages = {e2625362123},
doi = {10.1073/pnas.2625362123},
pmid = {43050315},
issn = {1091-6490},
support = {AF-9685 2021//Alzheimerfonden (Alzheimer's Foundation)/ ; 188-0100 219-0166//Olle Engkvists Stiftelse (Stiftelsen Olle Engkvist Byggmästare)/ ; 21-0387 2021//Swedish Brain Power (SBP)/ ; F210040 2021//Anna och Edwin Bergers Stiftelse (Anna and Edwin Bergers Foundation)/ ; F210040 2021//Greta och Johan Kocks stiftelser (Johan and Greta Kock Trust)/ ; PID2024-157400OB-I00//Ministerio de Ciencia, Innovación y Universidades (MCIU)/ ; PID2023-146447OA-I00//Ministerio de Ciencia e Innovación (MCIN)/ ; PI21/00915//MEC | Instituto de Salud Carlos III (ISCIII)/ ; PI24/00274//MEC | Instituto de Salud Carlos III (ISCIII)/ ; 0005//Ministerio de Ciencia, Tecnología e Innovación (MINCyT)/ ; 0032//Fundación Sales (Sales Foundation)/ ; 2023-02//Fundación René Barón (fundacion_renebaron)/ ; },
mesh = {Animals ; *Microglia/metabolism/pathology ; *Lysosomes/metabolism/pathology ; *Amyloid beta-Peptides/metabolism ; Mice ; *Galectin 3/metabolism/genetics ; *Alzheimer Disease/metabolism/pathology/genetics ; Humans ; Plaque, Amyloid/metabolism/pathology ; *Neuroinflammatory Diseases/metabolism/pathology ; Brain/metabolism/pathology ; Receptors, Immunologic/metabolism ; Mice, Transgenic ; Amyloid beta-Protein Precursor/genetics/metabolism ; Membrane Glycoproteins/metabolism ; Galectins/metabolism ; },
abstract = {Neuroinflammation is a hallmark of Alzheimer's disease (AD), yet the molecular mechanisms linking microglial dysfunction to amyloid-β (Aβ) pathology remain incompletely understood. Here, we identify galectin-3 (Gal3) as a regulator of plaque-associated microglial responses, linking Aβ aggregation, lysosomal function, and neuritic pathology. Using postmortem brain tissue from AD patients, we found that Gal3[+] microglia preferentially associate with cored plaques and correlate with increased LAMP1[+] dystrophic neurites. Gal3 was also detected in microglial lysosomal compartments, extramicroglial dystrophic structures, and in association with extracellular amyloid fibrils, suggesting roles in both intracellular and extracellular Aβ processing. In APP mice, Gal3 deficiency reduced plaque burden and neuritic dystrophy, increased plaque compaction, and enhanced TREM2 coverage around amyloid plaques. Mechanistically, in vitro microglial experiments showed that Gal3 modulates Aβ uptake and lysosomal processing, whereas lysosomal dysfunction promoted the accumulation of fibrillar Aβ from initially monomeric species, particularly in Gal3-deficient cells. Cell-free assays demonstrated that Gal3 preferentially binds fibrillar Aβ, inhibits secondary nucleation, and alters fibril morphology, while Gal3-modified fibrillar Aβ reduces N2a neuronal cell number. Finally, in silico structural analyses identified candidate Gal3 interactors enriched in leucine-rich-repeat and immunoglobulin-like proteins, supporting a role for this lectin in immune receptor regulation. Complementary in vivo transcriptomic profiling showed that Gal3 deletion suppresses type I interferon and microglial neurodegenerative transcriptional signatures. Together, these findings position Gal3 at the interface between Aβ remodeling, lysosomal homeostasis, and plaque-associated microglial responses in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Microglia/metabolism/pathology
*Lysosomes/metabolism/pathology
*Amyloid beta-Peptides/metabolism
Mice
*Galectin 3/metabolism/genetics
*Alzheimer Disease/metabolism/pathology/genetics
Humans
Plaque, Amyloid/metabolism/pathology
*Neuroinflammatory Diseases/metabolism/pathology
Brain/metabolism/pathology
Receptors, Immunologic/metabolism
Mice, Transgenic
Amyloid beta-Protein Precursor/genetics/metabolism
Membrane Glycoproteins/metabolism
Galectins/metabolism
RevDate: 2026-11-18
Associations between atherogenic index of plasma, Alzheimer's biomarkers, and the risk of cognitive impairment: Hubei Memory and Aging Cohort Study.
Neuroepidemiology pii:9090094 [Epub ahead of print].
INTRODUCTION: The atherogenic index of plasma (AIP) is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment in older adults is limited. We examined whether AIP was associated with incident cognitive impairment, and explored associations with plasma Alzheimer's disease (AD) biomarkers and apolipoprotein E (APOE) ε4 status.
METHODS: This study included 1,143 adults aged ≥ 65 years from the Hubei Memory and Aging Cohort Study. AIP was calculated as log(triglyceride/high-density lipoprotein cholesterol). The association of AIP with incident cognitive impairment and its joint effects with plasma AD biomarkers were evaluated using Cox models. Dose-response associations were assessed by restricted cubic splines. Cognitive domain declines were analyzed using linear mixed-effects models. Analyses were stratified by APOE ε4 status.
RESULTS: After adjustment, higher baseline AIP was independently associated with greater risk of cognitive impairment, showing a nonlinear dose-response relationship (inflection point: 0.758). Compared to the lowest quartile, the highest quartile exhibited a higher risk (Hazard Ratio [HR] = 2.15; 95% Confidence Interval [CI]: 1.47-3.12). Higher AIP also correlated with faster memory decline (β = -0.14, 95% CI: -0.26 to -0.01). Participants with higher AIP and elevated p-tau181 had an increased risk of cognitive impairment (HR = 3.46, 95% CI: 1.58-7.61). These effects were more pronounced among APOE ε4 carriers.
CONCLUSIONS: Higher AIP was associated with cognitive impairment and faster memory decline. High AIP combined with elevated p-tau181 was associated with greater risk, particularly among APOE ε4 carriers, supporting refined risk stratification in older adults.
Additional Links: PMID-43050366
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050366,
year = {2026},
author = {Xie, X and Tian, Y and Deng, X and Liu, X and Tang, Q and Chen, L and Liu, X and Fu, M and Cheng, G and Liu, D and Hu, F and Xu, L and Ouyang, M and Zhou, Y and Zeng, Y},
title = {Associations between atherogenic index of plasma, Alzheimer's biomarkers, and the risk of cognitive impairment: Hubei Memory and Aging Cohort Study.},
journal = {Neuroepidemiology},
volume = {},
number = {},
pages = {},
doi = {10.1159/ned/adwag072},
pmid = {43050366},
issn = {1423-0208},
abstract = {INTRODUCTION: The atherogenic index of plasma (AIP) is a reliable marker of atherogenic dyslipidemia, but prospective evidence on its association with cognitive impairment in older adults is limited. We examined whether AIP was associated with incident cognitive impairment, and explored associations with plasma Alzheimer's disease (AD) biomarkers and apolipoprotein E (APOE) ε4 status.
METHODS: This study included 1,143 adults aged ≥ 65 years from the Hubei Memory and Aging Cohort Study. AIP was calculated as log(triglyceride/high-density lipoprotein cholesterol). The association of AIP with incident cognitive impairment and its joint effects with plasma AD biomarkers were evaluated using Cox models. Dose-response associations were assessed by restricted cubic splines. Cognitive domain declines were analyzed using linear mixed-effects models. Analyses were stratified by APOE ε4 status.
RESULTS: After adjustment, higher baseline AIP was independently associated with greater risk of cognitive impairment, showing a nonlinear dose-response relationship (inflection point: 0.758). Compared to the lowest quartile, the highest quartile exhibited a higher risk (Hazard Ratio [HR] = 2.15; 95% Confidence Interval [CI]: 1.47-3.12). Higher AIP also correlated with faster memory decline (β = -0.14, 95% CI: -0.26 to -0.01). Participants with higher AIP and elevated p-tau181 had an increased risk of cognitive impairment (HR = 3.46, 95% CI: 1.58-7.61). These effects were more pronounced among APOE ε4 carriers.
CONCLUSIONS: Higher AIP was associated with cognitive impairment and faster memory decline. High AIP combined with elevated p-tau181 was associated with greater risk, particularly among APOE ε4 carriers, supporting refined risk stratification in older adults.},
}
RevDate: 2026-11-18
Cross-modality Knowledge Transfer Between fMRI and EEG for Improved Single-modality Alzheimer's Disease Diagnosis.
IEEE transactions on medical imaging, PP: [Epub ahead of print].
Alzheimer's disease (AD) disrupts brain function in both spatial organization and temporal dynamics, which can be characterized by complementary fMRI and EEG measurements. In particular, fMRI provides higher spatial resolution to characterize multi-scale functional organization of brain networks, whereas EEG offers higher temporal resolution to capture dynamic neural activities across frequency bands. Thus, integrating the two modalities can characterize AD-related spatiotemporal disruptions more comprehensively than either modality alone. However, it is impractical to acquire paired fMRI and EEG data in real-world applications. To address this problem, we propose the fMRI-EEG Knowledge Transfer Network (FE-KTNet) to learn spatiotemporal representations from paired data and then transfer them back to modality-specific models through three stages. Specifically, in Stage 1, it learns modality-specific representations from fMRI and EEG FCNs, emphasizing multi-scale network organization for fMRI and frequency-specific electrophysiological coupling for EEG. Building on these representations, in Stage 2, it performs scale-wise bidirectional cross-modality fusion to integrate complementary information into fused multi-scale spatiotemporal representations. Finally, in Stage 3, it transfers the fused representations back to each modality-specific encoder through scale-wise feature alignment and logit-level knowledge distillation. We evaluate FE-KTNet on 14 multicenter datasets comprising 2,766 fMRI subjects and 1,842 EEG subjects, covering AD-NC, MCI-NC, and AD-MCI classifications. Compared with the corresponding baseline models, FE-KTNet increases fMRI-only and EEG-only accuracy by 3.4% and 6.1% for AD-NC classification, 5.2% and 8.0% for MCI-NC classification, and 3.5% and 7.1% for AD-MCI classification, respectively, and achieves the best overall performance among all evaluated methods. Our code is available at GitHub Repository.
Additional Links: PMID-43050378
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050378,
year = {2026},
author = {Lin, X and Liu, Y and Yu, W and Xu, J and Dou, Y and Li, W and Wu, Z and Qin, J and Du, X and Lin, J and Tan, M and He, Y and Shi, F and Guo, Y and Cui, Z and Shen, D},
title = {Cross-modality Knowledge Transfer Between fMRI and EEG for Improved Single-modality Alzheimer's Disease Diagnosis.},
journal = {IEEE transactions on medical imaging},
volume = {PP},
number = {},
pages = {},
doi = {10.1109/TMI.2026.3754829},
pmid = {43050378},
issn = {1558-254X},
abstract = {Alzheimer's disease (AD) disrupts brain function in both spatial organization and temporal dynamics, which can be characterized by complementary fMRI and EEG measurements. In particular, fMRI provides higher spatial resolution to characterize multi-scale functional organization of brain networks, whereas EEG offers higher temporal resolution to capture dynamic neural activities across frequency bands. Thus, integrating the two modalities can characterize AD-related spatiotemporal disruptions more comprehensively than either modality alone. However, it is impractical to acquire paired fMRI and EEG data in real-world applications. To address this problem, we propose the fMRI-EEG Knowledge Transfer Network (FE-KTNet) to learn spatiotemporal representations from paired data and then transfer them back to modality-specific models through three stages. Specifically, in Stage 1, it learns modality-specific representations from fMRI and EEG FCNs, emphasizing multi-scale network organization for fMRI and frequency-specific electrophysiological coupling for EEG. Building on these representations, in Stage 2, it performs scale-wise bidirectional cross-modality fusion to integrate complementary information into fused multi-scale spatiotemporal representations. Finally, in Stage 3, it transfers the fused representations back to each modality-specific encoder through scale-wise feature alignment and logit-level knowledge distillation. We evaluate FE-KTNet on 14 multicenter datasets comprising 2,766 fMRI subjects and 1,842 EEG subjects, covering AD-NC, MCI-NC, and AD-MCI classifications. Compared with the corresponding baseline models, FE-KTNet increases fMRI-only and EEG-only accuracy by 3.4% and 6.1% for AD-NC classification, 5.2% and 8.0% for MCI-NC classification, and 3.5% and 7.1% for AD-MCI classification, respectively, and achieves the best overall performance among all evaluated methods. Our code is available at GitHub Repository.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
The global burden of Alzheimer's disease and related dementias: New public health intervention targets driven by the long-term impact of COVID-19 and sex and age differences.
PloS one, 21(11):e0359947 pii:PONE-D-25-30957.
INTRODUCTION: This study focuses on the impact and future trends of COVID-19 on the burden of Alzheimer's disease and related dementias (ADRD), analyzing multidimensional differences in the burden of disease for ADRD in 204 countries between 1990 and 2021.
METHODS: Using Global Burden of Disease (GBD) data (1990-2021), we analyzed Alzheimer's disease and related dementias (ADRD) prevalence and burden across 204 countries, stratified by sex and age. Joinpoint regression identified temporal inflection points in incidence, mortality, disability-adjusted life years (DALYs), and years of life lost (YLL), while age-standardized rates and estimated annual percentage changes assessed global burden trends. We further evaluated ADRD-associated risk factors, quantified COVID-19's impact through excess burden attribution models, and projected incidence trajectories to 2050 via Bayesian Age-Period-Cohort analysis.
RESULTS: Global Burden of Disease analyses (1990-2021) show 2021 ADRD incidence of 119.76/100,000, with 450.98 DALYs and 309.03 YLL/100,000. Post-2019 COVID-19 onset, all SDI regions except high-SDI exhibited significant ADRD incidence increases (P < 0.05). Women ≥55 years had the highest burden, with behavioral risks contributing most to DALYs (2021). China showed the steepest ADRD incidence rise (1990-2021), accelerating post-COVID-19, contrasting declines in Denmark and Australia. COVID-19 ASIR (2020) and ADRD ASPR (2020) had a standardized path coefficient of 0.237 (P < 0.05); COVID-19 ASIR (2020) and ADRD ASPR (2021) covariance reached 0.275 (P < 0.05). Projections suggest declining ASIR for ages 40-79 but rising ASIR for ≥80 by 2050.
CONCLUSION: To effectively mitigate the ongoing rise in ADRD, particularly among older women and middle-high SDI populations, targeted prevention and control strategies must be developed, with careful consideration of socioeconomic factors and the long-term impacts of COVID-19.
Additional Links: PMID-43050399
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050399,
year = {2026},
author = {Chen, S and Cai, M and Song, Y and Xu, Z and Bai, Y and Zheng, W},
title = {The global burden of Alzheimer's disease and related dementias: New public health intervention targets driven by the long-term impact of COVID-19 and sex and age differences.},
journal = {PloS one},
volume = {21},
number = {11},
pages = {e0359947},
doi = {10.1371/journal.pone.0359947},
pmid = {43050399},
issn = {1932-6203},
mesh = {Humans ; *COVID-19/epidemiology ; Female ; *Alzheimer Disease/epidemiology ; Global Burden of Disease/trends ; Incidence ; Aged ; Male ; Disability-Adjusted Life Years ; *Dementia/epidemiology ; Age Factors ; Aged, 80 and over ; Sex Factors ; Middle Aged ; SARS-CoV-2/isolation & purification ; Public Health ; Risk Factors ; Prevalence ; Global Health ; Bayes Theorem ; },
abstract = {INTRODUCTION: This study focuses on the impact and future trends of COVID-19 on the burden of Alzheimer's disease and related dementias (ADRD), analyzing multidimensional differences in the burden of disease for ADRD in 204 countries between 1990 and 2021.
METHODS: Using Global Burden of Disease (GBD) data (1990-2021), we analyzed Alzheimer's disease and related dementias (ADRD) prevalence and burden across 204 countries, stratified by sex and age. Joinpoint regression identified temporal inflection points in incidence, mortality, disability-adjusted life years (DALYs), and years of life lost (YLL), while age-standardized rates and estimated annual percentage changes assessed global burden trends. We further evaluated ADRD-associated risk factors, quantified COVID-19's impact through excess burden attribution models, and projected incidence trajectories to 2050 via Bayesian Age-Period-Cohort analysis.
RESULTS: Global Burden of Disease analyses (1990-2021) show 2021 ADRD incidence of 119.76/100,000, with 450.98 DALYs and 309.03 YLL/100,000. Post-2019 COVID-19 onset, all SDI regions except high-SDI exhibited significant ADRD incidence increases (P < 0.05). Women ≥55 years had the highest burden, with behavioral risks contributing most to DALYs (2021). China showed the steepest ADRD incidence rise (1990-2021), accelerating post-COVID-19, contrasting declines in Denmark and Australia. COVID-19 ASIR (2020) and ADRD ASPR (2020) had a standardized path coefficient of 0.237 (P < 0.05); COVID-19 ASIR (2020) and ADRD ASPR (2021) covariance reached 0.275 (P < 0.05). Projections suggest declining ASIR for ages 40-79 but rising ASIR for ≥80 by 2050.
CONCLUSION: To effectively mitigate the ongoing rise in ADRD, particularly among older women and middle-high SDI populations, targeted prevention and control strategies must be developed, with careful consideration of socioeconomic factors and the long-term impacts of COVID-19.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*COVID-19/epidemiology
Female
*Alzheimer Disease/epidemiology
Global Burden of Disease/trends
Incidence
Aged
Male
Disability-Adjusted Life Years
*Dementia/epidemiology
Age Factors
Aged, 80 and over
Sex Factors
Middle Aged
SARS-CoV-2/isolation & purification
Public Health
Risk Factors
Prevalence
Global Health
Bayes Theorem
RevDate: 2026-11-18
CmpDate: 2026-11-18
Neuropathologic Correlates of Cognitive Functions in Patients With Essential Tremor Without Dementia: Beyond the Cerebellum.
Neurology, 107(12):e218764.
BACKGROUND AND OBJECTIVES: Essential tremor (ET) is characterized not only by motor disturbances but also, in many cases, by a wide array of cognitive symptoms. Accumulating evidence implicates pathways beyond the cerebellum by which cognitive changes emerge. However, the extracerebellar neuropathologic correlates of specific cognitive symptoms have not been examined. This study evaluated these potential clinicopathologic associations in older adults with ET.
METHODS: Participants were adults ≥55 years with ET who were followed prospectively and longitudinally and donated their brains for neuropathologic evaluation as part of the Clinical-Pathological Study of Cognitive Impairment in Essential Tremor study. Cognitive outcomes included attention, executive function, language, memory, and visuospatial function. Postmortem neuropathologic assessment included Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque scores, Thal β-amyloid A score, Braak and Braak neurofibrillary tangle (NFT) stage, and Braak Lewy pathology stage. Regional cerebral cortical atrophy ratings (neocortical and hippocampal), cerebral amyloid angiopathy, and markers of cerebrovascular health were also rated. Regression models examined neuropathologic correlates of cognitive function, adjusting for numerous confounders. Sensitivity analyses examined robustness of findings.
RESULTS: The sample consisted of 57 individuals with ET and without dementia (mean age = 88.6 ± 5.4 years; 54.4% female, 71.9% cognitively normal, 28.1% with mild cognitive impairment). Higher amyloid burden was associated with lower attention (CERAD β = -0.48, p < 0.001; Thal β = -0.37, p < 0.01) and lower executive function (CERAD β = -0.40, p 0.01; Thal β = -0.33, p = 0.01). CERAD score was associated with lower language (β = -0.31, p = 0.04). Braak NFT stage was associated with lower attention (β = -0.26, p = 0.04) and lower executive function (β = -0.28, p = 0.03). Hippocampal atrophy was associated with lower memory performance (β = -0.29, p = 0.04).
DISCUSSION: Core pathologies of AD, amyloid and tau, are associated with decrements in attention and executive function in older adults with ET and without dementia, while hippocampal atrophy is associated with lower memory performance. These results, consistent with a growing literature on extracerebellar pathologies in ET, suggest that multidomain cognitive symptoms among older adults with ET and without dementia may be driven in large part by AD-related cortical degenerative processes. Ongoing work is examining the molecular basis of these processes. Limitations include a highly educated, demographically homogeneous, and relatively small sample, as well as a lack of a control group.
Additional Links: PMID-43050637
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050637,
year = {2026},
author = {Cosentino, SA and Chapman, S and Guy, TO and Rizer, S and Berry, DS and Wainman, E and Hernandez, NC and Huey, ED and Faust, PL and Louis, ED},
title = {Neuropathologic Correlates of Cognitive Functions in Patients With Essential Tremor Without Dementia: Beyond the Cerebellum.},
journal = {Neurology},
volume = {107},
number = {12},
pages = {e218764},
doi = {10.1212/WNL.0000000000218764},
pmid = {43050637},
issn = {1526-632X},
mesh = {Humans ; Female ; *Essential Tremor/pathology/psychology/complications ; Male ; Aged ; *Cerebellum/pathology ; *Brain/pathology ; Middle Aged ; Executive Function/physiology ; *Cognition/physiology ; Aged, 80 and over ; Longitudinal Studies ; Dementia/pathology ; Atrophy/pathology ; Neuropsychological Tests ; Neurofibrillary Tangles/pathology ; Prospective Studies ; *Cognitive Dysfunction/pathology ; },
abstract = {BACKGROUND AND OBJECTIVES: Essential tremor (ET) is characterized not only by motor disturbances but also, in many cases, by a wide array of cognitive symptoms. Accumulating evidence implicates pathways beyond the cerebellum by which cognitive changes emerge. However, the extracerebellar neuropathologic correlates of specific cognitive symptoms have not been examined. This study evaluated these potential clinicopathologic associations in older adults with ET.
METHODS: Participants were adults ≥55 years with ET who were followed prospectively and longitudinally and donated their brains for neuropathologic evaluation as part of the Clinical-Pathological Study of Cognitive Impairment in Essential Tremor study. Cognitive outcomes included attention, executive function, language, memory, and visuospatial function. Postmortem neuropathologic assessment included Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque scores, Thal β-amyloid A score, Braak and Braak neurofibrillary tangle (NFT) stage, and Braak Lewy pathology stage. Regional cerebral cortical atrophy ratings (neocortical and hippocampal), cerebral amyloid angiopathy, and markers of cerebrovascular health were also rated. Regression models examined neuropathologic correlates of cognitive function, adjusting for numerous confounders. Sensitivity analyses examined robustness of findings.
RESULTS: The sample consisted of 57 individuals with ET and without dementia (mean age = 88.6 ± 5.4 years; 54.4% female, 71.9% cognitively normal, 28.1% with mild cognitive impairment). Higher amyloid burden was associated with lower attention (CERAD β = -0.48, p < 0.001; Thal β = -0.37, p < 0.01) and lower executive function (CERAD β = -0.40, p 0.01; Thal β = -0.33, p = 0.01). CERAD score was associated with lower language (β = -0.31, p = 0.04). Braak NFT stage was associated with lower attention (β = -0.26, p = 0.04) and lower executive function (β = -0.28, p = 0.03). Hippocampal atrophy was associated with lower memory performance (β = -0.29, p = 0.04).
DISCUSSION: Core pathologies of AD, amyloid and tau, are associated with decrements in attention and executive function in older adults with ET and without dementia, while hippocampal atrophy is associated with lower memory performance. These results, consistent with a growing literature on extracerebellar pathologies in ET, suggest that multidomain cognitive symptoms among older adults with ET and without dementia may be driven in large part by AD-related cortical degenerative processes. Ongoing work is examining the molecular basis of these processes. Limitations include a highly educated, demographically homogeneous, and relatively small sample, as well as a lack of a control group.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
*Essential Tremor/pathology/psychology/complications
Male
Aged
*Cerebellum/pathology
*Brain/pathology
Middle Aged
Executive Function/physiology
*Cognition/physiology
Aged, 80 and over
Longitudinal Studies
Dementia/pathology
Atrophy/pathology
Neuropsychological Tests
Neurofibrillary Tangles/pathology
Prospective Studies
*Cognitive Dysfunction/pathology
RevDate: 2026-11-18
Cognition in Essential Tremor: Alzheimer Disease Pathology Before Dementia.
Neurology, 107(12):e218918.
Additional Links: PMID-43050644
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050644,
year = {2026},
author = {Benito-León, J and Benito-Rodríguez, CM},
title = {Cognition in Essential Tremor: Alzheimer Disease Pathology Before Dementia.},
journal = {Neurology},
volume = {107},
number = {12},
pages = {e218918},
doi = {10.1212/WNL.0000000000218918},
pmid = {43050644},
issn = {1526-632X},
}
RevDate: 2026-11-18
ALSFRS-R item comparability and respiratory validation in data-driven ALS progression modeling.
Additional Links: PMID-43050726
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050726,
year = {2026},
author = {Yang, B},
title = {ALSFRS-R item comparability and respiratory validation in data-driven ALS progression modeling.},
journal = {Journal of the neurological sciences},
volume = {492},
number = {},
pages = {126249},
doi = {10.1016/j.jns.2026.126249},
pmid = {43050726},
issn = {1878-5883},
}
RevDate: 2026-11-18
Spider Pattern: An adaptive EEG feature extraction method for Alzheimer's disease and frontotemporal dementia classification.
Psychiatry research. Neuroimaging, 365:112366 pii:S0925-4927(26)00231-3 [Epub ahead of print].
Dementia is a major and growing health challenge, and electroencephalography (EEG) provides a non-invasive and comparatively accessible modality for computational investigation of dementia-related brain activity. This study evaluates an adaptive time-domain feature extraction technique named Spider Pattern (SP), combined with Social Spider Algorithm (SSA) feature selection and feedforward neural network (FFNN) classification, for Alzheimer's disease (AD), frontotemporal dementia (FTD), and normal control (NC) discrimination. The preprocessed public EEG dataset contains 88 participants (36 AD, 23 FTD, and 29 NC). Using 15-second non-overlapping segmentation, 4535 segments were analyzed and represented by 608 SP features. The primary evaluation used nested leave-one-subject-out (LOSO) validation in which SSA feature selection was performed only within each outer training fold. Subject-level accuracies were 78.46% for AD vs. NC (AUC 0.810), 71.15% for FTD vs. NC (AUC 0.712), and 52.54% for AD vs. FTD (AUC 0.562). Exact paired McNemar tests showed no significant difference between SSA and either full-feature or mRMR comparators. A secondary segment-wise 10-fold analysis using all 608 SP features produced higher accuracies of 90.83%, 93.08%, and 90.87%, respectively; however, every fold contained test participants also represented in training, so these values are not estimates of unseen-subject generalization. The gap between the two estimates quantifies the effect of participant leakage on this widely used public dataset. Sensitivity analyses showed task-dependent effects of SP design choices, while repeated SSA runs showed limited feature-subset stability. The results support further investigation of SP for case-control EEG classification but do not establish reliable AD-vs.-FTD discrimination or clinical deployment.
Additional Links: PMID-43050742
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050742,
year = {2026},
author = {Akbari, H and Sadiq, MT and Shamsi, H and Singh, K and Ghazvini, M and Siuly, S and Mete, M},
title = {Spider Pattern: An adaptive EEG feature extraction method for Alzheimer's disease and frontotemporal dementia classification.},
journal = {Psychiatry research. Neuroimaging},
volume = {365},
number = {},
pages = {112366},
doi = {10.1016/j.pscychresns.2026.112366},
pmid = {43050742},
issn = {1872-7506},
abstract = {Dementia is a major and growing health challenge, and electroencephalography (EEG) provides a non-invasive and comparatively accessible modality for computational investigation of dementia-related brain activity. This study evaluates an adaptive time-domain feature extraction technique named Spider Pattern (SP), combined with Social Spider Algorithm (SSA) feature selection and feedforward neural network (FFNN) classification, for Alzheimer's disease (AD), frontotemporal dementia (FTD), and normal control (NC) discrimination. The preprocessed public EEG dataset contains 88 participants (36 AD, 23 FTD, and 29 NC). Using 15-second non-overlapping segmentation, 4535 segments were analyzed and represented by 608 SP features. The primary evaluation used nested leave-one-subject-out (LOSO) validation in which SSA feature selection was performed only within each outer training fold. Subject-level accuracies were 78.46% for AD vs. NC (AUC 0.810), 71.15% for FTD vs. NC (AUC 0.712), and 52.54% for AD vs. FTD (AUC 0.562). Exact paired McNemar tests showed no significant difference between SSA and either full-feature or mRMR comparators. A secondary segment-wise 10-fold analysis using all 608 SP features produced higher accuracies of 90.83%, 93.08%, and 90.87%, respectively; however, every fold contained test participants also represented in training, so these values are not estimates of unseen-subject generalization. The gap between the two estimates quantifies the effect of participant leakage on this widely used public dataset. Sensitivity analyses showed task-dependent effects of SP design choices, while repeated SSA runs showed limited feature-subset stability. The results support further investigation of SP for case-control EEG classification but do not establish reliable AD-vs.-FTD discrimination or clinical deployment.},
}
RevDate: 2026-11-18
Autoimmune disease and incident dementia: A UK Biobank cohort study.
Psychiatry research, 367:117580 pii:S0165-1781(26)00639-6 [Epub ahead of print].
INTRODUCTION: Autoimmune diseases may be associated with dementia, but disease heterogeneity, competing mortality and ascertainment bias complicate interpretation. We examined incident dementia alongside brain MRI measures and longitudinal cognitive performance.
METHODS: The primary analysis included 400,777 UK Biobank participants who were alive, under observation and dementia-free one year after recruitment. Baseline autoimmune disease was identified from nurse-recorded self-report. We estimated cause-specific Cox and Fine-Gray associations with all-cause dementia (ACD), Alzheimer's disease (AD) and vascular dementia (VD). Sensitivity analyses addressed matching, missing covariates, multiple sclerosis (MS), longer exclusion windows and record ascertainment. MRI analyses were cross-sectional; repeated cognition was examined across nine tests.
RESULTS: During a median 12.8 years of observed follow-up after the one-year landmark, 7476 ACD, 3327 CE and 1621 VD events were recorded. Fully adjusted cause-specific HRs were 1.34 (95% CI 1.22-1.47) for ACD, 1.35 (95% CI 1.17-1.56) for AD and 1.38 (95% CI 1.13-1.68) for VD. Corresponding Fine-Gray subdistribution HRs were 1.29, 1.31 and 1.34. Associations persisted after excluding MS. Adjustment for hospital-contact proxies attenuated estimates, with the VD confidence interval crossing 1. Autoimmune disease was associated with higher log-WMH burden (standardized difference 0.163, 95% CI 0.111-0.215), but not clearly with hippocampal or total gray matter volume. None of nine cognitive slope differences survived false-discovery-rate correction.
CONCLUSION: Baseline autoimmune disease was associated with higher recorded dementia incidence and greater WMH burden. Ascertainment and residual confounding remain plausible explanations for part of the association. These observational findings do not establish causality, accelerated brain atrophy or faster cognitive decline.
Additional Links: PMID-43050834
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050834,
year = {2026},
author = {Fei, ZC and Wang, QH and Yi, X and Fan, DY and Li, XP and Zeng, GH and Zhang, LL and Wang, YJ and Liu, YH},
title = {Autoimmune disease and incident dementia: A UK Biobank cohort study.},
journal = {Psychiatry research},
volume = {367},
number = {},
pages = {117580},
doi = {10.1016/j.psychres.2026.117580},
pmid = {43050834},
issn = {1872-7123},
abstract = {INTRODUCTION: Autoimmune diseases may be associated with dementia, but disease heterogeneity, competing mortality and ascertainment bias complicate interpretation. We examined incident dementia alongside brain MRI measures and longitudinal cognitive performance.
METHODS: The primary analysis included 400,777 UK Biobank participants who were alive, under observation and dementia-free one year after recruitment. Baseline autoimmune disease was identified from nurse-recorded self-report. We estimated cause-specific Cox and Fine-Gray associations with all-cause dementia (ACD), Alzheimer's disease (AD) and vascular dementia (VD). Sensitivity analyses addressed matching, missing covariates, multiple sclerosis (MS), longer exclusion windows and record ascertainment. MRI analyses were cross-sectional; repeated cognition was examined across nine tests.
RESULTS: During a median 12.8 years of observed follow-up after the one-year landmark, 7476 ACD, 3327 CE and 1621 VD events were recorded. Fully adjusted cause-specific HRs were 1.34 (95% CI 1.22-1.47) for ACD, 1.35 (95% CI 1.17-1.56) for AD and 1.38 (95% CI 1.13-1.68) for VD. Corresponding Fine-Gray subdistribution HRs were 1.29, 1.31 and 1.34. Associations persisted after excluding MS. Adjustment for hospital-contact proxies attenuated estimates, with the VD confidence interval crossing 1. Autoimmune disease was associated with higher log-WMH burden (standardized difference 0.163, 95% CI 0.111-0.215), but not clearly with hippocampal or total gray matter volume. None of nine cognitive slope differences survived false-discovery-rate correction.
CONCLUSION: Baseline autoimmune disease was associated with higher recorded dementia incidence and greater WMH burden. Ascertainment and residual confounding remain plausible explanations for part of the association. These observational findings do not establish causality, accelerated brain atrophy or faster cognitive decline.},
}
RevDate: 2026-11-18
Baseline sarcopenia and subsequent dementia after incident atrial fibrillation or flutter in the UK Biobank.
The journal of nutrition, health & aging, 31(2):101036 pii:S1279-7707(26)00269-1 [Epub ahead of print].
BACKGROUND: The association between sarcopenia and dementia after incident atrial fibrillation or flutter (AF/flutter) remains uncertain.
METHODS: We studied 30,743 UK Biobank participants free of AF/flutter at recruitment who subsequently had a first recorded AF/flutter event. Sarcopenia was assessed at recruitment; dementia follow-up began at that event. Analyses used Cox and Fine-Gray models, propensity-score matching and restricted cubic splines. Exploratory analyses tested interactions with AF/flutter, heart failure and coronary artery disease status at entry.
RESULTS: Sarcopenia was present in 2,279 participants (7.4%). Over a median 4.27 years after AF/flutter entry, 1,155 developed dementia. Recruitment preceded entry by a median 8.50 years. Fully adjusted analyses included 26,430 participants and 998 all-cause dementia events. Sarcopenia was associated with all-cause dementia in Cox (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.16-1.72) and Fine-Gray models (subdistribution HR, 1.31; 95% CI, 1.08-1.59). The matched Cox HR was 1.35 (95% CI, 1.09-1.66). Fully adjusted Cox HRs were 1.64 (95% CI, 1.15-2.35) for vascular dementia and 1.34 (95% CI, 0.92-1.93) for Alzheimer's disease. No interactions with cardiovascular condition status were detected.
CONCLUSIONS: Sarcopenia assessed at recruitment was associated with all-cause dementia after incident AF/flutter. Prospective studies should assess the clinical value of muscle measurements near AF/flutter diagnosis.
Additional Links: PMID-43050930
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43050930,
year = {2026},
author = {Yu, Y and Ling, T and Li, X and Zhang, N and Pan, W and Lin, C and Xie, Y and Bao, Y and Luo, Q and Wei, Y and Qi, J and Liqun, W},
title = {Baseline sarcopenia and subsequent dementia after incident atrial fibrillation or flutter in the UK Biobank.},
journal = {The journal of nutrition, health & aging},
volume = {31},
number = {2},
pages = {101036},
doi = {10.1016/j.jnha.2026.101036},
pmid = {43050930},
issn = {1760-4788},
abstract = {BACKGROUND: The association between sarcopenia and dementia after incident atrial fibrillation or flutter (AF/flutter) remains uncertain.
METHODS: We studied 30,743 UK Biobank participants free of AF/flutter at recruitment who subsequently had a first recorded AF/flutter event. Sarcopenia was assessed at recruitment; dementia follow-up began at that event. Analyses used Cox and Fine-Gray models, propensity-score matching and restricted cubic splines. Exploratory analyses tested interactions with AF/flutter, heart failure and coronary artery disease status at entry.
RESULTS: Sarcopenia was present in 2,279 participants (7.4%). Over a median 4.27 years after AF/flutter entry, 1,155 developed dementia. Recruitment preceded entry by a median 8.50 years. Fully adjusted analyses included 26,430 participants and 998 all-cause dementia events. Sarcopenia was associated with all-cause dementia in Cox (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.16-1.72) and Fine-Gray models (subdistribution HR, 1.31; 95% CI, 1.08-1.59). The matched Cox HR was 1.35 (95% CI, 1.09-1.66). Fully adjusted Cox HRs were 1.64 (95% CI, 1.15-2.35) for vascular dementia and 1.34 (95% CI, 0.92-1.93) for Alzheimer's disease. No interactions with cardiovascular condition status were detected.
CONCLUSIONS: Sarcopenia assessed at recruitment was associated with all-cause dementia after incident AF/flutter. Prospective studies should assess the clinical value of muscle measurements near AF/flutter diagnosis.},
}
RevDate: 2026-11-18
Hybrid framework utilizing interval Type-2 fuzzy entropy and ScaleDual-CNN for differential diagnosis of dementia using rest-state EEG signals.
Computers in biology and medicine, 219:112061 pii:S0010-4825(26)00635-9 [Epub ahead of print].
Differential diagnosis of Alzheimer's disease (AD) and frontotemporal dementia (FTD) is challenging because of their similarity in early stages. Electroencephalogram (EEG) signals offer a non-invasive, inexpensive tool for automated screening. However, traditional approaches cannot handle environmental noise and high inter-individual variance. In this study, interval type-2 fuzzy entropy (IT2-FE) was evaluated as a biomarker for diagnosing dementia under uncertainty. We utilized the public OpenNeuro ds004504 database (88 resting-state subjects). Signals were segmented into 4-s windows. Then we extracted IT2-FE in the alpha and theta bands, Hjorth and connectivity features. A dual evaluation framework was developed. First, we evaluated a subject-independent pipeline by combining fuzzy features, deep network, and SVM classifier. Second, we implemented an epoch-based model by combining the customized ScaleDual-CNN with fuzzy/spectral features and the XGBoost classifier. Compared to spectral entropy, the IT2-FE method identified approximately 11.7 times more statistically significant features (35 versus 3; pFDR < 0.05). These findings indicate statistically significant differences between the groups. For entropy-based classification, IT2-FE achieved 67.64% accuracy and 61.72% macro-F1, compared with 62.50% and 60.55% for spectral entropy, and 62.50% and 60.01% for Type-1 fuzzy entropy, respectively. These results suggest that IT2-FE captures discriminative EEG characteristics, although its classification performance advantage over other entropy measures remains limited. Subject-independent AUC for control, AD, and FTD were 0.96, 0.93, and 0.89, respectively. Epoch-level accuracy and F1 scores reached 95.29% and 94.85%. Ablation analysis demonstrated that combining deep embeddings with IT2-FE features improved classification performance. The proposed framework holds promise for computer-aided dementia diagnosis.
Additional Links: PMID-43051069
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43051069,
year = {2026},
author = {Ahmadieh, H and TehraniYazdi, A},
title = {Hybrid framework utilizing interval Type-2 fuzzy entropy and ScaleDual-CNN for differential diagnosis of dementia using rest-state EEG signals.},
journal = {Computers in biology and medicine},
volume = {219},
number = {},
pages = {112061},
doi = {10.1016/j.compbiomed.2026.112061},
pmid = {43051069},
issn = {1879-0534},
abstract = {Differential diagnosis of Alzheimer's disease (AD) and frontotemporal dementia (FTD) is challenging because of their similarity in early stages. Electroencephalogram (EEG) signals offer a non-invasive, inexpensive tool for automated screening. However, traditional approaches cannot handle environmental noise and high inter-individual variance. In this study, interval type-2 fuzzy entropy (IT2-FE) was evaluated as a biomarker for diagnosing dementia under uncertainty. We utilized the public OpenNeuro ds004504 database (88 resting-state subjects). Signals were segmented into 4-s windows. Then we extracted IT2-FE in the alpha and theta bands, Hjorth and connectivity features. A dual evaluation framework was developed. First, we evaluated a subject-independent pipeline by combining fuzzy features, deep network, and SVM classifier. Second, we implemented an epoch-based model by combining the customized ScaleDual-CNN with fuzzy/spectral features and the XGBoost classifier. Compared to spectral entropy, the IT2-FE method identified approximately 11.7 times more statistically significant features (35 versus 3; pFDR < 0.05). These findings indicate statistically significant differences between the groups. For entropy-based classification, IT2-FE achieved 67.64% accuracy and 61.72% macro-F1, compared with 62.50% and 60.55% for spectral entropy, and 62.50% and 60.01% for Type-1 fuzzy entropy, respectively. These results suggest that IT2-FE captures discriminative EEG characteristics, although its classification performance advantage over other entropy measures remains limited. Subject-independent AUC for control, AD, and FTD were 0.96, 0.93, and 0.89, respectively. Epoch-level accuracy and F1 scores reached 95.29% and 94.85%. Ablation analysis demonstrated that combining deep embeddings with IT2-FE features improved classification performance. The proposed framework holds promise for computer-aided dementia diagnosis.},
}
RevDate: 2026-11-18
Epigenetic control of neural homeostasis by REST.
Cell chemical biology pii:S2451-9456(26)00408-3 [Epub ahead of print].
Neural network stability relies on homeostatic plasticity mechanisms acting across intrinsic, synaptic, and glial levels to counter persistent deviations in activity. In hyperexcitable or chronically stressed brain states, including epilepsy, neuroinflammation, ageing, and early Alzheimer's disease, sustained stress can destabilize these compensatory programs and network function. Alongside its established roles in neuronal differentiation and neurological disease when dysregulated, repressor element-1 silencing transcription (REST), also known as neuron-restrictive silencer factor (NRSF) is emerging as a multilevel, long-timescale epigenetic hub linking neuronal activity to coordinated homeostatic transcriptional programs. This review examines this less explored homeostatic dimension of REST biology. Rather than acting as a binary repressor, REST functions as a tunable chromatin-regulatory platform whose output depends on RE1 architecture, chromatin context, cellular state, and activation dynamics. We discuss how REST-dependent programs regulate intrinsic homeostasis, excitatory and inhibitory synaptic scaling, and astrocyte-mediated homeostatic support. Finally, we propose that neuronal energy metabolism may bias REST signaling toward adaptive compensation rather than maladaptive repression.
Additional Links: PMID-43051157
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43051157,
year = {2026},
author = {Baldelli, P and Valente, P},
title = {Epigenetic control of neural homeostasis by REST.},
journal = {Cell chemical biology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.chembiol.2026.10.008},
pmid = {43051157},
issn = {2451-9448},
abstract = {Neural network stability relies on homeostatic plasticity mechanisms acting across intrinsic, synaptic, and glial levels to counter persistent deviations in activity. In hyperexcitable or chronically stressed brain states, including epilepsy, neuroinflammation, ageing, and early Alzheimer's disease, sustained stress can destabilize these compensatory programs and network function. Alongside its established roles in neuronal differentiation and neurological disease when dysregulated, repressor element-1 silencing transcription (REST), also known as neuron-restrictive silencer factor (NRSF) is emerging as a multilevel, long-timescale epigenetic hub linking neuronal activity to coordinated homeostatic transcriptional programs. This review examines this less explored homeostatic dimension of REST biology. Rather than acting as a binary repressor, REST functions as a tunable chromatin-regulatory platform whose output depends on RE1 architecture, chromatin context, cellular state, and activation dynamics. We discuss how REST-dependent programs regulate intrinsic homeostasis, excitatory and inhibitory synaptic scaling, and astrocyte-mediated homeostatic support. Finally, we propose that neuronal energy metabolism may bias REST signaling toward adaptive compensation rather than maladaptive repression.},
}
RevDate: 2026-11-18
Rethinking recruitment to clinical trials in Alzheimer's disease.
The Lancet. Neurology, 25(12):1053.
Additional Links: PMID-43051169
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43051169,
year = {2026},
author = {The Lancet Neurology, },
title = {Rethinking recruitment to clinical trials in Alzheimer's disease.},
journal = {The Lancet. Neurology},
volume = {25},
number = {12},
pages = {1053},
doi = {10.1016/S1474-4422(26)00406-0},
pmid = {43051169},
issn = {1474-4465},
}
RevDate: 2026-11-18
Aerobic exercise attenuates hippocampal mitochondrial fragmentation and preserves synaptic integrity in an AD-like rat model: Associations with FNDC5/Irisin and Drp1-related mitochondrial fission.
Life sciences pii:S0024-3205(26)00592-8 [Epub ahead of print].
AIMS: Alzheimer's disease (AD) is a major neurodegenerative disorder without an effective cure. This study explores the effect of aerobic exercise (AE) on hippocampal mitochondrial fission and synaptic integrity in an AD-like rat model.
METHODS: The AD-like rat model was induced by D-galactose and sodium nitrite, with AE administered concurrently. An Aβ25-35-induced PC12 cell model was used to examine the effects of exogenous Irisin.
KEY FINDING: AE ameliorated cognitive deficits and reduced hippocampal Aβ42 levels, while increasing synaptic density and PSD95 and SYP expression during the formation process of AD. The AD-like model exhibited mitochondrial fragmentation and increased p-Drp1/Drp1, accompanied by reduced FNDC5/Irisin levels in skeletal muscle, plasma, and hippocampus. AE intervention attenuated these alterations. Exercise-associated hippocampal Irisin changes may involve peripheral skeletal muscle-derived Irisin, although its precise tissue origin remains unclear. In PC12 cells, Irisin supplementation effectively mitigated mitochondrial fragmentation and the increase in p-Drp1/Drp1, suggesting a potential association between Irisin and Drp1-related mitochondrial fission.
SIGNIFICANCE: Thus, AE may attenuate cognitive impairment and hippocampal mitochondrial fission while preserving synaptic integrity, with potential involvement of FNDC5/Irisin signaling and Drp1-associated mitochondrial fission.
Additional Links: PMID-43051449
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43051449,
year = {2026},
author = {Shi, W and Chen, C and Ma, Y and Liu, T and Fan, M and Wei, T and Jin, Q and Shen, W},
title = {Aerobic exercise attenuates hippocampal mitochondrial fragmentation and preserves synaptic integrity in an AD-like rat model: Associations with FNDC5/Irisin and Drp1-related mitochondrial fission.},
journal = {Life sciences},
volume = {},
number = {},
pages = {124783},
doi = {10.1016/j.lfs.2026.124783},
pmid = {43051449},
issn = {1879-0631},
abstract = {AIMS: Alzheimer's disease (AD) is a major neurodegenerative disorder without an effective cure. This study explores the effect of aerobic exercise (AE) on hippocampal mitochondrial fission and synaptic integrity in an AD-like rat model.
METHODS: The AD-like rat model was induced by D-galactose and sodium nitrite, with AE administered concurrently. An Aβ25-35-induced PC12 cell model was used to examine the effects of exogenous Irisin.
KEY FINDING: AE ameliorated cognitive deficits and reduced hippocampal Aβ42 levels, while increasing synaptic density and PSD95 and SYP expression during the formation process of AD. The AD-like model exhibited mitochondrial fragmentation and increased p-Drp1/Drp1, accompanied by reduced FNDC5/Irisin levels in skeletal muscle, plasma, and hippocampus. AE intervention attenuated these alterations. Exercise-associated hippocampal Irisin changes may involve peripheral skeletal muscle-derived Irisin, although its precise tissue origin remains unclear. In PC12 cells, Irisin supplementation effectively mitigated mitochondrial fragmentation and the increase in p-Drp1/Drp1, suggesting a potential association between Irisin and Drp1-related mitochondrial fission.
SIGNIFICANCE: Thus, AE may attenuate cognitive impairment and hippocampal mitochondrial fission while preserving synaptic integrity, with potential involvement of FNDC5/Irisin signaling and Drp1-associated mitochondrial fission.},
}
RevDate: 2026-11-18
Melatonin, brain clearance, and dementia prevention: Revisiting the pineal-perivascular Axis.
Frontiers in neuroendocrinology pii:S0091-3022(26)00072-5 [Epub ahead of print].
BACKGROUND: Melatonin has been proposed to support brain clearance of amyloid-β and tau, and its decline with age and in Alzheimer's disease has been interpreted as a contributor to clearance failure. The evidence underlying this proposal has not been appraised separately for endogenous pineal physiology and for administered melatonin.
OBJECTIVE: To review the evidence relating melatonin to perivascular transport and brain clearance, and to assess what that evidence can support.
METHODS: A critical narrative review. MEDLINE via PubMed, Scopus and the Cochrane Library were searched from inception to 31 August 2026, with an identical update search on 31 October 2026; database-specific strategies, dates, eligibility criteria and the selection process are reported in Section 3. Studies were appraised by what was manipulated (the organism's own pineal output, or administered melatonin at physiological or higher exposure, or actions not requiring receptor occupancy) and by the strength of design supporting each mechanistic claim. Animal doses were converted to human-equivalent doses by body-surface-area normalisation, with the method and its limitations stated in Section 3.6. The classification is applied in the tables; the text uses plain descriptions.
FINDINGS: In the literature identified, no study manipulated endogenous pineal melatonin while measuring perivascular transport or clearance, and no study combined a melatonin receptor antagonist or receptor deletion with a clearance readout. A causal role for endogenous melatonin therefore remains untested. Positive preclinical findings used administered melatonin at exposures estimated to be two to four orders of magnitude above standard clinical dosing on a body-weight basis, and approximately 40 to 900 times standard dosing after body-surface-area normalisation, which limits their extension to routine supplementation. The timing of melatonin secretion relative to sleep-associated clearance differs between nocturnal rodents and diurnal humans, which constrains translation from rodent models. Human data are limited by the absence of a validated non-invasive measure of brain clearance.
CONCLUSION: Available evidence is consistent with pharmacological modulation of components of the clearance system. Whether endogenous pineal melatonin regulates brain clearance has not been tested. Pinealectomy with timed replacement in a melatonin-proficient animal, and the addition of a receptor antagonist arm to existing designs, would address the principal gaps.
Additional Links: PMID-43051465
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43051465,
year = {2026},
author = {Dabiry, G and Mohamed, D and Kumar, KDS and Fazah, YA and Ghazali, Z and Ahad, A},
title = {Melatonin, brain clearance, and dementia prevention: Revisiting the pineal-perivascular Axis.},
journal = {Frontiers in neuroendocrinology},
volume = {},
number = {},
pages = {101301},
doi = {10.1016/j.yfrne.2026.101301},
pmid = {43051465},
issn = {1095-6808},
abstract = {BACKGROUND: Melatonin has been proposed to support brain clearance of amyloid-β and tau, and its decline with age and in Alzheimer's disease has been interpreted as a contributor to clearance failure. The evidence underlying this proposal has not been appraised separately for endogenous pineal physiology and for administered melatonin.
OBJECTIVE: To review the evidence relating melatonin to perivascular transport and brain clearance, and to assess what that evidence can support.
METHODS: A critical narrative review. MEDLINE via PubMed, Scopus and the Cochrane Library were searched from inception to 31 August 2026, with an identical update search on 31 October 2026; database-specific strategies, dates, eligibility criteria and the selection process are reported in Section 3. Studies were appraised by what was manipulated (the organism's own pineal output, or administered melatonin at physiological or higher exposure, or actions not requiring receptor occupancy) and by the strength of design supporting each mechanistic claim. Animal doses were converted to human-equivalent doses by body-surface-area normalisation, with the method and its limitations stated in Section 3.6. The classification is applied in the tables; the text uses plain descriptions.
FINDINGS: In the literature identified, no study manipulated endogenous pineal melatonin while measuring perivascular transport or clearance, and no study combined a melatonin receptor antagonist or receptor deletion with a clearance readout. A causal role for endogenous melatonin therefore remains untested. Positive preclinical findings used administered melatonin at exposures estimated to be two to four orders of magnitude above standard clinical dosing on a body-weight basis, and approximately 40 to 900 times standard dosing after body-surface-area normalisation, which limits their extension to routine supplementation. The timing of melatonin secretion relative to sleep-associated clearance differs between nocturnal rodents and diurnal humans, which constrains translation from rodent models. Human data are limited by the absence of a validated non-invasive measure of brain clearance.
CONCLUSION: Available evidence is consistent with pharmacological modulation of components of the clearance system. Whether endogenous pineal melatonin regulates brain clearance has not been tested. Pinealectomy with timed replacement in a melatonin-proficient animal, and the addition of a receptor antagonist arm to existing designs, would address the principal gaps.},
}
RevDate: 2026-11-16
Metabolic, Hepatic, and Neuropathological Effects of Palm[11]-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice.
Neuropharmacology pii:S0028-3908(26)00438-7 [Epub ahead of print].
Metabolic stress is known to accelerate Alzheimer's disease (AD) progression. In our previous study, we demonstrated that long-term high-fat diet (HFD) feeding exacerbated not only amyloid-β (Aβ) burden but also liver steatosis in APP/PS1 mice, a transgenic model of AD, with effects worsening with age. The present study investigated whether a three-month treatment (from 6 to 9 months of age) with anorexigenic peptides (palm[11]-PrRP31 or liraglutide) could attenuate AD-like pathology, neuroinflammation, liver steatosis, and Aβ clearance in APP/PS1 male mice on HFD. The two compounds exhibited distinct therapeutic effects. Liraglutide reduced body weight and improved glucose tolerance in both genotypes, while also attenuating insulin resistance in APP/PS1 mice. In contrast, palm[11]-PrRP31 significantly reduced Aβ plaque burden and showed a tendency to decrease astrocytosis. Notably, both peptides markedly reduced microgliosis and pathological tau phosphorylation at Ser202 and Thr205 in the hippocampus and cerebral cortex. HFD induced pronounced hepatic steatosis in both genotypes; however, APP/PS1 mice exhibited more severe lipid imbalance, characterized by increased triacylglycerols and decreased phospholipids and cardiolipins compared to wild-type controls. While both compounds reduced liver steatosis and inflammation in wild-type mice, only liraglutide normalized lipid composition in APP/PS1 mice. Furthermore, Aβ deposits colocalized with CD11b clusters were absent in the liver of liraglutide-treated APP/PS1 mice. In conclusion, both peptides exert neuroprotective effects under metabolic stress, but through distinct mechanisms. Palm[11]-PrRP31 primarily reduces amyloid pathology and neuroinflammation, whereas liraglutide acts mainly through metabolic improvement.
Additional Links: PMID-43039332
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039332,
year = {2026},
author = {Mengr, A and Sopko, Z and Vaculová, P and Charvát, V and Neprašová, B and Vrkoslav, V and Strnad, Š and Železná, B and Maletínská, L and Pačesová, A},
title = {Metabolic, Hepatic, and Neuropathological Effects of Palm[11]-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice.},
journal = {Neuropharmacology},
volume = {},
number = {},
pages = {111263},
doi = {10.1016/j.neuropharm.2026.111263},
pmid = {43039332},
issn = {1873-7064},
abstract = {Metabolic stress is known to accelerate Alzheimer's disease (AD) progression. In our previous study, we demonstrated that long-term high-fat diet (HFD) feeding exacerbated not only amyloid-β (Aβ) burden but also liver steatosis in APP/PS1 mice, a transgenic model of AD, with effects worsening with age. The present study investigated whether a three-month treatment (from 6 to 9 months of age) with anorexigenic peptides (palm[11]-PrRP31 or liraglutide) could attenuate AD-like pathology, neuroinflammation, liver steatosis, and Aβ clearance in APP/PS1 male mice on HFD. The two compounds exhibited distinct therapeutic effects. Liraglutide reduced body weight and improved glucose tolerance in both genotypes, while also attenuating insulin resistance in APP/PS1 mice. In contrast, palm[11]-PrRP31 significantly reduced Aβ plaque burden and showed a tendency to decrease astrocytosis. Notably, both peptides markedly reduced microgliosis and pathological tau phosphorylation at Ser202 and Thr205 in the hippocampus and cerebral cortex. HFD induced pronounced hepatic steatosis in both genotypes; however, APP/PS1 mice exhibited more severe lipid imbalance, characterized by increased triacylglycerols and decreased phospholipids and cardiolipins compared to wild-type controls. While both compounds reduced liver steatosis and inflammation in wild-type mice, only liraglutide normalized lipid composition in APP/PS1 mice. Furthermore, Aβ deposits colocalized with CD11b clusters were absent in the liver of liraglutide-treated APP/PS1 mice. In conclusion, both peptides exert neuroprotective effects under metabolic stress, but through distinct mechanisms. Palm[11]-PrRP31 primarily reduces amyloid pathology and neuroinflammation, whereas liraglutide acts mainly through metabolic improvement.},
}
RevDate: 2026-11-16
An open agentic AI co-scientist for clinical and biomedical discovery.
Nature medicine pii:10.1038/s41591-026-04808-6 [Epub ahead of print].
Biomedical research is constrained by the time and domain expertise required to analyze increasingly large and complex datasets. Here we present OpenScientist, an open-source agentic AI co-scientist designed to address this gap by investigating scientist-defined queries and generating verifiable, data-grounded analyses. OpenScientist was evaluated by domain experts across five biomedical case studies, completing analyses in minutes that otherwise would take months of human time and expertise. It accurately quantified Alzheimer's blood biomarker performance, generated a plasma proteomic survival model that predicted survival in a hidden-evaluation cohort, proposed a reproducible mechanism linking tau pathology to altered lysosomal acidification, generated multiple myeloma hypotheses validated in an external cohort with attenuated signal in randomized controls, and demonstrated concordance with an independent human analysis in a blinded, prespecified proteomic comparison. These results support the use of OpenScientist to assist biomedical data analysis in concert with human experts. To support research involving sensitive clinical datasets, OpenScientist can operate in a fully air-gapped environment using open-source models for inference. OpenScientist demonstrates that open, auditable, agentic AI can support real-world clinical research by researching the literature, generating hypotheses, executing analyses, and generating insights from complex datasets.
Additional Links: PMID-43039361
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039361,
year = {2026},
author = {Roberts, KF and Abrams, ZB and Cappelletti, L and Moqri, M and Heugel, N and Caufield, JH and Bourdenx, M and Li, Y and Banerjee, J and Foschini, L and Galeano, D and Harris, NL and Li, M and Ying, K and Melendez, JA and Barthélemy, NR and Bollinger, JG and He, Y and Ovod, V and Benzinger, TLS and Flores, S and Gordon, BA and Pedersen, T and Yu, J and Lucey, BP and Musiek, ES and Naylor, SA and Ojewole, AA and Phatak, M and Elbert, DL and Biber, S and Landsness, EC and Mungall, CJ and Bateman, RJ and Reese, JT},
title = {An open agentic AI co-scientist for clinical and biomedical discovery.},
journal = {Nature medicine},
volume = {},
number = {},
pages = {},
doi = {10.1038/s41591-026-04808-6},
pmid = {43039361},
issn = {1546-170X},
support = {DE-AC02-05CH11231//U.S. Department of Energy (DOE)/ ; DE-AC02-05CH11231//U.S. Department of Energy (DOE)/ ; DE-AC02-05CH11231//U.S. Department of Energy (DOE)/ ; DE-AC02-05CH11231//U.S. Department of Energy (DOE)/ ; RF1AG061900//U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)/ ; },
abstract = {Biomedical research is constrained by the time and domain expertise required to analyze increasingly large and complex datasets. Here we present OpenScientist, an open-source agentic AI co-scientist designed to address this gap by investigating scientist-defined queries and generating verifiable, data-grounded analyses. OpenScientist was evaluated by domain experts across five biomedical case studies, completing analyses in minutes that otherwise would take months of human time and expertise. It accurately quantified Alzheimer's blood biomarker performance, generated a plasma proteomic survival model that predicted survival in a hidden-evaluation cohort, proposed a reproducible mechanism linking tau pathology to altered lysosomal acidification, generated multiple myeloma hypotheses validated in an external cohort with attenuated signal in randomized controls, and demonstrated concordance with an independent human analysis in a blinded, prespecified proteomic comparison. These results support the use of OpenScientist to assist biomedical data analysis in concert with human experts. To support research involving sensitive clinical datasets, OpenScientist can operate in a fully air-gapped environment using open-source models for inference. OpenScientist demonstrates that open, auditable, agentic AI can support real-world clinical research by researching the literature, generating hypotheses, executing analyses, and generating insights from complex datasets.},
}
RevDate: 2026-11-16
Advancing Advance Care Planning for Dementia: From Stakeholder Participation to Sustained, Preference-Concordant Care.
Additional Links: PMID-43039445
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039445,
year = {2026},
author = {Yang, Y and Wen, J and Zhou, J},
title = {Advancing Advance Care Planning for Dementia: From Stakeholder Participation to Sustained, Preference-Concordant Care.},
journal = {Journal of clinical nursing},
volume = {},
number = {},
pages = {},
doi = {10.1111/jocn.70660},
pmid = {43039445},
issn = {1365-2702},
support = {2022538//the Scientific Research Plan of Hebei Provincial Administration of Traditional Chinese Medicine/ ; },
}
RevDate: 2026-11-16
Advancing the Alzheimer's disease research and care pipeline with agentic artificial intelligence: Opportunities, challenges, and priorities from the international clinical trials on Alzheimer's disease (CTAD) task force.
The journal of prevention of Alzheimer's disease pii:S2274-5807(26)00201-3 [Epub ahead of print].
Artificial Intelligence (AI) holds unprecedented potential to transform the entire Alzheimer's Disease and related dementias (ADRD) research and care continuum. During the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference, the CTAD Task Force reviewed recent advances in the field, highlighting the emerging role of agentic AI, and discussed priorities to guide future AI-driven innovation in ADRD. Agentic AI co-scientists are emerging as transformative tools to accelerate scientific discovery by autonomously integrating multimodal data, generating and evaluating new hypotheses, and connecting previously siloed knowledge into actionable insights. Operationalized through end-to-end translational pipelines, such platforms can also link mechanistic insights to therapeutic design by automating molecular docking and drug repurposing. Complementary initiatives are creating digital wet labs for in silico experimentation. At the same time, agentic AI is increasingly being used to address pre-discovery bottlenecks by automating data harmonization and inferring missing information through digital twins and synthetic data. AI is also reshaping next-generation ADRD clinical trials, through automated assessment of clinical outcomes, precision participant stratification, individualized disease trajectory modeling and prediction of treatment response. These approaches could substantially improve trial efficiency through responder enrichment. Importantly, AI applications are expanding beyond discovery and clinical trials to support diagnosis, care navigation, and personalized disease management. To translate the momentum surrounding AI innovation into meaningful and sustainable impact across the ADRD continuum, the Task Force identified priorities including the development of AI-ready ecosystems, closer collaboration between clinicians, researchers and computer scientists, AI-enabled optimization of clinical trials and robust ethical and governance frameworks for responsible AI adoption.
Additional Links: PMID-43039790
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039790,
year = {2026},
author = {Rouch, L and Middleton, L and Aisen, P and Weiner, M and Kourtzi, Z and Pinheiro-Chagas, P and Nosheny, R and Possin, K and Vellas, B and Bose, N and Andrieu, S and , },
title = {Advancing the Alzheimer's disease research and care pipeline with agentic artificial intelligence: Opportunities, challenges, and priorities from the international clinical trials on Alzheimer's disease (CTAD) task force.},
journal = {The journal of prevention of Alzheimer's disease},
volume = {},
number = {},
pages = {100678},
doi = {10.1016/j.tjpad.2026.100678},
pmid = {43039790},
issn = {2426-0266},
abstract = {Artificial Intelligence (AI) holds unprecedented potential to transform the entire Alzheimer's Disease and related dementias (ADRD) research and care continuum. During the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference, the CTAD Task Force reviewed recent advances in the field, highlighting the emerging role of agentic AI, and discussed priorities to guide future AI-driven innovation in ADRD. Agentic AI co-scientists are emerging as transformative tools to accelerate scientific discovery by autonomously integrating multimodal data, generating and evaluating new hypotheses, and connecting previously siloed knowledge into actionable insights. Operationalized through end-to-end translational pipelines, such platforms can also link mechanistic insights to therapeutic design by automating molecular docking and drug repurposing. Complementary initiatives are creating digital wet labs for in silico experimentation. At the same time, agentic AI is increasingly being used to address pre-discovery bottlenecks by automating data harmonization and inferring missing information through digital twins and synthetic data. AI is also reshaping next-generation ADRD clinical trials, through automated assessment of clinical outcomes, precision participant stratification, individualized disease trajectory modeling and prediction of treatment response. These approaches could substantially improve trial efficiency through responder enrichment. Importantly, AI applications are expanding beyond discovery and clinical trials to support diagnosis, care navigation, and personalized disease management. To translate the momentum surrounding AI innovation into meaningful and sustainable impact across the ADRD continuum, the Task Force identified priorities including the development of AI-ready ecosystems, closer collaboration between clinicians, researchers and computer scientists, AI-enabled optimization of clinical trials and robust ethical and governance frameworks for responsible AI adoption.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
[Mechanism of acupuncture at governor vessel acupoints in improving cognitive dysfunction in AD mice based on complement C1q-mediated microglial synaptic phagocytosis].
Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 46(11):1802-1808.
OBJECTIVE: To explore the possible mechanism of acupuncture at governor vessel (GV) acupoints in improving cognitive dysfunction in Alzheimer's disease (AD) mice based on complement C1q-mediated aberrant activation of microglia and excessive synaptic phagocytosis.
METHODS: Twenty male APP/PS1 double transgenic mice were randomly divided into a model group and an acupuncture group, with 10 mice in each group; ten male C57BL/6 mice were selected as the control group. In the acupuncture group, acupuncture was applied at "Baihui" (GV20), "Dazhui" (GV14) and "Mingmen" (GV4), 20 min each time, once daily, 5 times a week for 4 consecutive weeks. The learning-memory ability of mice was assessed by Morris water maze test, the synaptic ultrastructure in hippocampal CA1 region was observed by transmission electron microscope, the positive expression of postsynaptic density protein 95 (PSD-95) and ionized calcium-binding adapter molecule 1 (IBA-1) in hippocampal tissue was detected by immunofluorescence, the protein expression of IBA-1, complement C1q and SMAD-specific E3 ubiquitin protein ligase 1 (SMURF1) in hippocampal tissue was detected by Western blot, the ubiquitination modification of C1q protein was predicted by UbiBrowser and further verified by co-immunoprecipitation (Co-IP).
RESULTS: Compared with the control group, in the model group, the escape latency was prolonged (P<0.01), the number of platform crossings was reduced (P<0.01); decreased number of synapses, damaged synaptic structure, and thinner and looser postsynaptic density could be observed in the hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were increased (P<0.01), the positive expression of PSD-95 and the protein expression of SMURF1 were decreased (P<0.01) in hippocampal tissue. Compared with the model group, in the acupuncture group, the escape latency was shortened (P<0.05), the number of platform crossings was increased (P<0.05); increased number of synapses, improved synaptic structure, and thicker and denser postsynaptic density could be observed in hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were decreased (P<0.01, P<0.05), the positive expression of PSD-95 and the protein expression of SMURF1 were increased (P<0.01, P<0.05) in hippocampal tissue. SMURF1 was identified as the E3 ligase for C1q protein, and SMURF1 could bind to C1q.
CONCLUSION: Acupuncture at GV acupoints directly or indirectly reduces C1q level in the hippocampus, inhibits the classical complement system and excessive microglial activation, reduces aberrant synaptic phagocytosis, and thereby improves cognitive dysfunction in AD mice.
Additional Links: PMID-43039835
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039835,
year = {2026},
author = {Liu, H and Liu, Y and Li, W and Sun, P and Wu, J and Li, P},
title = {[Mechanism of acupuncture at governor vessel acupoints in improving cognitive dysfunction in AD mice based on complement C1q-mediated microglial synaptic phagocytosis].},
journal = {Zhongguo zhen jiu = Chinese acupuncture & moxibustion},
volume = {46},
number = {11},
pages = {1802-1808},
doi = {10.13703/j.0255-2930.20250724-k0008},
pmid = {43039835},
issn = {0255-2930},
mesh = {Animals ; *Complement C1q/metabolism/genetics ; Male ; *Microglia/metabolism/cytology ; Mice ; *Alzheimer Disease/therapy/psychology/genetics/metabolism/physiopathology/immunology ; *Acupuncture Points ; Mice, Inbred C57BL ; *Acupuncture Therapy ; Humans ; *Phagocytosis ; *Synapses/metabolism ; Mice, Transgenic ; *Cognitive Dysfunction/therapy/genetics ; },
abstract = {OBJECTIVE: To explore the possible mechanism of acupuncture at governor vessel (GV) acupoints in improving cognitive dysfunction in Alzheimer's disease (AD) mice based on complement C1q-mediated aberrant activation of microglia and excessive synaptic phagocytosis.
METHODS: Twenty male APP/PS1 double transgenic mice were randomly divided into a model group and an acupuncture group, with 10 mice in each group; ten male C57BL/6 mice were selected as the control group. In the acupuncture group, acupuncture was applied at "Baihui" (GV20), "Dazhui" (GV14) and "Mingmen" (GV4), 20 min each time, once daily, 5 times a week for 4 consecutive weeks. The learning-memory ability of mice was assessed by Morris water maze test, the synaptic ultrastructure in hippocampal CA1 region was observed by transmission electron microscope, the positive expression of postsynaptic density protein 95 (PSD-95) and ionized calcium-binding adapter molecule 1 (IBA-1) in hippocampal tissue was detected by immunofluorescence, the protein expression of IBA-1, complement C1q and SMAD-specific E3 ubiquitin protein ligase 1 (SMURF1) in hippocampal tissue was detected by Western blot, the ubiquitination modification of C1q protein was predicted by UbiBrowser and further verified by co-immunoprecipitation (Co-IP).
RESULTS: Compared with the control group, in the model group, the escape latency was prolonged (P<0.01), the number of platform crossings was reduced (P<0.01); decreased number of synapses, damaged synaptic structure, and thinner and looser postsynaptic density could be observed in the hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were increased (P<0.01), the positive expression of PSD-95 and the protein expression of SMURF1 were decreased (P<0.01) in hippocampal tissue. Compared with the model group, in the acupuncture group, the escape latency was shortened (P<0.05), the number of platform crossings was increased (P<0.05); increased number of synapses, improved synaptic structure, and thicker and denser postsynaptic density could be observed in hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were decreased (P<0.01, P<0.05), the positive expression of PSD-95 and the protein expression of SMURF1 were increased (P<0.01, P<0.05) in hippocampal tissue. SMURF1 was identified as the E3 ligase for C1q protein, and SMURF1 could bind to C1q.
CONCLUSION: Acupuncture at GV acupoints directly or indirectly reduces C1q level in the hippocampus, inhibits the classical complement system and excessive microglial activation, reduces aberrant synaptic phagocytosis, and thereby improves cognitive dysfunction in AD mice.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Complement C1q/metabolism/genetics
Male
*Microglia/metabolism/cytology
Mice
*Alzheimer Disease/therapy/psychology/genetics/metabolism/physiopathology/immunology
*Acupuncture Points
Mice, Inbred C57BL
*Acupuncture Therapy
Humans
*Phagocytosis
*Synapses/metabolism
Mice, Transgenic
*Cognitive Dysfunction/therapy/genetics
RevDate: 2026-11-16
CmpDate: 2026-11-16
APOE ε4 carriership status enhances age-related changes in Alzheimer's disease plasma biomarkers concentrations.
Nature communications, 17(1):.
Alzheimer's disease (AD) plasma biomarkers are cost-effective tools to detect early stage amyloid pathology. We investigated how interactions between AD genetic risk (apolipoprotein E (APOE) ε4, AD polygenic risk score (excluding APOE; PRSAD)), age, and sex affected AD plasma biomarkers concentrations in a population-based cohort. We included 5913 participants from the Netherlands Twin Register age 30 - 80 (64.1% females, 29.8% ε4 carriers) and measured plasma phosphorylated-tau-217 (p-tau217), amyloid-β-42/40 (Aβ-42/40), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). We showed that the PRSAD did not associate with biomarker concentrations over age. In ε4 carriers, decreases in Aβ-42/40 became steeper after age 50, and increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively. Analyses in a separate longitudinal cohort (EMIF-AD) confirmed that p-tau217 concentration changes in ε4 carriers reflect AD pathology. These results highlight the potential of plasma biomarkers, especially p-tau217, for early detection of preclinical AD pathology.
Additional Links: PMID-43039924
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43039924,
year = {2026},
author = {Rousset, RZ and den Braber, A and Bongers, B and Boonkamp, L and Wilson, D and Ligthart, L and Pool, R and Visser, PJ and van der Landen, SM and de Geus, E and Teunissen, CE},
title = {APOE ε4 carriership status enhances age-related changes in Alzheimer's disease plasma biomarkers concentrations.},
journal = {Nature communications},
volume = {17},
number = {1},
pages = {},
pmid = {43039924},
issn = {2041-1723},
support = {985-10-002//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; 480-04-004//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; 400-05-717//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; Addiction-31160008//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; 016-115-035//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; 400-07-080//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; Middelgroot-911-09-032//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; NWO-Groot 480-15-001/674//Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)/ ; 01254//EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))/ ; 01413//EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))/ ; },
mesh = {Humans ; *Alzheimer Disease/blood/genetics ; *Biomarkers/blood ; Female ; Male ; *Apolipoprotein E4/genetics ; Glial Fibrillary Acidic Protein/blood ; Amyloid beta-Peptides/blood ; Neurofilament Proteins/blood ; Aged ; tau Proteins/blood ; Aged, 80 and over ; Middle Aged ; Heterozygote ; Netherlands ; *Aging/blood/genetics ; Peptide Fragments/blood ; Genetic Risk Score ; Longitudinal Studies ; Phosphorylation ; },
abstract = {Alzheimer's disease (AD) plasma biomarkers are cost-effective tools to detect early stage amyloid pathology. We investigated how interactions between AD genetic risk (apolipoprotein E (APOE) ε4, AD polygenic risk score (excluding APOE; PRSAD)), age, and sex affected AD plasma biomarkers concentrations in a population-based cohort. We included 5913 participants from the Netherlands Twin Register age 30 - 80 (64.1% females, 29.8% ε4 carriers) and measured plasma phosphorylated-tau-217 (p-tau217), amyloid-β-42/40 (Aβ-42/40), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). We showed that the PRSAD did not associate with biomarker concentrations over age. In ε4 carriers, decreases in Aβ-42/40 became steeper after age 50, and increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively. Analyses in a separate longitudinal cohort (EMIF-AD) confirmed that p-tau217 concentration changes in ε4 carriers reflect AD pathology. These results highlight the potential of plasma biomarkers, especially p-tau217, for early detection of preclinical AD pathology.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/blood/genetics
*Biomarkers/blood
Female
Male
*Apolipoprotein E4/genetics
Glial Fibrillary Acidic Protein/blood
Amyloid beta-Peptides/blood
Neurofilament Proteins/blood
Aged
tau Proteins/blood
Aged, 80 and over
Middle Aged
Heterozygote
Netherlands
*Aging/blood/genetics
Peptide Fragments/blood
Genetic Risk Score
Longitudinal Studies
Phosphorylation
RevDate: 2026-11-16
CmpDate: 2026-11-17
Association of life-course production work and Lewy body neuropathology.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: The occupational exposome-the summation of lifetime workplace exposures-impacts Alzheimer's disease and related dementias (ADRD). Examining the role of high-risk occupational exposures on ADRD pathology, including Lewy bodies, may enable disease mitigation strategies.
METHODS: This retrospective cohort study included brain donors with neuropathological characterization (n = 1079, 47.5% female, mean age at death: 80.9). Donor occupational histories were derived and assigned Standardized Occupation Classification Codes. The association between Lewy body neuropathology and "production occupations" (i.e., assemblers, fabricators, manufacturers, etc.) was modeled via logistic regression adjusting for age, sex, and year of death.
RESULTS: Lewy bodies were present in 32% of the total sample. Donors with a history of "production occupations" (12%) had 23% increased adjusted odds of having Lewy bodies (adjusted odds ratio = 1.23, 95% confidence interval = 1.11-1.35).
DISCUSSION: This is the first study demonstrating increased levels of Lewy body neuropathology in those with "production occupations." Precise categorization of hazardous exposures is needed to identify mechanistic pathways.
Additional Links: PMID-43040586
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040586,
year = {2026},
author = {Melcher, EM and Otte, RC and Lim, S and Etter, L and Pfaff, A and DeWitt, A and Lee, ARS and Salamat, S and Soneye, O and Zuelsdorff, ML and Goutman, SA and Bakulski, KM and Rissman, RA and Powell, WR},
title = {Association of life-course production work and Lewy body neuropathology.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
doi = {10.1002/alz.71993},
pmid = {43040586},
issn = {1552-5279},
support = {R21AG079277/AG/NIA NIH HHS/United States ; R01AG070883/AG/NIA NIH HHS/United States ; 2R01AG070883/AG/NIA NIH HHS/United States ; P30AG062715/AG/NIA NIH HHS/United States ; R01AG079303/AG/NIA NIH HHS/United States ; P30AG066530/AG/NIA NIH HHS/United States ; P30AG092931/AG/NIA NIH HHS/United States ; 1F30AG094119-01A1/AG/NIA NIH HHS/United States ; T32GM140935//the University of Wisconsin Medical Scientist Training Program/ ; },
mesh = {Humans ; Female ; Male ; Retrospective Studies ; *Occupational Exposure/adverse effects ; Aged, 80 and over ; *Lewy Body Disease/pathology ; Aged ; *Lewy Bodies/pathology ; *Brain/pathology ; *Occupations ; Alzheimer Disease/pathology ; },
abstract = {INTRODUCTION: The occupational exposome-the summation of lifetime workplace exposures-impacts Alzheimer's disease and related dementias (ADRD). Examining the role of high-risk occupational exposures on ADRD pathology, including Lewy bodies, may enable disease mitigation strategies.
METHODS: This retrospective cohort study included brain donors with neuropathological characterization (n = 1079, 47.5% female, mean age at death: 80.9). Donor occupational histories were derived and assigned Standardized Occupation Classification Codes. The association between Lewy body neuropathology and "production occupations" (i.e., assemblers, fabricators, manufacturers, etc.) was modeled via logistic regression adjusting for age, sex, and year of death.
RESULTS: Lewy bodies were present in 32% of the total sample. Donors with a history of "production occupations" (12%) had 23% increased adjusted odds of having Lewy bodies (adjusted odds ratio = 1.23, 95% confidence interval = 1.11-1.35).
DISCUSSION: This is the first study demonstrating increased levels of Lewy body neuropathology in those with "production occupations." Precise categorization of hazardous exposures is needed to identify mechanistic pathways.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Male
Retrospective Studies
*Occupational Exposure/adverse effects
Aged, 80 and over
*Lewy Body Disease/pathology
Aged
*Lewy Bodies/pathology
*Brain/pathology
*Occupations
Alzheimer Disease/pathology
RevDate: 2026-11-17
CmpDate: 2026-11-17
Diagnostic performance of blood-based biomarker thresholds and ratios across the cognitive continuum in a diverse South Asian cohort.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: The rising burden of dementia in the Global South is compounded by a substantial diagnostic gap limiting access to biomarker-based diagnosis. We evaluated the diagnostic performance of non-invasive blood-based biomarkers and their ratios across the cognitive continuum in a South Asian cohort to address a lack of evidence beyond Western populations.
METHODS: This study included participants from a Cognitive Disorders Clinic (n = 315), comprising individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), frontotemporal dementia (FTD), and cognitively unimpaired (CU) controls. All participants underwent standardized cognitive assessment and structural brain imaging. Serum phosphorylated tau (p-tau217), p-tau181, and neurofilament light (NfL) were quantified using a Simoa HD-X analyzer. Diagnostic performance of biomarkers and their ratios were assessed, and a novel multi-threshold approach was applied to facilitate their clinical interpretation in routine practice.
RESULTS: Serum p-tau217 and NfL levels were significantly higher in the cognitively impaired group compared to CU, whereas p-tau181 showed no significant difference. Across the diagnostic groups, p-tau217 was highest in AD (F = 12.61, p < 0.001), and NfL in FTD (F = 20.84, p < 0.001). NfL best discriminated FTD versus CU, whereas p-tau217 showed optimal discrimination for AD (area under the curve [AUC] = 0.85). The NfL/p-tau217 ratio improved discrimination between AD and FTD (AUC = 0.78). The multi-threshold approach demonstrated superior diagnostic performance compared to single cut-off.
DISCUSSION: Serum p-tau217, NfL, and NfL/p-tau217 ratio showed robust diagnostic accuracy in this diverse South Asian cohort. The multi-threshold approach improved the clinical interpretability, supporting the integration of blood-based biomarkers (BBMs) in clinical practice, enabling timely diagnosis and accurate determination of therapeutic eligibility.
Additional Links: PMID-43040622
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040622,
year = {2026},
author = {Arshad, F and Tripathi, PP and Shetye, N and Prasad, S and Mohan, M and Mathur, S and Kumar, SS and Thejas N, JA and Ramakrishnan, S and Subramanian, S and Alladi, S},
title = {Diagnostic performance of blood-based biomarker thresholds and ratios across the cognitive continuum in a diverse South Asian cohort.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
doi = {10.1002/alz.71975},
pmid = {43040622},
issn = {1552-5279},
mesh = {Humans ; *Biomarkers/blood ; Female ; Male ; *tau Proteins/blood ; *Alzheimer Disease/diagnosis/blood ; *Cognitive Dysfunction/diagnosis/blood ; Aged ; *Frontotemporal Dementia/diagnosis/blood ; *Neurofilament Proteins/blood ; Cohort Studies ; Asia, Southern ; Middle Aged ; South Asian People ; Neuropsychological Tests ; },
abstract = {INTRODUCTION: The rising burden of dementia in the Global South is compounded by a substantial diagnostic gap limiting access to biomarker-based diagnosis. We evaluated the diagnostic performance of non-invasive blood-based biomarkers and their ratios across the cognitive continuum in a South Asian cohort to address a lack of evidence beyond Western populations.
METHODS: This study included participants from a Cognitive Disorders Clinic (n = 315), comprising individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), frontotemporal dementia (FTD), and cognitively unimpaired (CU) controls. All participants underwent standardized cognitive assessment and structural brain imaging. Serum phosphorylated tau (p-tau217), p-tau181, and neurofilament light (NfL) were quantified using a Simoa HD-X analyzer. Diagnostic performance of biomarkers and their ratios were assessed, and a novel multi-threshold approach was applied to facilitate their clinical interpretation in routine practice.
RESULTS: Serum p-tau217 and NfL levels were significantly higher in the cognitively impaired group compared to CU, whereas p-tau181 showed no significant difference. Across the diagnostic groups, p-tau217 was highest in AD (F = 12.61, p < 0.001), and NfL in FTD (F = 20.84, p < 0.001). NfL best discriminated FTD versus CU, whereas p-tau217 showed optimal discrimination for AD (area under the curve [AUC] = 0.85). The NfL/p-tau217 ratio improved discrimination between AD and FTD (AUC = 0.78). The multi-threshold approach demonstrated superior diagnostic performance compared to single cut-off.
DISCUSSION: Serum p-tau217, NfL, and NfL/p-tau217 ratio showed robust diagnostic accuracy in this diverse South Asian cohort. The multi-threshold approach improved the clinical interpretability, supporting the integration of blood-based biomarkers (BBMs) in clinical practice, enabling timely diagnosis and accurate determination of therapeutic eligibility.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Biomarkers/blood
Female
Male
*tau Proteins/blood
*Alzheimer Disease/diagnosis/blood
*Cognitive Dysfunction/diagnosis/blood
Aged
*Frontotemporal Dementia/diagnosis/blood
*Neurofilament Proteins/blood
Cohort Studies
Asia, Southern
Middle Aged
South Asian People
Neuropsychological Tests
RevDate: 2026-11-17
Two new blood tests for Alzheimer's disease.
The Medical letter on drugs and therapeutics, 68(1768):185-186.
Additional Links: PMID-43040625
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040625,
year = {2026},
author = {},
title = {Two new blood tests for Alzheimer's disease.},
journal = {The Medical letter on drugs and therapeutics},
volume = {68},
number = {1768},
pages = {185-186},
doi = {10.58347/tml.2026.1768a},
pmid = {43040625},
issn = {1523-2859},
}
RevDate: 2026-11-17
Integrative computational and in-vitro evidence implicates BCL2-associated apoptotic signaling in acetyl tributyl citrate-induced microglial toxicity.
Drug and chemical toxicology [Epub ahead of print].
Acetyl tributyl citrate (ATBC), a synthetic plasticizer, exhibits neurotoxic potential. Microglia sustain brain homeostasis, and their apoptosis and dysfunction are key drivers of Alzheimer's disease (AD) pathogenesis. However, the mechanism connecting ATBC exposure to microglial impairment and AD susceptibility remains unclear. Here, we applied an integrative computational and in-vitro framework to investigate BCL2-centered apoptotic signaling mediating ATBC-induced microglial toxicity. We retrieved ATBC targets from five prediction databases and AD-related genes from GeneCards and OMIM, obtaining 380 overlapping genes. Five hub genes (SRC, TNF, EGFR, BCL2, and ESR1) were screened via four centrality algorithms. Functional enrichment highlighted neurodegenerative disease pathways and microglia-related apoptotic cascades. We built 127 machine-learning models using two AD GEO cohorts (GSE122603, GSE97760). The robust Lasso + XGBoost ensemble (training AUC = 0.994) identified BCL2, SRC, ESR1, and EGFR as predictive features, with SHAP analysis pinpointing BCL2 as the top contributor. Molecular docking predicted favorable ATBC-BCL2 binding (-5.363 kcal/mol), and 100 ns molecular dynamics simulations supported stable complex formation. In BV2 microglia, ATBC dose-dependently reduced cell viability (IC50 = 59.59 μM), downregulated BCL2 expression, and activated caspase-dependent apoptosis. Collectively, our integrated evidence indicates that BCL2-associated apoptotic signaling mediates ATBC-provoked microglial toxicity, suggesting a plausible mechanistic link between ATBC exposure and AD-related signatures. This study proposes a microglia-oriented mechanistic hypothesis for AD susceptibility and offers a multi-omics paradigm for plasticizer risk assessment.
Additional Links: PMID-43040848
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43040848,
year = {2026},
author = {Zou, S and Li, L and Xiang, W and Li, Y and Wang, F and Wei, P and Lai, Y and Zou, S and Chen, L},
title = {Integrative computational and in-vitro evidence implicates BCL2-associated apoptotic signaling in acetyl tributyl citrate-induced microglial toxicity.},
journal = {Drug and chemical toxicology},
volume = {},
number = {},
pages = {1-17},
doi = {10.1080/01480545.2026.2753476},
pmid = {43040848},
issn = {1525-6014},
abstract = {Acetyl tributyl citrate (ATBC), a synthetic plasticizer, exhibits neurotoxic potential. Microglia sustain brain homeostasis, and their apoptosis and dysfunction are key drivers of Alzheimer's disease (AD) pathogenesis. However, the mechanism connecting ATBC exposure to microglial impairment and AD susceptibility remains unclear. Here, we applied an integrative computational and in-vitro framework to investigate BCL2-centered apoptotic signaling mediating ATBC-induced microglial toxicity. We retrieved ATBC targets from five prediction databases and AD-related genes from GeneCards and OMIM, obtaining 380 overlapping genes. Five hub genes (SRC, TNF, EGFR, BCL2, and ESR1) were screened via four centrality algorithms. Functional enrichment highlighted neurodegenerative disease pathways and microglia-related apoptotic cascades. We built 127 machine-learning models using two AD GEO cohorts (GSE122603, GSE97760). The robust Lasso + XGBoost ensemble (training AUC = 0.994) identified BCL2, SRC, ESR1, and EGFR as predictive features, with SHAP analysis pinpointing BCL2 as the top contributor. Molecular docking predicted favorable ATBC-BCL2 binding (-5.363 kcal/mol), and 100 ns molecular dynamics simulations supported stable complex formation. In BV2 microglia, ATBC dose-dependently reduced cell viability (IC50 = 59.59 μM), downregulated BCL2 expression, and activated caspase-dependent apoptosis. Collectively, our integrated evidence indicates that BCL2-associated apoptotic signaling mediates ATBC-provoked microglial toxicity, suggesting a plausible mechanistic link between ATBC exposure and AD-related signatures. This study proposes a microglia-oriented mechanistic hypothesis for AD susceptibility and offers a multi-omics paradigm for plasticizer risk assessment.},
}
RevDate: 2026-11-17
TFEB overexpression in excitatory neurons ameliorates amyloid-β pathology via coordinated enhancement of autophagy-lysosome and mitochondrial function.
The Journal of pathology [Epub ahead of print].
The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.
Additional Links: PMID-43041152
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041152,
year = {2026},
author = {Wang, L and Jing, LP and Chen, HC and Ma, YZ and Cao, JX and Zhang, YS and Wang, YG and Jing, YH and Zhang, ZC},
title = {TFEB overexpression in excitatory neurons ameliorates amyloid-β pathology via coordinated enhancement of autophagy-lysosome and mitochondrial function.},
journal = {The Journal of pathology},
volume = {},
number = {},
pages = {},
doi = {10.1002/path.70153},
pmid = {43041152},
issn = {1096-9896},
support = {GSWSQNPY2025-03//Gansu Provincial Health Industry Science and Technology Innovation Project/ ; 21JR7RA425//Natural Science Foundation of Science and Technology Department of Gansu/ ; 82602845//National Natural Science Foundation of China, Youth Science Fund Project/ ; CY2025-MS-A08//Cuiying Scientific and Technological Innovation Program of The Second Hospital & Clinical Medical School, Lanzhou University/ ; //Clinical advantage specialty construction project of Gansu Province and the Academician Longde Wang Expert Workstation of Lanzhou University Second Hospital/ ; },
abstract = {The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Normative references of corpus callosum across lifespan and application in neurological and neuroimmunological disorders.
Frontiers in neurology, 17:1970514.
BACKGROUND: The corpus callosum (CC) is the largest white matter structure and is often affected in neurological and neuroimmunological disorders. However, previous studies mainly used group-level comparisons. This limits patient-level magnetic resonance imaging (MRI) assessment.
METHODS: In this multicenter retrospective study, 3D T1-weighted MRI data from 24,305 healthy controls aged 4-85 years were used to construct age-,sex-, and estimated total intracranial volume (eTIV)- adjusted normative references for the whole CC and five subregions. Deviation scores were calculated and applied to 4,081 patients with multiple sclerosis (MS, n = 573), neuromyelitis optica spectrum disorder (NMOSD, n = 389), mild cognitive impairment (MCI, n = 308), Alzheimer's disease (AD, n = 623), Parkinson's disease (PD, n = 1,285), and cerebral small vessel disease (CSVD, n = 903). Classification, clinical correlation, and prognostic analyses were performed as exploratory applications.
RESULTS: The volume of CC subregions peaked from early adulthood (central, 26.0 years) to midlife (posterior, 47.2 years; anterior, 47.5 years), forming a "centre-to-periphery" pattern. MS showed negative deviations mainly in central and mid-anterior regions (Cohen's d = -0.28 to -0.30, pFDR<0.001), while CSVD and AD showed widespread negative deviations (d = -0.13 to -0.49). NMOSD, MCI, and PD showed relatively small or regionally limited deviations. Deviation score based classification performance ranged from AUC = 0.598-0.775. Exploratory analyses identified weak correlations between deviation scores and processing speed in MS (Spearman's ρ up to 0.22, p < 0.05) and cognition in CSVD (ρ = 0.12-0.19, p < 0.05) and AD (ρ = 0.10-0.16, p < 0.05). None survived FDR correction. Baseline deviation-based risk groups stratified subsequent relapse and disability outcomes in MS and NMOSD (p < 0.001). An exploratory comparison suggested a nominal difference in baseline CC deviation burden between MCI converters and non-converters to AD.
CONCLUSION: Lifespan normative references of the CC provide a quantitative framework for characterizing individual structural deviations across neurological and neuroimmunological disorders. Exploratory clinical analyses suggest potential applications that require further validation.
Additional Links: PMID-43041236
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041236,
year = {2026},
author = {Luo, Y and Chai, L and Chen, K and Du, X and Gao, T and Lizhu, Y and Qiu, J and Tian, D and Weng, J and Xu, J and Xu, S and Xu, X and Zhang, R and Duan, Y and Cole, J and Yuan, Z and Wu, H and Zhuo, Z and Liu, Y and , },
title = {Normative references of corpus callosum across lifespan and application in neurological and neuroimmunological disorders.},
journal = {Frontiers in neurology},
volume = {17},
number = {},
pages = {1970514},
pmid = {43041236},
issn = {1664-2295},
mesh = {Humans ; Female ; Adolescent ; Adult ; Child ; Aged ; *Corpus Callosum/diagnostic imaging/pathology ; Magnetic Resonance Imaging ; Child, Preschool ; Middle Aged ; Male ; Young Adult ; Retrospective Studies ; Aged, 80 and over ; Reference Values ; *Nervous System Diseases/diagnostic imaging/pathology ; },
abstract = {BACKGROUND: The corpus callosum (CC) is the largest white matter structure and is often affected in neurological and neuroimmunological disorders. However, previous studies mainly used group-level comparisons. This limits patient-level magnetic resonance imaging (MRI) assessment.
METHODS: In this multicenter retrospective study, 3D T1-weighted MRI data from 24,305 healthy controls aged 4-85 years were used to construct age-,sex-, and estimated total intracranial volume (eTIV)- adjusted normative references for the whole CC and five subregions. Deviation scores were calculated and applied to 4,081 patients with multiple sclerosis (MS, n = 573), neuromyelitis optica spectrum disorder (NMOSD, n = 389), mild cognitive impairment (MCI, n = 308), Alzheimer's disease (AD, n = 623), Parkinson's disease (PD, n = 1,285), and cerebral small vessel disease (CSVD, n = 903). Classification, clinical correlation, and prognostic analyses were performed as exploratory applications.
RESULTS: The volume of CC subregions peaked from early adulthood (central, 26.0 years) to midlife (posterior, 47.2 years; anterior, 47.5 years), forming a "centre-to-periphery" pattern. MS showed negative deviations mainly in central and mid-anterior regions (Cohen's d = -0.28 to -0.30, pFDR<0.001), while CSVD and AD showed widespread negative deviations (d = -0.13 to -0.49). NMOSD, MCI, and PD showed relatively small or regionally limited deviations. Deviation score based classification performance ranged from AUC = 0.598-0.775. Exploratory analyses identified weak correlations between deviation scores and processing speed in MS (Spearman's ρ up to 0.22, p < 0.05) and cognition in CSVD (ρ = 0.12-0.19, p < 0.05) and AD (ρ = 0.10-0.16, p < 0.05). None survived FDR correction. Baseline deviation-based risk groups stratified subsequent relapse and disability outcomes in MS and NMOSD (p < 0.001). An exploratory comparison suggested a nominal difference in baseline CC deviation burden between MCI converters and non-converters to AD.
CONCLUSION: Lifespan normative references of the CC provide a quantitative framework for characterizing individual structural deviations across neurological and neuroimmunological disorders. Exploratory clinical analyses suggest potential applications that require further validation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Adolescent
Adult
Child
Aged
*Corpus Callosum/diagnostic imaging/pathology
Magnetic Resonance Imaging
Child, Preschool
Middle Aged
Male
Young Adult
Retrospective Studies
Aged, 80 and over
Reference Values
*Nervous System Diseases/diagnostic imaging/pathology
RevDate: 2026-11-17
CmpDate: 2026-11-17
Sex-specific alterations in gut microbiome composition in patients with Alzheimer's disease.
Frontiers in microbiology, 17:1915847.
BACKGROUND: The microbiota-gut-brain axis plays a significant role in the pathology of Alzheimer's disease (AD). However, alterations in the gut microbiome structure of AD patients and the sex-specific differences in signature microbial taxa remain inadequately characterized.
METHODS: A total of 100 participants were enrolled, including 60 in the AD case group. Gut microbiota was analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Models incorporating disease group, sex, and a disease-sex interaction term were constructed to test whether sex modifies the effect of AD on gut microbiota α diversity. Stratified analyses were performed to compare α and β diversity between the AD and healthy control (HC) groups in male and female populations, respectively. Differential signature taxa between the two groups were explored using linear discriminant analysis effect size (LEfSe) and random forest analysis.
RESULTS: A total of 36,168 amplicon sequence variants (ASVs) were obtained, with 1,917 ASVs shared between the AD and HC groups. No interaction effect between AD and sex on gut microbiota diversity was observed (interaction p-FDR > 0.05). In the sex-stratified analysis, gut microbiota evenness indices (Simpson, Shannon, and Pielou's indices) were lower in AD patients than in controls among both male and female populations (p-FDR < 0.05), whereas species richness (Chao1 and Observed_species) was significantly reduced only in female AD patients (p-FDR < 0.05). Significant differences in gut microbiota beta diversity were observed between the AD and control groups in both the male population (Stress = 0.213) and the female population (Stress = 0.253) (ANOSIM; males: R = 0.365, p = 0.001; females: R = 0.133, p = 0.001). In the male population, 11 signature taxa, including Bacilli, Lactobacillales, and Macellibacteroides, were significantly enriched in the AD group; in the female population, 12 signature taxa, including [Ruminococcus], Alistipes, and Rikenellaceae, were significantly enriched in the AD group. In the overall prediction of the random forest model distinguishing the AD group from the control group, the accuracy was 85.71% and 90.77% in the male and female populations, respectively, and the taxa contributing most to group classification were Pseudoramibacter_Eubacterium and Lachnospira, respectively (Gini importance = 0.059 for both).
CONCLUSION: The gut microbiota of AD patients exhibits distinct, sex-specific signature taxa.
Additional Links: PMID-43041466
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041466,
year = {2026},
author = {Lin, XQ and Hua, HH and Zhang, XY and Lv, DP and Cheng, ZS and Qi, HY and Xu, LL},
title = {Sex-specific alterations in gut microbiome composition in patients with Alzheimer's disease.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1915847},
pmid = {43041466},
issn = {1664-302X},
abstract = {BACKGROUND: The microbiota-gut-brain axis plays a significant role in the pathology of Alzheimer's disease (AD). However, alterations in the gut microbiome structure of AD patients and the sex-specific differences in signature microbial taxa remain inadequately characterized.
METHODS: A total of 100 participants were enrolled, including 60 in the AD case group. Gut microbiota was analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Models incorporating disease group, sex, and a disease-sex interaction term were constructed to test whether sex modifies the effect of AD on gut microbiota α diversity. Stratified analyses were performed to compare α and β diversity between the AD and healthy control (HC) groups in male and female populations, respectively. Differential signature taxa between the two groups were explored using linear discriminant analysis effect size (LEfSe) and random forest analysis.
RESULTS: A total of 36,168 amplicon sequence variants (ASVs) were obtained, with 1,917 ASVs shared between the AD and HC groups. No interaction effect between AD and sex on gut microbiota diversity was observed (interaction p-FDR > 0.05). In the sex-stratified analysis, gut microbiota evenness indices (Simpson, Shannon, and Pielou's indices) were lower in AD patients than in controls among both male and female populations (p-FDR < 0.05), whereas species richness (Chao1 and Observed_species) was significantly reduced only in female AD patients (p-FDR < 0.05). Significant differences in gut microbiota beta diversity were observed between the AD and control groups in both the male population (Stress = 0.213) and the female population (Stress = 0.253) (ANOSIM; males: R = 0.365, p = 0.001; females: R = 0.133, p = 0.001). In the male population, 11 signature taxa, including Bacilli, Lactobacillales, and Macellibacteroides, were significantly enriched in the AD group; in the female population, 12 signature taxa, including [Ruminococcus], Alistipes, and Rikenellaceae, were significantly enriched in the AD group. In the overall prediction of the random forest model distinguishing the AD group from the control group, the accuracy was 85.71% and 90.77% in the male and female populations, respectively, and the taxa contributing most to group classification were Pseudoramibacter_Eubacterium and Lachnospira, respectively (Gini importance = 0.059 for both).
CONCLUSION: The gut microbiota of AD patients exhibits distinct, sex-specific signature taxa.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Gut microbial metabolites: linking gut-immune-brain crosstalk to mental and neuropsychiatric health.
Frontiers in immunology, 17:1993237.
This narrative review adopts the gut-immune-brain axis as the core framework. Literature published 2010-2025 was retrieved from PubMed, Web of Science and ScienceDirect; landmark pre-2010 studies from top journals were also included. Literature was analyzed across five dimensions: metabolite synthesis-transport, intestinal immune regulation, central mediation, disease-pathology links and clinical translation. We elucidate how short-chain fatty acids, tryptophan metabolites and bile acids act as immune messengers to modulate neural homeostasis. Under physiological conditions, they maintain barrier integrity and central immune balance; when dysregulated, they trigger immune disturbance, blood-brain barrier damage and neuroinflammation, promoting Alzheimer's disease, Parkinson's disease, major depressive disorder and chronic insomnia. Moving beyond conventional gut-brain-axis reviews focused merely on gut-brain communication, this work highlights immunity as the critical intermediate node and constructs the cascade "gut microbial metabolites-immune regulation-neural homeostasis-disease". We further summarize biomarker prospects and intervention strategies including dietary fiber, pre-/probiotics and fecal microbiota transplantation. Notably, an ICH-M10-aligned five-stage biomarker validation framework and a gut-brain-immune tri-culture microfluidic model are proposed, offering new directions for mechanistic research and precision therapy for neurological disorders.
Additional Links: PMID-43041521
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041521,
year = {2026},
author = {Wu, Y and Xie, X and Lyu, W and Xu, JE and Fan, F and Mao, R and Pan, S and Zhang, L and Fu, M},
title = {Gut microbial metabolites: linking gut-immune-brain crosstalk to mental and neuropsychiatric health.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1993237},
pmid = {43041521},
issn = {1664-3224},
mesh = {Humans ; *Gastrointestinal Microbiome/immunology ; Animals ; *Brain/metabolism/immunology ; *Mental Disorders/metabolism ; *Mental Health ; *Brain-Gut Axis ; },
abstract = {This narrative review adopts the gut-immune-brain axis as the core framework. Literature published 2010-2025 was retrieved from PubMed, Web of Science and ScienceDirect; landmark pre-2010 studies from top journals were also included. Literature was analyzed across five dimensions: metabolite synthesis-transport, intestinal immune regulation, central mediation, disease-pathology links and clinical translation. We elucidate how short-chain fatty acids, tryptophan metabolites and bile acids act as immune messengers to modulate neural homeostasis. Under physiological conditions, they maintain barrier integrity and central immune balance; when dysregulated, they trigger immune disturbance, blood-brain barrier damage and neuroinflammation, promoting Alzheimer's disease, Parkinson's disease, major depressive disorder and chronic insomnia. Moving beyond conventional gut-brain-axis reviews focused merely on gut-brain communication, this work highlights immunity as the critical intermediate node and constructs the cascade "gut microbial metabolites-immune regulation-neural homeostasis-disease". We further summarize biomarker prospects and intervention strategies including dietary fiber, pre-/probiotics and fecal microbiota transplantation. Notably, an ICH-M10-aligned five-stage biomarker validation framework and a gut-brain-immune tri-culture microfluidic model are proposed, offering new directions for mechanistic research and precision therapy for neurological disorders.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Gastrointestinal Microbiome/immunology
Animals
*Brain/metabolism/immunology
*Mental Disorders/metabolism
*Mental Health
*Brain-Gut Axis
RevDate: 2026-11-17
CmpDate: 2026-11-17
Regional and progressive protein abundance changes in the App[NLGF] mouse model do not reflect changes in human Alzheimer's disease.
Brain communications, 8(6):fcag427.
There remains a lack of effective disease-modifying treatments for human Alzheimer's disease. Early intervention is key, so there is a need to discover targets present in early disease stages. Obtaining human tissue from patients with early disease is difficult, so mouse models are commonly used to explore (relatively) early events in Alzheimer's disease development, such as the response to amyloid deposition. Here, we investigated early changes in protein abundance in the widely used App[NLGF] Alzheimer's disease model using liquid chromatography-mass spectrometry. Tissue was collected from the hippocampus and cortex of six App[NLGF] and six wild-type (WT) mice at 3 and 6 months to assess regional differences and the impact of aging. Whereas age-related comparisons within the same mouse genotype (3-month versus 6-month) revealed relatively few protein changes, comparisons between App[NLGF] and WT mice demonstrated extensive alterations, with the cortex being more affected than the hippocampus (763 changes versus control in the cortex at 6 months versus 304 in the hippocampus). While many of the changes at 6 months were also present at 3 months, distinct pathways were affected across the two regions. We compared these data to a previous analysis of human post-mortem Alzheimer's disease brain, matched for the regions studied. Comparison of the disease-associated pathways in these data displayed significant divergence between human Alzheimer's disease and the mouse model. This comparison suggests that there are both regional differences in protein abundance in the mouse brain and substantial differences in the mouse response to amyloid deposition compared to that in human Alzheimer's disease. Models should be well characterized and selected with care.
Additional Links: PMID-43041636
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041636,
year = {2026},
author = {Torvell, M and Tierney, AL and Castillo Morales, A and Morgan, BP and Unwin, RD},
title = {Regional and progressive protein abundance changes in the App[NLGF] mouse model do not reflect changes in human Alzheimer's disease.},
journal = {Brain communications},
volume = {8},
number = {6},
pages = {fcag427},
pmid = {43041636},
issn = {2632-1297},
abstract = {There remains a lack of effective disease-modifying treatments for human Alzheimer's disease. Early intervention is key, so there is a need to discover targets present in early disease stages. Obtaining human tissue from patients with early disease is difficult, so mouse models are commonly used to explore (relatively) early events in Alzheimer's disease development, such as the response to amyloid deposition. Here, we investigated early changes in protein abundance in the widely used App[NLGF] Alzheimer's disease model using liquid chromatography-mass spectrometry. Tissue was collected from the hippocampus and cortex of six App[NLGF] and six wild-type (WT) mice at 3 and 6 months to assess regional differences and the impact of aging. Whereas age-related comparisons within the same mouse genotype (3-month versus 6-month) revealed relatively few protein changes, comparisons between App[NLGF] and WT mice demonstrated extensive alterations, with the cortex being more affected than the hippocampus (763 changes versus control in the cortex at 6 months versus 304 in the hippocampus). While many of the changes at 6 months were also present at 3 months, distinct pathways were affected across the two regions. We compared these data to a previous analysis of human post-mortem Alzheimer's disease brain, matched for the regions studied. Comparison of the disease-associated pathways in these data displayed significant divergence between human Alzheimer's disease and the mouse model. This comparison suggests that there are both regional differences in protein abundance in the mouse brain and substantial differences in the mouse response to amyloid deposition compared to that in human Alzheimer's disease. Models should be well characterized and selected with care.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Unravelling the anti-Alzheimer potential of Annona muricata fruit through network pharmacology, molecular docking, DFT, molecular dynamics simulations, and MM/PBSA analysis.
Frontiers in bioinformatics, 6:1965394.
BACKGROUND: Alzheimer's disease is characterized by progressive neuronal degeneration that culminates in cognitive impairment. Botanicals represent attractive therapeutic candidates owing to their wide margin of safety and their capacity to act through multiple mechanisms.
MATERIALS AND METHODS: We deployed an integrated computational framework, combining ADME filtering, target-network mapping, binding-affinity prediction, molecular dynamics simulations, binding free-energy calculations, and quantum-chemical analysis to investigate the potential anti-Alzheimer relevance of Annona muricata fruit constituents.
RESULTS: Network pharmacology identified 56 targets shared between 37 screened compounds and Alzheimer's disease, among which APP, TNF, IL6, and AKT1 emerged as the principal hub genes. Among the AD-associated targets, α-synyclein (SNCA) was prioritized for detailed structural analysis based on its docking interactions with the screened constituents. Molecular docking identified T9, T17, and T19 as the constituents showing the most favourable predicted interactions with SNCA, with binding energies of -7.20, -7.001, and -7.25 kcal/mol, respectively. MD simulations indicated stable predicted protein-ligand interactions over the simulated trajectories, while MM/PBSA calculations yielded binding free energies of -12.63 ± 0.37, -12.57 ± 0.01, and -7.89 ± 0.27 kcal/mol for T9, T17, and T19, respectively. density functional theory analysis provided additional information about the chemical reactivity of these 3 compounds.
DISCUSSION: The integrated computational results suggest that selected A. muricata constituents interact with molecular targets and pathways implicated in neuroinflammation and apoptosis pathways in Alzheimer's disease. The structural stability and favourable electronic properties of T9 and T17 highlight their potential as lead scaffolds against SNCA-associated neurodegeneration.
CONCLUSION: Collectively, these computational insights nominate the phytoconstituents T9 and T17 as promising lead candidates for Alzheimer's disease intervention, although prospective cell-based and animal studies remain necessary to confirm their bioactivity.
Additional Links: PMID-43041666
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041666,
year = {2026},
author = {Mandalamari, MT and Kumar, P and Dwivedi, PSR},
title = {Unravelling the anti-Alzheimer potential of Annona muricata fruit through network pharmacology, molecular docking, DFT, molecular dynamics simulations, and MM/PBSA analysis.},
journal = {Frontiers in bioinformatics},
volume = {6},
number = {},
pages = {1965394},
pmid = {43041666},
issn = {2673-7647},
abstract = {BACKGROUND: Alzheimer's disease is characterized by progressive neuronal degeneration that culminates in cognitive impairment. Botanicals represent attractive therapeutic candidates owing to their wide margin of safety and their capacity to act through multiple mechanisms.
MATERIALS AND METHODS: We deployed an integrated computational framework, combining ADME filtering, target-network mapping, binding-affinity prediction, molecular dynamics simulations, binding free-energy calculations, and quantum-chemical analysis to investigate the potential anti-Alzheimer relevance of Annona muricata fruit constituents.
RESULTS: Network pharmacology identified 56 targets shared between 37 screened compounds and Alzheimer's disease, among which APP, TNF, IL6, and AKT1 emerged as the principal hub genes. Among the AD-associated targets, α-synyclein (SNCA) was prioritized for detailed structural analysis based on its docking interactions with the screened constituents. Molecular docking identified T9, T17, and T19 as the constituents showing the most favourable predicted interactions with SNCA, with binding energies of -7.20, -7.001, and -7.25 kcal/mol, respectively. MD simulations indicated stable predicted protein-ligand interactions over the simulated trajectories, while MM/PBSA calculations yielded binding free energies of -12.63 ± 0.37, -12.57 ± 0.01, and -7.89 ± 0.27 kcal/mol for T9, T17, and T19, respectively. density functional theory analysis provided additional information about the chemical reactivity of these 3 compounds.
DISCUSSION: The integrated computational results suggest that selected A. muricata constituents interact with molecular targets and pathways implicated in neuroinflammation and apoptosis pathways in Alzheimer's disease. The structural stability and favourable electronic properties of T9 and T17 highlight their potential as lead scaffolds against SNCA-associated neurodegeneration.
CONCLUSION: Collectively, these computational insights nominate the phytoconstituents T9 and T17 as promising lead candidates for Alzheimer's disease intervention, although prospective cell-based and animal studies remain necessary to confirm their bioactivity.},
}
RevDate: 2026-11-17
An interpretable physics-informed graph neural network for forecasting longitudinal tau progression in Alzheimer's disease.
Machine learning. Health, 2(2):025025.
Forecasting the progression of tau pathology by modeling its spatiotemporal dynamics is critical for characterizing Alzheimer's disease (AD), where tau is a key driver of disease progression. Tau is an important prognostic biomarker for AD and is a primary endpoint for many ongoing clinical therapeutic trials. Tau burden can be quantified in vivo using positron emission tomography (PET), while its propagation is hypothesized to follow the structural connectome derived from diffusion tensor imaging (DTI), providing a framework for modeling network-driven tau spread. Deep learning approaches, particularly graph neural networks (GNNs), enable data-driven learning of regional changes in tau burden by leveraging brain connectivity. However, purely data-driven models are prone to overfitting and may fail to capture biologically meaningful propagation patterns. To address this, we present here a physics-informed GNN framework for tau forecasting that incorporates prior models of tau propagation, specifically the Fisher-Kolmogorov-Petrovsky-Piskunov (FKPP) equation and the epidemic spreading model (ESM), as regularization terms in the latent space of the network. Our analysis relies on PET and DTI data from N = 462 amyloid-positive human subjects from the Alzheimer's Disease Neuroimaging Initiative. Our results demonstrate that physics-informed models improve model performance over the unregularized baseline across multiple evaluation metrics, with regularization in the latent space improving robustness compared to that in the feature space. The FKPP formulation achieves the best mean predictive performance, followed closely by ESM. We further implement post-hoc interpretability using Integrated Gradients to identify key regions and connections driving the model's predictions. The interpretability analysis is consistent with the observed performance gains, indicating that physics-based regularization yields more localized attribution within biologically relevant regions. Overall, our findings demonstrate that integrating prior formulations of tau propagation with GNNs enhances predictive accuracy and interpretability, providing a promising framework for modeling network-driven spread of tau pathology.
Additional Links: PMID-43041692
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041692,
year = {2026},
author = {Balaji, V and Song, TA and Yang, F and Wang, Z and Dutta, J},
title = {An interpretable physics-informed graph neural network for forecasting longitudinal tau progression in Alzheimer's disease.},
journal = {Machine learning. Health},
volume = {2},
number = {2},
pages = {025025},
pmid = {43041692},
issn = {3049-477X},
abstract = {Forecasting the progression of tau pathology by modeling its spatiotemporal dynamics is critical for characterizing Alzheimer's disease (AD), where tau is a key driver of disease progression. Tau is an important prognostic biomarker for AD and is a primary endpoint for many ongoing clinical therapeutic trials. Tau burden can be quantified in vivo using positron emission tomography (PET), while its propagation is hypothesized to follow the structural connectome derived from diffusion tensor imaging (DTI), providing a framework for modeling network-driven tau spread. Deep learning approaches, particularly graph neural networks (GNNs), enable data-driven learning of regional changes in tau burden by leveraging brain connectivity. However, purely data-driven models are prone to overfitting and may fail to capture biologically meaningful propagation patterns. To address this, we present here a physics-informed GNN framework for tau forecasting that incorporates prior models of tau propagation, specifically the Fisher-Kolmogorov-Petrovsky-Piskunov (FKPP) equation and the epidemic spreading model (ESM), as regularization terms in the latent space of the network. Our analysis relies on PET and DTI data from N = 462 amyloid-positive human subjects from the Alzheimer's Disease Neuroimaging Initiative. Our results demonstrate that physics-informed models improve model performance over the unregularized baseline across multiple evaluation metrics, with regularization in the latent space improving robustness compared to that in the feature space. The FKPP formulation achieves the best mean predictive performance, followed closely by ESM. We further implement post-hoc interpretability using Integrated Gradients to identify key regions and connections driving the model's predictions. The interpretability analysis is consistent with the observed performance gains, indicating that physics-based regularization yields more localized attribution within biologically relevant regions. Overall, our findings demonstrate that integrating prior formulations of tau propagation with GNNs enhances predictive accuracy and interpretability, providing a promising framework for modeling network-driven spread of tau pathology.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Impact of Cognitive Remediation Combined With Transcranial Direct Current Stimulation on Gray Matter Macrostructure and Microstructure in Older Adults at Risk for Alzheimer's Dementia.
Biological psychiatry global open science, 7(1):100834.
BACKGROUND: Older adults with remitted major depressive disorder or mild cognitive impairment (MCI) are at an increased risk for Alzheimer's dementia (AD). Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) slows cognitive decline in this population; however, its effects on gray matter macro- and microstructure have not been characterized. We investigated whether CR+tDCS alters cortical structure and whether baseline factors such as brain structure moderate potential changes.
METHODS: Participants from the PACt-MD (Prevention of Alzheimer's Dementia with CR plus tDCS in Mild Cognitive Impairment and Depression) trial received active or sham CR+sham tDCS for 8 weeks and were followed for 2 to 7 years. Gray matter macrostructure (cortical thickness and surface area) was measured via T1-weighted magnetic resonance imaging at baseline, after acute treatment (N = 181), and at study completion (n = 102). Microstructure was assessed using neurite orientation dispersion and density imaging (NODDI). Mixed-effects models examined treatment effects and moderation by baseline factors across brain regions.
RESULTS: No effects of CR+tDCS were observed on gray matter macro- or microstructure. Baseline cortical thickness moderated temporal lobe thickness changes, strongest in the entorhinal cortex over follow-up (p FDR = .010). Baseline NODDI measures moderated microstructural changes, strongest in the rostral middle frontal orientation dispersion index after acute treatment (p FDR < .001). There were no moderation effects of diagnosis or APOE status.
CONCLUSIONS: CR+tDCS does not produce uniform structural changes but interacts with baseline macro- and microstructure to shape longitudinal trajectories. Findings support the potential for precision approaches in preventive interventions for older adults at risk for AD.
Additional Links: PMID-43041805
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041805,
year = {2027},
author = {Chen, Y and Rajji, TK and Zhukovsky, P and Abdulrasul, H and Fischer, CE and Flint, AJ and Herrmann, N and Ho, NCW and Lanctot, K and Lee, A and Ma, C and Mah, L and Mansour, S and Pan, R and Park, JY and Pollock, BG and Mulsant, BH and Voineskos, AN and , },
title = {Impact of Cognitive Remediation Combined With Transcranial Direct Current Stimulation on Gray Matter Macrostructure and Microstructure in Older Adults at Risk for Alzheimer's Dementia.},
journal = {Biological psychiatry global open science},
volume = {7},
number = {1},
pages = {100834},
pmid = {43041805},
issn = {2667-1743},
abstract = {BACKGROUND: Older adults with remitted major depressive disorder or mild cognitive impairment (MCI) are at an increased risk for Alzheimer's dementia (AD). Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) slows cognitive decline in this population; however, its effects on gray matter macro- and microstructure have not been characterized. We investigated whether CR+tDCS alters cortical structure and whether baseline factors such as brain structure moderate potential changes.
METHODS: Participants from the PACt-MD (Prevention of Alzheimer's Dementia with CR plus tDCS in Mild Cognitive Impairment and Depression) trial received active or sham CR+sham tDCS for 8 weeks and were followed for 2 to 7 years. Gray matter macrostructure (cortical thickness and surface area) was measured via T1-weighted magnetic resonance imaging at baseline, after acute treatment (N = 181), and at study completion (n = 102). Microstructure was assessed using neurite orientation dispersion and density imaging (NODDI). Mixed-effects models examined treatment effects and moderation by baseline factors across brain regions.
RESULTS: No effects of CR+tDCS were observed on gray matter macro- or microstructure. Baseline cortical thickness moderated temporal lobe thickness changes, strongest in the entorhinal cortex over follow-up (p FDR = .010). Baseline NODDI measures moderated microstructural changes, strongest in the rostral middle frontal orientation dispersion index after acute treatment (p FDR < .001). There were no moderation effects of diagnosis or APOE status.
CONCLUSIONS: CR+tDCS does not produce uniform structural changes but interacts with baseline macro- and microstructure to shape longitudinal trajectories. Findings support the potential for precision approaches in preventive interventions for older adults at risk for AD.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Accelerated Hit Identification and Optimization of a Novel Class of Cellularly Active QPCT/L Inhibitors.
ACS medicinal chemistry letters, 17(11):2274-2282.
QPCT and its Golgi-bound analogue QPCTL catalyze the conversion of N-terminal glutamines into pyroglutamates, a modification that influences diverse biological processes, including Aβ oligomerization, chemokine stabilization, and CD47-SIRPα signaling. Consequently, QPCT/L inhibitors have therapeutic potential in Alzheimer's disease, cancer, and fibrosis. Here, we describe the identification of QPCT/L inhibitors using a virtual screening strategy in which less than 0.1% of our in-house compound library was selected based on similarity to the bioactive conformations of known QPCT/L inhibitors. This approach yielded previously unknown QPCT/L inhibitor chemotypes and substantially accelerated hit discovery. Structure-guided optimization of one quinazolidinone series afforded a potent cellular tool compound BI-3614 with improved activity over previously reported inhibitors, which is available free of charge on opnMe.com. The campaign provided valuable insights, revealing the critical impact of water networks on binding-mode prediction and the profound influence of subtle electronic changes on π-stacking interactions, emphasizing the importance of experimental validation of computational design hypotheses.
Additional Links: PMID-43041854
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43041854,
year = {2026},
author = {Handschuh, S and Reindl, S and Binder, F and Dahmann, G and Hamilton, JY and Winter, M and Mracek, P and Beck, B and Willwacher, J},
title = {Accelerated Hit Identification and Optimization of a Novel Class of Cellularly Active QPCT/L Inhibitors.},
journal = {ACS medicinal chemistry letters},
volume = {17},
number = {11},
pages = {2274-2282},
pmid = {43041854},
issn = {1948-5875},
abstract = {QPCT and its Golgi-bound analogue QPCTL catalyze the conversion of N-terminal glutamines into pyroglutamates, a modification that influences diverse biological processes, including Aβ oligomerization, chemokine stabilization, and CD47-SIRPα signaling. Consequently, QPCT/L inhibitors have therapeutic potential in Alzheimer's disease, cancer, and fibrosis. Here, we describe the identification of QPCT/L inhibitors using a virtual screening strategy in which less than 0.1% of our in-house compound library was selected based on similarity to the bioactive conformations of known QPCT/L inhibitors. This approach yielded previously unknown QPCT/L inhibitor chemotypes and substantially accelerated hit discovery. Structure-guided optimization of one quinazolidinone series afforded a potent cellular tool compound BI-3614 with improved activity over previously reported inhibitors, which is available free of charge on opnMe.com. The campaign provided valuable insights, revealing the critical impact of water networks on binding-mode prediction and the profound influence of subtle electronic changes on π-stacking interactions, emphasizing the importance of experimental validation of computational design hypotheses.},
}
▼ ▼ LOAD NEXT 100 CITATIONS
RJR Experience and Expertise
Researcher
Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.
Educator
Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.
Administrator
Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.
Technologist
Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.
Publisher
While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.
Speaker
Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.
Facilitator
Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.
Designer
Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.
RJR Picks from Around the Web (updated 11 MAY 2018 )
Old Science
Weird Science
Treating Disease with Fecal Transplantation
Fossils of miniature humans (hobbits) discovered in Indonesia
Paleontology
Dinosaur tail, complete with feathers, found preserved in amber.
Astronomy
Mysterious fast radio burst (FRB) detected in the distant universe.
Big Data & Informatics
Big Data: Buzzword or Big Deal?
Hacking the genome: Identifying anonymized human subjects using publicly available data.